{"cf03feaa814c150f703e19c8aecae4ce5cf6f62c": [["AN ONGOING epidemic by a novel coronavirus first was reported during late 2019 in Wuhan, China, and has attracted considerable attention worldwide.", [["coronavirus", "ORGANISM", 31, 42], ["a novel coronavirus", "PROBLEM", 23, 42]]], ["1-3 On January 7, 2020, the novel coronavirus was identified by the Chinese Center for Disease Control and Prevention and subsequently was named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) by the World Health Organization.", [["acute respiratory syndrome coronavirus", "DISEASE", 152, 190], ["coronavirus", "ORGANISM", 34, 45], ["severe acute respiratory syndrome coronavirus", "SPECIES", 145, 190], ["SARS-CoV-2", "SPECIES", 194, 204], ["the novel coronavirus", "PROBLEM", 24, 45], ["Disease Control", "TREATMENT", 87, 102], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 145, 190], ["coronavirus", "OBSERVATION", 34, 45], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["acute", "OBSERVATION_MODIFIER", 152, 157], ["respiratory syndrome", "OBSERVATION", 158, 178]]], ["4, 5 The disease caused by SARS-CoV-2 infection was named coronavirus disease 2019 (COVID-19), with clinical presentation resembling severe acute respiratory syndrome and Middle East respiratory syndrome and manifesting as cough, fever, and dyspnea.", [["SARS-CoV-2 infection", "DISEASE", 27, 47], ["coronavirus disease", "DISEASE", 58, 77], ["acute respiratory syndrome", "DISEASE", 140, 166], ["Middle East respiratory syndrome", "DISEASE", 171, 203], ["cough", "DISEASE", 223, 228], ["fever", "DISEASE", 230, 235], ["dyspnea", "DISEASE", 241, 248], ["SARS-CoV-2", "ORGANISM", 27, 37], ["CoV-2", "SPECIES", 32, 37], ["SARS-CoV-2", "SPECIES", 27, 37], ["The disease", "PROBLEM", 5, 16], ["SARS", "PROBLEM", 27, 31], ["CoV-2 infection", "PROBLEM", 32, 47], ["coronavirus disease", "PROBLEM", 58, 77], ["COVID", "TEST", 84, 89], ["severe acute respiratory syndrome", "PROBLEM", 133, 166], ["Middle East respiratory syndrome", "PROBLEM", 171, 203], ["cough", "PROBLEM", 223, 228], ["fever", "PROBLEM", 230, 235], ["dyspnea", "PROBLEM", 241, 248], ["disease", "OBSERVATION", 9, 16], ["SARS", "OBSERVATION", 27, 31], ["severe", "OBSERVATION_MODIFIER", 133, 139], ["acute", "OBSERVATION_MODIFIER", 140, 145], ["respiratory syndrome", "OBSERVATION", 146, 166], ["Middle", "ANATOMY_MODIFIER", 171, 177], ["respiratory syndrome", "OBSERVATION", 183, 203], ["cough", "OBSERVATION", 223, 228]]], ["[5] [6] [7] [8] [9] In particular, accumulating evidence has shown that SARS-CoV-2 exhibits effective human-to-human transmission, causing an exponential growth of new cases.", [["[5] [6] [7] [8] [9", "SIMPLE_CHEMICAL", 0, 18], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 72, 82], ["human", "ORGANISM", 102, 107], ["human", "ORGANISM", 111, 116], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 111, 116], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 111, 116], ["SARS", "TEST", 72, 76], ["CoV", "TEST", 77, 80], ["an exponential growth of new cases", "PROBLEM", 139, 173], ["exponential", "OBSERVATION_MODIFIER", 142, 153], ["growth", "OBSERVATION_MODIFIER", 154, 160]]], ["6, [10] [11] [12] The strong transmissibility of SARS-CoV-2 and a substantial number of patients who are either asymptomatic or have only mild symptoms 2,3,12 present great challenges for anesthesiologists to perform anesthetic management and successful infection prevention and control.", [["SARS", "DISEASE", 49, 53], ["infection", "DISEASE", 254, 263], ["[10] [11] [12]", "SIMPLE_CHEMICAL", 3, 17], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["SARS-CoV", "SPECIES", 49, 57], ["SARS", "TEST", 49, 53], ["CoV", "TEST", 54, 57], ["mild symptoms", "PROBLEM", 138, 151], ["anesthetic management", "TREATMENT", 217, 238], ["successful infection prevention", "TREATMENT", 243, 274], ["mild", "OBSERVATION_MODIFIER", 138, 142], ["infection", "OBSERVATION", 254, 263]]], ["Even though studies have been published for SARS-CoV-2\u00c0related infection prevention and control during anesthesia in emergency surgery, 13 unfortunately, there are no guidelines on the anesthetic management for patients with suspected SARS-CoV-2 infection undergoing long, complicated cardiac surgeries.", [["cardiac", "ANATOMY", 285, 292], ["infection", "DISEASE", 63, 72], ["SARS-CoV-2 infection", "DISEASE", 235, 255], ["SARS-CoV-2\u00c0related", "ORGANISM", 44, 62], ["patients", "ORGANISM", 211, 219], ["cardiac", "ORGAN", 285, 292], ["patients", "SPECIES", 211, 219], ["SARS-CoV", "SPECIES", 44, 52], ["studies", "TEST", 12, 19], ["SARS", "PROBLEM", 44, 48], ["CoV", "PROBLEM", 49, 52], ["2\u00c0related infection prevention", "TREATMENT", 53, 83], ["emergency surgery", "TREATMENT", 117, 134], ["the anesthetic management", "TREATMENT", 181, 206], ["SARS", "PROBLEM", 235, 239], ["CoV-2 infection", "PROBLEM", 240, 255], ["complicated cardiac surgeries", "TREATMENT", 273, 302], ["infection", "OBSERVATION", 63, 72], ["infection", "OBSERVATION", 246, 255], ["cardiac", "ANATOMY", 285, 292], ["surgeries", "OBSERVATION", 293, 302]]]], "185e505daa1da8ee7ece18212693b2550410a190": [["microcephaly 10, 11 , and in adults with the Guillain-Barr\u00e9 syndrome 10, 12, 13 .", [["microcephaly", "DISEASE", 0, 12], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 45, 68], ["Guillain-Barr\u00e9", "ORGANISM", 45, 59], ["Guillain-Barr\u00e9 syndrome 10", "SPECIES", 45, 71], ["microcephaly", "PROBLEM", 0, 12], ["the Guillain-Barr\u00e9 syndrome", "PROBLEM", 41, 68], ["Barr\u00e9 syndrome", "ANATOMY", 54, 68]]], ["ZIKV is primary transmitted to humans through the bite of infected mosquitoes 11 .", [["ZIKV", "CHEMICAL", 0, 4], ["primary transmitted to humans through the bite", "DISEASE", 8, 54], ["ZIKV", "GENE_OR_GENE_PRODUCT", 0, 4], ["humans", "ORGANISM", 31, 37], ["humans", "SPECIES", 31, 37], ["ZIKV", "SPECIES", 0, 4], ["humans", "SPECIES", 31, 37], ["infected mosquitoes", "PROBLEM", 58, 77], ["infected", "OBSERVATION", 58, 66]]], ["However, non-vector ZIKV transmission can occur through sexual contact 14, 15 or vertical transmission from infected mothers 16, 17 .", [["ZIKV", "SPECIES", 20, 24], ["non-vector ZIKV transmission", "PROBLEM", 9, 37], ["infected", "OBSERVATION", 108, 116]]], ["Currently, there are no approved vaccines or antivirals to prevent or treat ZIKV infection.", [["infection", "DISEASE", 81, 90], ["ZIKV", "SPECIES", 76, 80], ["approved vaccines", "TREATMENT", 24, 41], ["antivirals", "TREATMENT", 45, 55], ["ZIKV infection", "PROBLEM", 76, 90], ["no", "UNCERTAINTY", 21, 23]]]], "PMC3130781": [["IntroductionCeacam1 is a member of a large family of carcinoembryonic antigen proteins [2].", [["IntroductionCeacam1", "GENE_OR_GENE_PRODUCT", 0, 19], ["carcinoembryonic antigen", "GENE_OR_GENE_PRODUCT", 53, 77], ["IntroductionCeacam1", "PROTEIN", 0, 19], ["carcinoembryonic antigen proteins", "PROTEIN", 53, 86], ["carcinoembryonic antigen proteins", "TREATMENT", 53, 86]]], ["It is primarily a type I transmembrane protein with multiple splice variants [9], though soluble forms also exist.", [["type I transmembrane protein", "PROTEIN", 18, 46], ["a type I transmembrane protein", "PROBLEM", 16, 46], ["multiple splice variants", "PROBLEM", 52, 76], ["splice variants", "OBSERVATION", 61, 76]]], ["Ceacam1 is widely expressed on a variety of tissues including endothelium [10], epithelium [11], hematopoietic cells [12] and both hematologic and solid tumors, and interacts in a homophilic and heterophilic fashion with physiological and pathogen-associated ligands, including carcinoembryonic antigen and the Neisseria spp. proteins [13].IntroductionSome Ceacam1 isoforms contain intracellular ITIM motifs, and activation of Ceacam1 results in the recruitment of the SHP-1 and SHP-2 phosphatases [8], [14], which dephosphorylate substrates across a range of signaling pathways.", [["tissues", "ANATOMY", 44, 51], ["endothelium", "ANATOMY", 62, 73], ["epithelium", "ANATOMY", 80, 90], ["hematopoietic cells", "ANATOMY", 97, 116], ["hematologic", "ANATOMY", 131, 142], ["solid tumors", "ANATOMY", 147, 159], ["intracellular", "ANATOMY", 382, 395], ["Ceacam1", "CHEMICAL", 0, 7], ["hematologic and solid tumors", "DISEASE", 131, 159], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 0, 7], ["tissues", "TISSUE", 44, 51], ["endothelium", "TISSUE", 62, 73], ["epithelium", "TISSUE", 80, 90], ["hematopoietic cells", "CELL", 97, 116], ["hematologic", "CANCER", 131, 142], ["solid tumors", "CANCER", 147, 159], ["carcinoembryonic antigen", "GENE_OR_GENE_PRODUCT", 278, 302], ["Neisseria spp", "ORGANISM", 311, 324], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 357, 364], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 382, 395], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 427, 434], ["SHP-1", "GENE_OR_GENE_PRODUCT", 469, 474], ["SHP-2", "GENE_OR_GENE_PRODUCT", 479, 484], ["[14]", "SIMPLE_CHEMICAL", 503, 507], ["Ceacam1", "PROTEIN", 0, 7], ["hematopoietic cells", "CELL_TYPE", 97, 116], ["carcinoembryonic antigen", "PROTEIN", 278, 302], ["Ceacam1 isoforms", "PROTEIN", 357, 373], ["intracellular ITIM motifs", "PROTEIN", 382, 407], ["Ceacam1", "PROTEIN", 427, 434], ["SHP-1 and SHP-2 phosphatases", "PROTEIN", 469, 497], ["Ceacam1", "TREATMENT", 0, 7], ["hematopoietic cells", "TEST", 97, 116], ["both hematologic and solid tumors", "PROBLEM", 126, 159], ["physiological and pathogen-associated ligands", "PROBLEM", 221, 266], ["carcinoembryonic antigen", "TEST", 278, 302], ["the Neisseria spp", "PROBLEM", 307, 324], ["proteins", "TEST", 326, 334], ["IntroductionSome Ceacam1 isoforms", "TREATMENT", 340, 373], ["intracellular ITIM motifs", "TREATMENT", 382, 407], ["Ceacam1 results", "TEST", 427, 442], ["the SHP", "TEST", 465, 472], ["SHP", "TEST", 479, 482], ["dephosphorylate substrates", "TREATMENT", 515, 541], ["hematopoietic cells", "OBSERVATION", 97, 116], ["hematologic", "ANATOMY", 131, 142], ["solid", "OBSERVATION_MODIFIER", 147, 152], ["tumors", "OBSERVATION", 153, 159], ["Neisseria spp", "OBSERVATION", 311, 324], ["intracellular ITIM", "OBSERVATION", 382, 400]]], ["Ceacam1 thus inhibits T cell receptor (TCR) signaling and suppresses multiple aspects of T cell function.", [["T cell", "ANATOMY", 22, 28], ["T cell", "ANATOMY", 89, 95], ["Ceacam1", "CHEMICAL", 0, 7], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 0, 7], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 22, 37], ["TCR", "GENE_OR_GENE_PRODUCT", 39, 42], ["T cell", "CELL", 89, 95], ["Ceacam1", "PROTEIN", 0, 7], ["T cell receptor", "PROTEIN", 22, 37], ["TCR", "PROTEIN", 39, 42], ["Ceacam1", "TREATMENT", 0, 7], ["T cell receptor", "TREATMENT", 22, 37], ["cell function", "OBSERVATION", 91, 104]]], ["Ceacam1 agonists attenuate cytokine secretion, T cell polarization and cytolytic function.", [["T cell", "ANATOMY", 47, 53], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 0, 7], ["T cell", "CELL", 47, 53], ["cytokine", "PROTEIN", 27, 35], ["Ceacam1 agonists", "TREATMENT", 0, 16], ["cytokine secretion", "PROBLEM", 27, 45], ["T cell polarization", "TEST", 47, 66], ["cytolytic function", "TEST", 71, 89], ["cytolytic function", "OBSERVATION", 71, 89]]], ["In vivo, ligation of Ceacam1 with soluble ligands or over-expression of ITIM-containing Ceacam1 isoforms on T cells attenuates experimental colitis [7], [8].", [["T cells", "ANATOMY", 108, 115], ["colitis", "DISEASE", 140, 147], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 21, 28], ["ITIM", "GENE_OR_GENE_PRODUCT", 72, 76], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 88, 95], ["T cells", "CELL", 108, 115], ["Ceacam1", "PROTEIN", 21, 28], ["ITIM", "PROTEIN", 72, 76], ["Ceacam1 isoforms", "PROTEIN", 88, 104], ["T cells", "CELL_TYPE", 108, 115], ["ligation", "TREATMENT", 9, 17], ["Ceacam1 with soluble ligands", "TREATMENT", 21, 49], ["ITIM", "PROBLEM", 72, 76], ["Ceacam1 isoforms", "PROBLEM", 88, 104], ["experimental colitis", "PROBLEM", 127, 147], ["colitis", "OBSERVATION", 140, 147]]], ["Additionally, Ceacam1 is also expressed on intestinal T cells in patients with Celiac disease [15] and ulcerative colitis [16], and may represent an attempt by the immune system to negatively regulate these inflammatory processes.IntroductionIn addition to immune regulation, Ceacam1 exerts a wide variety of other biological functions.", [["intestinal T cells", "ANATOMY", 43, 61], ["Celiac disease", "DISEASE", 79, 93], ["ulcerative colitis", "DISEASE", 103, 121], ["Ceacam1", "CHEMICAL", 276, 283], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 14, 21], ["intestinal T cells", "CELL", 43, 61], ["patients", "ORGANISM", 65, 73], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 276, 283], ["Ceacam1", "PROTEIN", 14, 21], ["intestinal T cells", "CELL_TYPE", 43, 61], ["Ceacam1", "PROTEIN", 276, 283], ["patients", "SPECIES", 65, 73], ["intestinal T cells", "TREATMENT", 43, 61], ["Celiac disease", "PROBLEM", 79, 93], ["ulcerative colitis", "PROBLEM", 103, 121], ["these inflammatory processes", "PROBLEM", 201, 229], ["IntroductionIn", "TREATMENT", 230, 244], ["immune regulation", "TREATMENT", 257, 274], ["Ceacam1", "TREATMENT", 276, 283], ["Ceacam1", "OBSERVATION", 14, 21], ["intestinal", "ANATOMY", 43, 53], ["Celiac", "ANATOMY", 79, 85], ["ulcerative", "OBSERVATION_MODIFIER", 103, 113], ["colitis", "OBSERVATION", 114, 121], ["may represent", "UNCERTAINTY", 132, 145], ["inflammatory", "OBSERVATION", 207, 219]]], ["It is a cell-cell adhesion molecule [17], [18], and a receptor for a variety of commensal and pathogenic microbes in mouse and man [17], [19], [20], [21].", [["cell", "ANATOMY", 8, 12], ["cell", "ANATOMY", 13, 17], ["cell-cell adhesion molecule [17]", "GENE_OR_GENE_PRODUCT", 8, 40], ["[18]", "SIMPLE_CHEMICAL", 42, 46], ["mouse", "ORGANISM", 117, 122], ["[19]", "SIMPLE_CHEMICAL", 137, 141], ["[20]", "SIMPLE_CHEMICAL", 143, 147], ["[21]", "SIMPLE_CHEMICAL", 149, 153], ["cell-cell adhesion molecule", "PROTEIN", 8, 35], ["mouse", "SPECIES", 117, 122], ["man", "SPECIES", 127, 130], ["mouse", "SPECIES", 117, 122], ["a cell-cell adhesion molecule", "TREATMENT", 6, 35]]], ["Ceacam1 also regulates angiogenesis [6], energy homeostasis [22], and tumor biology [23], [24], [25].", [["tumor", "ANATOMY", 70, 75], ["Ceacam1", "CHEMICAL", 0, 7], ["tumor", "DISEASE", 70, 75], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 0, 7], ["tumor", "CANCER", 70, 75], ["[24]", "SIMPLE_CHEMICAL", 90, 94], ["Ceacam1", "PROTEIN", 0, 7]]], ["Ceacam1 regulates the tumorigenesis of colon cancers, and is a prognostic factor in lung adenocarcinoma.", [["colon cancers", "ANATOMY", 39, 52], ["lung adenocarcinoma", "ANATOMY", 84, 103], ["Ceacam1", "CHEMICAL", 0, 7], ["colon cancers", "DISEASE", 39, 52], ["lung adenocarcinoma", "DISEASE", 84, 103], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 0, 7], ["colon cancers", "CANCER", 39, 52], ["lung adenocarcinoma", "CANCER", 84, 103], ["Ceacam1", "PROTEIN", 0, 7], ["Ceacam1", "TREATMENT", 0, 7], ["colon cancers", "PROBLEM", 39, 52], ["a prognostic factor", "PROBLEM", 61, 80], ["lung adenocarcinoma", "PROBLEM", 84, 103], ["colon", "ANATOMY", 39, 44], ["cancers", "OBSERVATION", 45, 52], ["lung", "ANATOMY", 84, 88], ["adenocarcinoma", "OBSERVATION", 89, 103]]], ["Tumor expression of Ceacam1 may regulate tumor angiogenesis and invasion, and the expression of both Ceacam1 and CEA by tumors may inhibit the functions of tumor infiltrating lymphocytes.IntroductionAllo-BMT is an established therapy with curative intent for a variety of hematologic malignancies and non-malignant conditions [26].", [["Tumor", "ANATOMY", 0, 5], ["tumor", "ANATOMY", 41, 46], ["tumors", "ANATOMY", 120, 126], ["tumor infiltrating lymphocytes", "ANATOMY", 156, 186], ["hematologic malignancies", "ANATOMY", 272, 296], ["tumor", "DISEASE", 41, 46], ["tumors", "DISEASE", 120, 126], ["tumor", "DISEASE", 156, 161], ["malignancies", "DISEASE", 284, 296], ["Tumor", "CANCER", 0, 5], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 20, 27], ["tumor", "CANCER", 41, 46], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 101, 108], ["CEA", "GENE_OR_GENE_PRODUCT", 113, 116], ["tumors", "CANCER", 120, 126], ["tumor infiltrating lymphocytes", "CELL", 156, 186], ["hematologic malignancies", "CANCER", 272, 296], ["Ceacam1", "PROTEIN", 20, 27], ["Ceacam1", "PROTEIN", 101, 108], ["CEA", "PROTEIN", 113, 116], ["tumor infiltrating lymphocytes", "CELL_TYPE", 156, 186], ["Tumor expression of Ceacam1", "PROBLEM", 0, 27], ["tumor angiogenesis", "PROBLEM", 41, 59], ["invasion", "PROBLEM", 64, 72], ["both Ceacam1 and CEA", "PROBLEM", 96, 116], ["tumors", "PROBLEM", 120, 126], ["tumor infiltrating lymphocytes", "PROBLEM", 156, 186], ["an established therapy", "TREATMENT", 211, 233], ["curative intent", "TREATMENT", 239, 254], ["hematologic malignancies", "PROBLEM", 272, 296], ["non-malignant conditions", "PROBLEM", 301, 325], ["Ceacam1", "OBSERVATION", 20, 27], ["tumor", "OBSERVATION", 41, 46], ["invasion", "OBSERVATION_MODIFIER", 64, 72], ["both", "OBSERVATION_MODIFIER", 96, 100], ["Ceacam1", "OBSERVATION", 101, 108], ["CEA", "ANATOMY", 113, 116], ["tumors", "OBSERVATION", 120, 126], ["tumor", "OBSERVATION_MODIFIER", 156, 161], ["infiltrating lymphocytes", "OBSERVATION", 162, 186]]], ["Alloreactive T cells of donor origin play a criticial role in both GVHD, a major complication of allo-BMT, and graft-versus-tumor activity, a major contributor to the efficacy of allo-BMT as a cancer therapy.IntroductionDonor-recipient antigenic disparity, donor T cells, and tissue injury resulting in inflammation due to the conditioning regimen all contribute to GVHD, which primarily affects intestines, liver, skin and thymus [27].IntroductionCeacam1 is expressed both on leukocytes (especially T cells), as well as on epithelial and endothelial cells, which are prominent components of the parenchyma of the above-mentioned GVHD target organs.", [["T cells", "ANATOMY", 13, 20], ["graft", "ANATOMY", 111, 116], ["tumor", "ANATOMY", 124, 129], ["cancer", "ANATOMY", 193, 199], ["donor T cells", "ANATOMY", 257, 270], ["tissue", "ANATOMY", 276, 282], ["intestines", "ANATOMY", 396, 406], ["liver", "ANATOMY", 408, 413], ["skin", "ANATOMY", 415, 419], ["thymus", "ANATOMY", 424, 430], ["leukocytes", "ANATOMY", 477, 487], ["T cells", "ANATOMY", 500, 507], ["epithelial", "ANATOMY", 524, 534], ["endothelial cells", "ANATOMY", 539, 556], ["parenchyma", "ANATOMY", 596, 606], ["organs", "ANATOMY", 642, 648], ["GVHD", "DISEASE", 67, 71], ["tumor", "DISEASE", 124, 129], ["cancer", "DISEASE", 193, 199], ["tissue injury", "DISEASE", 276, 289], ["inflammation", "DISEASE", 303, 315], ["GVHD", "DISEASE", 366, 370], ["GVHD", "DISEASE", 630, 634], ["T cells", "CELL", 13, 20], ["graft", "TISSUE", 111, 116], ["-versus-tumor", "CANCER", 116, 129], ["allo-BMT", "SIMPLE_CHEMICAL", 179, 187], ["cancer", "CANCER", 193, 199], ["donor T cells", "CELL", 257, 270], ["tissue", "TISSUE", 276, 282], ["intestines", "ORGAN", 396, 406], ["liver", "ORGAN", 408, 413], ["skin", "ORGAN", 415, 419], ["thymus", "ORGAN", 424, 430], ["IntroductionCeacam1", "GENE_OR_GENE_PRODUCT", 436, 455], ["leukocytes", "CELL", 477, 487], ["T cells", "CELL", 500, 507], ["epithelial", "CELL", 524, 534], ["endothelial cells", "CELL", 539, 556], ["parenchyma", "TISSUE", 596, 606], ["organs", "ORGAN", 642, 648], ["Alloreactive T cells", "CELL_TYPE", 0, 20], ["donor T cells", "CELL_TYPE", 257, 270], ["IntroductionCeacam1", "PROTEIN", 436, 455], ["leukocytes", "CELL_TYPE", 477, 487], ["T cells", "CELL_TYPE", 500, 507], ["epithelial and endothelial cells", "CELL_TYPE", 524, 556], ["Alloreactive T cells", "TREATMENT", 0, 20], ["allo-BMT", "TREATMENT", 97, 105], ["graft", "TREATMENT", 111, 116], ["tumor activity", "PROBLEM", 124, 138], ["allo-BMT", "TREATMENT", 179, 187], ["a cancer therapy", "TREATMENT", 191, 207], ["IntroductionDonor", "TREATMENT", 208, 225], ["recipient antigenic disparity", "PROBLEM", 226, 255], ["donor T cells", "PROBLEM", 257, 270], ["tissue injury", "PROBLEM", 276, 289], ["inflammation", "PROBLEM", 303, 315], ["the conditioning regimen", "TREATMENT", 323, 347], ["GVHD", "PROBLEM", 366, 370], ["leukocytes", "TEST", 477, 487], ["epithelial and endothelial cells", "PROBLEM", 524, 556], ["GVHD", "OBSERVATION", 67, 71], ["graft", "OBSERVATION", 111, 116], ["tumor", "OBSERVATION", 124, 129], ["cancer", "OBSERVATION", 193, 199], ["tissue", "ANATOMY", 276, 282], ["injury", "OBSERVATION", 283, 289], ["inflammation", "OBSERVATION", 303, 315], ["GVHD", "OBSERVATION", 366, 370], ["intestines", "ANATOMY", 396, 406], ["liver", "ANATOMY", 408, 413], ["skin", "ANATOMY", 415, 419], ["thymus", "ANATOMY", 424, 430], ["leukocytes", "ANATOMY", 477, 487], ["epithelial", "ANATOMY_MODIFIER", 524, 534], ["endothelial cells", "OBSERVATION", 539, 556], ["prominent", "OBSERVATION_MODIFIER", 568, 577], ["components", "OBSERVATION_MODIFIER", 578, 588], ["parenchyma", "ANATOMY_MODIFIER", 596, 606], ["GVHD", "OBSERVATION", 630, 634]]], ["In addition, Ceacam1 is upregulated on many tumors.", [["tumors", "ANATOMY", 44, 50], ["tumors", "DISEASE", 44, 50], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 13, 20], ["tumors", "CANCER", 44, 50], ["Ceacam1", "PROTEIN", 13, 20], ["many tumors", "PROBLEM", 39, 50], ["Ceacam1", "OBSERVATION", 13, 20], ["many", "OBSERVATION_MODIFIER", 39, 43], ["tumors", "OBSERVATION", 44, 50]]], ["In this report, we assess the impact of Ceacam1 on alloreactive T cells in the donor allograft, as well as the effects of Ceacam1 deficiency on recipients of allo-BMT with respect to GVHD and GVT activity.Ceacam1 on donor T cells and recipient tissues can regulate GVHD mortality ::: ResultsWe assessed Ceacam1 regulation of GHVD on donor T cells or recipients in two well-described major histocompatibility complex (MHC) class I/II-disparate models C57BL/6 (B6, H-2b)\u2192BALB/c (H-2d) and BALB/c\u2192B10.BR (H-2k).", [["alloreactive T cells", "ANATOMY", 51, 71], ["allograft", "ANATOMY", 85, 94], ["T cells", "ANATOMY", 222, 229], ["tissues", "ANATOMY", 244, 251], ["T cells", "ANATOMY", 339, 346], ["Ceacam1", "CHEMICAL", 40, 47], ["Ceacam1", "CHEMICAL", 122, 129], ["GVHD", "DISEASE", 183, 187], ["Ceacam1", "CHEMICAL", 205, 212], ["GVHD", "DISEASE", 265, 269], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 40, 47], ["alloreactive T cells", "CELL", 51, 71], ["allograft", "ORGAN", 85, 94], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 122, 129], ["recipients", "ORGANISM", 144, 154], ["GVT", "CANCER", 192, 195], ["Ceacam1", "SIMPLE_CHEMICAL", 205, 212], ["donor T cells", "CELL", 216, 229], ["recipient tissues", "TISSUE", 234, 251], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 303, 310], ["GHVD", "GENE_OR_GENE_PRODUCT", 325, 329], ["donor T cells", "CELL", 333, 346], ["recipients", "ORGANISM", 350, 360], ["C57BL/6", "ORGANISM", 450, 457], ["B6, H-2b", "ORGANISM", 459, 467], ["H-2k", "GENE_OR_GENE_PRODUCT", 502, 506], ["Ceacam1", "PROTEIN", 40, 47], ["alloreactive T cells", "CELL_TYPE", 51, 71], ["Ceacam1", "PROTEIN", 122, 129], ["Ceacam1", "PROTEIN", 205, 212], ["donor T cells", "CELL_TYPE", 216, 229], ["Ceacam1", "PROTEIN", 303, 310], ["GHVD", "PROTEIN", 325, 329], ["donor T cells", "CELL_TYPE", 333, 346], ["major histocompatibility complex", "PROTEIN", 383, 415], ["MHC", "PROTEIN", 417, 420], ["BALB/c\u2192B10", "CELL_LINE", 487, 497], ["H-2k", "PROTEIN", 502, 506], ["Ceacam1", "PROBLEM", 40, 47], ["alloreactive T cells", "TREATMENT", 51, 71], ["the donor allograft", "TREATMENT", 75, 94], ["Ceacam1 deficiency", "PROBLEM", 122, 140], ["allo-BMT", "TREATMENT", 158, 166], ["GVHD", "PROBLEM", 183, 187], ["GVT activity", "PROBLEM", 192, 204], ["Ceacam1 on donor T cells", "TREATMENT", 205, 229], ["GHVD", "PROBLEM", 325, 329], ["donor T cells", "TREATMENT", 333, 346], ["B6", "TEST", 459, 461], ["BALB", "TEST", 469, 473], ["BALB/c\u2192B10", "TREATMENT", 487, 497], ["Ceacam1", "OBSERVATION", 40, 47], ["alloreactive T cells", "OBSERVATION", 51, 71], ["donor allograft", "OBSERVATION", 79, 94], ["Ceacam1 deficiency", "OBSERVATION", 122, 140], ["GVHD", "OBSERVATION", 183, 187], ["GVT activity", "OBSERVATION", 192, 204], ["GVHD", "OBSERVATION", 265, 269]]], ["We used Ceacam1\u2212/\u2212 B6 mice [28], Ceacam1-transgenic (Tg) B6 mice (described in Figure S1), and Ceacam1\u2212/\u2212 BALB/c mice [28] as the source of donor T cells or recipients.", [["T cells", "ANATOMY", 146, 153], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 33, 40], ["-transgenic (Tg) B6 mice", "ORGANISM", 40, 64], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 95, 102], ["donor T cells", "CELL", 140, 153], ["recipients", "ORGANISM", 157, 167], ["Ceacam1", "PROTEIN", 33, 40], ["Ceacam1", "PROTEIN", 95, 102], ["donor T cells", "CELL_TYPE", 140, 153], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 113, 117], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 113, 117], ["Ceacam1\u2212/\u2212 B6 mice", "TREATMENT", 8, 26], ["Ceacam1-transgenic (Tg) B6 mice", "TREATMENT", 33, 64], ["Ceacam1", "TREATMENT", 95, 102], ["donor T cells", "TREATMENT", 140, 153]]], ["In all experiments, recipients received split-dose lethal irradiation (BALB/c: 8.5 Gy, B10.BR: 11 Gy) and a graft of 5\u00d7106 allogeneic T cell depleted bone marrow (TCD-BM) of wildtype (WT) origin, with or without splenic T cells.Ceacam1 on donor T cells and recipient tissues can regulate GVHD mortality ::: ResultsWe first transplanted irradiated BALB/c mice with B6 TCD-BM with WT or Ceacam1\u2212/\u2212 T cells, and observed that recipients of Ceacam1\u2212/\u2212 T cells had significantly increased mortality compared to recipients of WT T cells (Figure 1A, left).", [["graft", "ANATOMY", 108, 113], ["T cell", "ANATOMY", 134, 140], ["bone marrow", "ANATOMY", 150, 161], ["TCD-BM", "ANATOMY", 163, 169], ["splenic T cells", "ANATOMY", 212, 227], ["T cells", "ANATOMY", 245, 252], ["tissues", "ANATOMY", 267, 274], ["B6 TCD-BM", "ANATOMY", 364, 373], ["Ceacam1\u2212/\u2212 T cells", "ANATOMY", 385, 403], ["Ceacam1\u2212/\u2212 T cells", "ANATOMY", 437, 455], ["T cells", "ANATOMY", 523, 530], ["Ceacam1", "CHEMICAL", 228, 235], ["GVHD", "DISEASE", 288, 292], ["recipients", "ORGANISM", 20, 30], ["graft", "TISSUE", 108, 113], ["T cell", "CELL", 134, 140], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 150, 161], ["TCD-BM", "CELL", 163, 169], ["splenic T cells", "CELL", 212, 227], ["Ceacam1", "SIMPLE_CHEMICAL", 228, 235], ["donor T cells", "CELL", 239, 252], ["recipient tissues", "TISSUE", 257, 274], ["BALB/c mice", "ORGANISM", 347, 358], ["B6 TCD-BM", "CELL", 364, 373], ["Ceacam1\u2212/\u2212 T cells", "CELL", 385, 403], ["recipients", "ORGANISM", 423, 433], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 437, 444], ["WT T cells", "CELL", 520, 530], ["splenic T cells", "CELL_TYPE", 212, 227], ["Ceacam1", "PROTEIN", 228, 235], ["donor T cells", "CELL_TYPE", 239, 252], ["Ceacam1\u2212/\u2212 T cells", "CELL_LINE", 385, 403], ["Ceacam1\u2212/\u2212 T cells", "CELL_LINE", 437, 455], ["WT T cells", "CELL_TYPE", 520, 530], ["mice", "SPECIES", 354, 358], ["mice", "SPECIES", 354, 358], ["split-dose lethal irradiation", "TREATMENT", 40, 69], ["a graft of 5\u00d7106 allogeneic T cell depleted bone marrow", "TREATMENT", 106, 161], ["wildtype (WT) origin", "PROBLEM", 174, 194], ["splenic T cells", "PROBLEM", 212, 227], ["Ceacam1 on donor T cells", "TREATMENT", 228, 252], ["B6 TCD", "TEST", 364, 370], ["WT", "TEST", 379, 381], ["Ceacam1\u2212/\u2212 T cells", "TREATMENT", 385, 403], ["Ceacam1", "TEST", 437, 444], ["T cells", "PROBLEM", 448, 455], ["significantly increased mortality", "PROBLEM", 460, 493], ["WT T cells", "PROBLEM", 520, 530], ["graft", "OBSERVATION", 108, 113], ["allogeneic T cell depleted bone marrow", "OBSERVATION", 123, 161], ["without", "UNCERTAINTY", 204, 211], ["splenic", "ANATOMY", 212, 219], ["T cells", "OBSERVATION", 220, 227], ["GVHD", "OBSERVATION", 288, 292], ["BM", "ANATOMY", 371, 373], ["left", "ANATOMY_MODIFIER", 543, 547]]], ["We confirmed this in a second MHC-disparate allo-BMT model, BALB/c\u2192B10.BR (Figure 1A, right).Ceacam1 on donor T cells and recipient tissues can regulate GVHD mortality ::: ResultsWe next asked whether T cells overexpressing Ceacam1 would cause less disease, and transplanted BALB/c recipients with 0.5\u00d7106 or 1\u00d7106 donor WT or Ceacam 1-Tg T cells.", [["T cells", "ANATOMY", 110, 117], ["tissues", "ANATOMY", 132, 139], ["T cells", "ANATOMY", 201, 208], ["Ceacam 1-Tg T cells", "ANATOMY", 327, 346], ["Ceacam1", "CHEMICAL", 93, 100], ["GVHD", "DISEASE", 153, 157], ["Ceacam1", "CHEMICAL", 224, 231], ["BALB/c\u2192B10", "ORGANISM", 60, 70], ["Ceacam1", "SIMPLE_CHEMICAL", 93, 100], ["donor T cells", "CELL", 104, 117], ["recipient tissues", "TISSUE", 122, 139], ["T cells", "CELL", 201, 208], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 224, 231], ["BALB/c recipients", "ORGANISM", 275, 292], ["Ceacam 1", "GENE_OR_GENE_PRODUCT", 327, 335], ["MHC", "PROTEIN", 30, 33], ["BALB/c\u2192B10", "CELL_LINE", 60, 70], ["BR", "PROTEIN", 71, 73], ["Ceacam1", "PROTEIN", 93, 100], ["donor T cells", "CELL_TYPE", 104, 117], ["T cells", "CELL_TYPE", 201, 208], ["Ceacam1", "PROTEIN", 224, 231], ["Ceacam 1-Tg T cells", "CELL_LINE", 327, 346], ["disparate allo-BMT model", "TREATMENT", 34, 58], ["BALB/c\u2192B10", "TREATMENT", 60, 70], ["Ceacam1 on donor T cells", "TREATMENT", 93, 117], ["less disease", "PROBLEM", 244, 256], ["transplanted BALB/c recipients", "TREATMENT", 262, 292], ["donor WT", "TEST", 315, 323], ["Ceacam", "TEST", 327, 333], ["right", "ANATOMY_MODIFIER", 86, 91], ["GVHD", "OBSERVATION", 153, 157]]], ["At both doses, recipients of Ceacam1-Tg T cells showed attenuated mortality (Figure 1B).Ceacam1 on donor T cells and recipient tissues can regulate GVHD mortality ::: ResultsFinally, we assessed the role of Ceacam1 on tissues of allo-BMT recipients, and transferred TCD-BM+T cells into WT vs. Ceacam1\u2212/\u2212 BALB/c recipients.", [["Ceacam1-Tg T cells", "ANATOMY", 29, 47], ["T cells", "ANATOMY", 105, 112], ["tissues", "ANATOMY", 127, 134], ["tissues", "ANATOMY", 218, 225], ["TCD-BM+T cells", "ANATOMY", 266, 280], ["Ceacam1", "CHEMICAL", 88, 95], ["GVHD", "DISEASE", 148, 152], ["recipients", "ORGANISM", 15, 25], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 29, 36], ["Ceacam1", "SIMPLE_CHEMICAL", 88, 95], ["donor T cells", "CELL", 99, 112], ["recipient tissues", "TISSUE", 117, 134], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 207, 214], ["tissues", "TISSUE", 218, 225], ["allo-BMT recipients", "CELL", 229, 248], ["TCD-BM+T cells", "CELL", 266, 280], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 293, 300], ["Ceacam1-Tg T cells", "CELL_LINE", 29, 47], ["Ceacam1", "PROTEIN", 88, 95], ["donor T cells", "CELL_TYPE", 99, 112], ["Ceacam1", "PROTEIN", 207, 214], ["TCD-BM+T cells", "CELL_TYPE", 266, 280], ["Ceacam1", "PROTEIN", 293, 300], ["Ceacam1", "TEST", 29, 36], ["attenuated mortality", "PROBLEM", 55, 75], ["Ceacam1 on donor T cells", "TREATMENT", 88, 112], ["allo-BMT recipients", "TREATMENT", 229, 248], ["Ceacam1", "TREATMENT", 293, 300], ["BALB/c recipients", "TREATMENT", 304, 321], ["GVHD", "OBSERVATION", 148, 152], ["BM", "ANATOMY", 270, 272]]], ["This revealed that Ceacam1\u2212/\u2212 recipients had increased early (but not overall) mortality, with nearly 50% of mice succumbing within the first week (Figure 1C).Ceacam1 is an important regulator of GVHD target organ damage ::: ResultsWe next asked whether Ceacam1 regulated GVHD target organ damage, and again assessed effects of Ceacam1 deficiency or overexpression on donor T cells, and Ceacam1\u2212/\u2212 allo-BMT recipients.Ceacam1 is an important regulator of GVHD target organ damage ::: ResultsWe observed that recipients of Ceacam1\u2212/\u2212 T cells had more severe large intestinal GVHD (Figure 2A).", [["organ", "ANATOMY", 208, 213], ["organ", "ANATOMY", 284, 289], ["donor T cells", "ANATOMY", 368, 381], ["organ", "ANATOMY", 467, 472], ["Ceacam1\u2212/\u2212 T cells", "ANATOMY", 522, 540], ["intestinal", "ANATOMY", 563, 573], ["GVHD", "DISEASE", 196, 200], ["organ damage", "DISEASE", 208, 220], ["GVHD", "DISEASE", 272, 276], ["organ damage", "DISEASE", 284, 296], ["Ceacam1", "CHEMICAL", 328, 335], ["GVHD", "DISEASE", 455, 459], ["organ damage", "DISEASE", 467, 479], ["GVHD", "DISEASE", 574, 578], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 19, 27], ["mice", "ORGANISM", 109, 113], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 159, 166], ["organ", "ORGAN", 208, 213], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 254, 261], ["organ", "ORGAN", 284, 289], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 328, 335], ["donor T cells", "CELL", 368, 381], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 387, 395], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 418, 425], ["organ", "ORGAN", 467, 472], ["recipients", "ORGANISM", 508, 518], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 522, 530], ["intestinal", "ORGAN", 563, 573], ["Ceacam1", "PROTEIN", 159, 166], ["Ceacam1", "PROTEIN", 254, 261], ["Ceacam1", "PROTEIN", 328, 335], ["donor T cells", "CELL_TYPE", 368, 381], ["Ceacam1", "PROTEIN", 418, 425], ["Ceacam1\u2212/\u2212 T cells", "CELL_LINE", 522, 540], ["mice", "SPECIES", 109, 113], ["mice", "SPECIES", 109, 113], ["Ceacam1\u2212/\u2212 recipients", "TREATMENT", 19, 40], ["Ceacam1", "TREATMENT", 159, 166], ["Ceacam1 regulated GVHD target organ damage", "PROBLEM", 254, 296], ["Ceacam1 deficiency", "PROBLEM", 328, 346], ["donor T cells", "TREATMENT", 368, 381], ["Ceacam1\u2212", "TREATMENT", 387, 395], ["allo-BMT recipients", "TREATMENT", 398, 417], ["Ceacam1", "TREATMENT", 418, 425], ["Ceacam1\u2212", "TEST", 522, 530], ["T cells", "PROBLEM", 533, 540], ["severe large intestinal GVHD", "PROBLEM", 550, 578], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["Ceacam1 deficiency", "OBSERVATION", 328, 346], ["severe", "OBSERVATION_MODIFIER", 550, 556], ["large", "OBSERVATION_MODIFIER", 557, 562], ["intestinal", "ANATOMY", 563, 573], ["GVHD", "OBSERVATION", 574, 578]]], ["Surprisingly however, these mice exhibited less thymic GVHD, as determined by thymic cellularity and numbers of CD4+CD8+ double-positive (DP) thymocytes (Figure 2).", [["thymic", "ANATOMY", 48, 54], ["thymic", "ANATOMY", 78, 84], ["CD4+CD8+ double-positive (DP) thymocytes", "ANATOMY", 112, 152], ["GVHD", "DISEASE", 55, 59], ["mice", "ORGANISM", 28, 32], ["thymic GVHD", "CANCER", 48, 59], ["CD4", "GENE_OR_GENE_PRODUCT", 112, 115], ["CD8", "GENE_OR_GENE_PRODUCT", 116, 119], ["CD4", "PROTEIN", 112, 115], ["CD8", "PROTEIN", 116, 119], ["double-positive (DP) thymocytes", "CELL_TYPE", 121, 152], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 28, 32], ["less thymic GVHD", "PROBLEM", 43, 59], ["thymic cellularity", "TEST", 78, 96], ["CD4", "TEST", 112, 115], ["CD8", "TEST", 116, 119], ["less", "OBSERVATION_MODIFIER", 43, 47], ["thymic GVHD", "OBSERVATION", 48, 59], ["thymic", "ANATOMY", 78, 84], ["cellularity", "OBSERVATION", 85, 96], ["thymocytes", "ANATOMY", 142, 152]]], ["Thymic cellularity from age/sex-matched non-transplanted animals are shown in Figure S2.", [["Thymic", "ANATOMY", 0, 6], ["Thymic cellularity", "CANCER", 0, 18], ["Thymic cellularity", "PROBLEM", 0, 18], ["cellularity", "OBSERVATION", 7, 18], ["Figure S2", "OBSERVATION", 78, 87]]], ["We also observed a modest trend towards less skin GVHD in recipients of Ceacam1\u2212/\u2212 T cells (Figure 2C), suggesting that Ceacam1\u2212/\u2212 T cells caused preferential damage to the (large) intestines.Ceacam1 is an important regulator of GVHD target organ damage ::: ResultsIn experiments comparing recipients of WT and Ceacam1-Tg T cells on day 21 post-transplant, we found that recipients of Ceacam1-Tg T cells demonstrated significantly less GVHD of the liver, intestines, and thymus compared to recipients of WT T cells, but similar skin GVHD (Figures 2D\u2013F).", [["skin", "ANATOMY", 45, 49], ["Ceacam1\u2212/\u2212 T cells", "ANATOMY", 72, 90], ["Ceacam1\u2212/\u2212 T cells", "ANATOMY", 120, 138], ["intestines", "ANATOMY", 181, 191], ["organ", "ANATOMY", 241, 246], ["Ceacam1-Tg T cells", "ANATOMY", 311, 329], ["Ceacam1-Tg T cells", "ANATOMY", 385, 403], ["liver", "ANATOMY", 448, 453], ["intestines", "ANATOMY", 455, 465], ["thymus", "ANATOMY", 471, 477], ["WT T cells", "ANATOMY", 504, 514], ["skin", "ANATOMY", 528, 532], ["GVHD", "DISEASE", 50, 54], ["GVHD", "DISEASE", 229, 233], ["organ damage", "DISEASE", 241, 253], ["GVHD", "DISEASE", 436, 440], ["GVHD", "DISEASE", 533, 537], ["skin", "ORGAN", 45, 49], ["recipients", "ORGANISM", 58, 68], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 72, 79], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 120, 127], ["intestines", "ORGAN", 181, 191], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 192, 199], ["organ", "ORGAN", 241, 246], ["recipients", "ORGANISM", 290, 300], ["Ceacam1-Tg T cells", "CELL", 311, 329], ["recipients", "ORGANISM", 371, 381], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 385, 392], ["liver", "ORGAN", 448, 453], ["intestines", "ORGAN", 455, 465], ["thymus", "ORGAN", 471, 477], ["recipients", "ORGANISM", 490, 500], ["WT T cells", "CELL", 504, 514], ["skin", "ORGAN", 528, 532], ["Ceacam1\u2212/\u2212 T cells", "CELL_LINE", 72, 90], ["Ceacam1\u2212/\u2212 T cells", "CELL_TYPE", 120, 138], ["Ceacam1", "PROTEIN", 192, 199], ["Ceacam1-Tg T cells", "CELL_LINE", 311, 329], ["Ceacam1-Tg T cells", "CELL_LINE", 385, 403], ["WT T cells", "CELL_TYPE", 504, 514], ["a modest trend", "PROBLEM", 17, 31], ["less skin GVHD", "PROBLEM", 40, 54], ["Ceacam1", "TEST", 72, 79], ["T cells", "PROBLEM", 83, 90], ["Ceacam1", "TEST", 120, 127], ["T cells", "PROBLEM", 131, 138], ["preferential damage to the (large) intestines", "PROBLEM", 146, 191], ["Ceacam1", "TREATMENT", 192, 199], ["WT", "TEST", 304, 306], ["Ceacam1", "TEST", 311, 318], ["transplant", "TREATMENT", 345, 355], ["Ceacam1", "TEST", 385, 392], ["Tg T cells", "TEST", 393, 403], ["significantly less GVHD of the liver", "PROBLEM", 417, 453], ["thymus", "PROBLEM", 471, 477], ["WT T cells", "PROBLEM", 504, 514], ["similar skin GVHD", "PROBLEM", 520, 537], ["modest", "OBSERVATION_MODIFIER", 19, 25], ["skin", "ANATOMY", 45, 49], ["GVHD", "OBSERVATION", 50, 54], ["preferential damage", "OBSERVATION", 146, 165], ["intestines", "ANATOMY", 181, 191], ["significantly", "OBSERVATION_MODIFIER", 417, 430], ["less", "OBSERVATION_MODIFIER", 431, 435], ["GVHD", "OBSERVATION", 436, 440], ["liver", "ANATOMY", 448, 453], ["intestines", "ANATOMY", 455, 465], ["thymus", "ANATOMY", 471, 477], ["skin", "ANATOMY", 528, 532], ["GVHD", "OBSERVATION", 533, 537]]], ["This appears to suggest that Ceacam1-Tg T cells caused less GVHD overall, with relatively little organ specificity.Ceacam1 is an important regulator of GVHD target organ damage ::: ResultsFinally, we assessed Ceacam1\u2212/\u2212 allo-BMT recipients on day 14 post-transplant.", [["Ceacam1-Tg T cells", "ANATOMY", 29, 47], ["organ", "ANATOMY", 97, 102], ["organ", "ANATOMY", 164, 169], ["GVHD", "DISEASE", 60, 64], ["GVHD", "DISEASE", 152, 156], ["organ damage", "DISEASE", 164, 176], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 29, 36], ["organ", "ORGAN", 97, 102], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 115, 122], ["organ", "ORGAN", 164, 169], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 209, 216], ["Ceacam1", "PROTEIN", 29, 36], ["Tg T cells", "CELL_TYPE", 37, 47], ["Ceacam1", "PROTEIN", 115, 122], ["Ceacam1", "PROTEIN", 209, 216], ["Ceacam1", "TEST", 29, 36], ["less GVHD", "PROBLEM", 55, 64], ["Ceacam1", "TREATMENT", 115, 122], ["Ceacam1", "TEST", 209, 216], ["allo-BMT recipients", "TREATMENT", 220, 239], ["transplant", "TREATMENT", 255, 265], ["appears to suggest", "UNCERTAINTY", 5, 23], ["Ceacam1", "OBSERVATION", 29, 36], ["less", "OBSERVATION_MODIFIER", 55, 59], ["GVHD", "OBSERVATION", 60, 64], ["transplant", "OBSERVATION", 255, 265]]], ["In correspondence with increased early GVHD mortality, Ceacam1\u2212/\u2212 allo-BMT recipients showed increased large bowel damage and thymic GVHD (Figure 2G\u2013H).Ceacam1 regulates donor T cell numbers in lymphoid tissues and target organs during GVHD ::: ResultsWe next assessed the numbers of donor CD4 and CD8 effector T cells after transfer of Ceacam1\u2212/\u2212 or Ceacam1-Tg T cell-containing allografts, or in Ceacam1\u2212/\u2212 allo-BMT recipients.Ceacam1 regulates donor T cell numbers in lymphoid tissues and target organs during GVHD ::: ResultsComparing recipients of WT T cells with those receiving Ceacam1\u2212/\u2212 T cells, we observed increased numbers of Ceacam1\u2212/\u2212 donor alloactivated effector T cells in the spleen, MLN, and IEL of allo-BMT recipients (Figure 3A), which was associated with a concomitant decrease in the number of Ceacam1\u2212/\u2212 alloactivated CD4 and CD8 T cells in the PLN and liver.Ceacam1 regulates donor T cell numbers in lymphoid tissues and target organs during GVHD ::: ResultsWhen we analyzed organs of recipients of allografts containing WT vs. Ceacam1-Tg T cells, we noted decreased numbers of donor effector T cells in the MLN, PLN, and liver (Figure 3B).", [["bowel", "ANATOMY", 109, 114], ["thymic", "ANATOMY", 126, 132], ["T cell", "ANATOMY", 176, 182], ["lymphoid tissues", "ANATOMY", 194, 210], ["organs", "ANATOMY", 222, 228], ["CD4", "ANATOMY", 290, 293], ["CD8 effector T cells", "ANATOMY", 298, 318], ["Ceacam1-Tg T cell", "ANATOMY", 351, 368], ["allografts", "ANATOMY", 380, 390], ["T cell", "ANATOMY", 453, 459], ["lymphoid tissues", "ANATOMY", 471, 487], ["organs", "ANATOMY", 499, 505], ["WT T cells", "ANATOMY", 553, 563], ["Ceacam1\u2212/\u2212 T cells", "ANATOMY", 585, 603], ["effector T cells", "ANATOMY", 669, 685], ["spleen", "ANATOMY", 693, 699], ["MLN", "ANATOMY", 701, 704], ["IEL", "ANATOMY", 710, 713], ["CD4", "ANATOMY", 841, 844], ["CD8 T cells", "ANATOMY", 849, 860], ["PLN", "ANATOMY", 868, 871], ["liver", "ANATOMY", 876, 881], ["T cell", "ANATOMY", 906, 912], ["lymphoid tissues", "ANATOMY", 924, 940], ["organs", "ANATOMY", 952, 958], ["organs", "ANATOMY", 999, 1005], ["allografts", "ANATOMY", 1023, 1033], ["Ceacam1-Tg T cells", "ANATOMY", 1052, 1070], ["effector T cells", "ANATOMY", 1108, 1124], ["MLN", "ANATOMY", 1132, 1135], ["PLN", "ANATOMY", 1137, 1140], ["liver", "ANATOMY", 1146, 1151], ["GVHD", "DISEASE", 39, 43], ["bowel damage", "DISEASE", 109, 121], ["GVHD", "DISEASE", 133, 137], ["GVHD", "DISEASE", 236, 240], ["GVHD", "DISEASE", 513, 517], ["GVHD", "DISEASE", 966, 970], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 55, 62], ["bowel", "ORGAN", 109, 114], ["thymic", "ORGAN", 126, 132], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 152, 159], ["donor T cell", "CELL", 170, 182], ["lymphoid tissues", "TISSUE", 194, 210], ["organs", "ORGAN", 222, 228], ["CD4", "GENE_OR_GENE_PRODUCT", 290, 293], ["CD8", "GENE_OR_GENE_PRODUCT", 298, 301], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 337, 345], ["\u2212", "GENE_OR_GENE_PRODUCT", 346, 347], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 351, 358], ["allografts", "TISSUE", 380, 390], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 398, 406], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 429, 436], ["donor T cell", "CELL", 447, 459], ["lymphoid tissues", "TISSUE", 471, 487], ["organs", "ORGAN", 499, 505], ["recipients", "ORGANISM", 539, 549], ["WT T cells", "CELL", 553, 563], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 585, 592], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 638, 646], ["T cells", "CELL", 678, 685], ["spleen", "ORGAN", 693, 699], ["MLN", "CELL", 701, 704], ["IEL", "CELL", 710, 713], ["allo-BMT recipients", "CELL", 717, 736], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 816, 824], ["CD4", "GENE_OR_GENE_PRODUCT", 841, 844], ["CD8 T", "GENE_OR_GENE_PRODUCT", 849, 854], ["PLN", "MULTI-TISSUE_STRUCTURE", 868, 871], ["liver", "ORGAN", 876, 881], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 882, 889], ["donor T cell", "CELL", 900, 912], ["lymphoid tissues", "TISSUE", 924, 940], ["organs", "ORGAN", 952, 958], ["organs", "ORGAN", 999, 1005], ["recipients", "ORGANISM", 1009, 1019], ["allografts", "TISSUE", 1023, 1033], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 1052, 1059], ["effector T cells", "CELL", 1108, 1124], ["MLN", "MULTI-TISSUE_STRUCTURE", 1132, 1135], ["PLN", "MULTI-TISSUE_STRUCTURE", 1137, 1140], ["liver", "ORGAN", 1146, 1151], ["Ceacam1", "PROTEIN", 55, 62], ["Ceacam1", "PROTEIN", 152, 159], ["donor CD4 and CD8 effector T cells", "CELL_TYPE", 284, 318], ["Ceacam1\u2212", "PROTEIN", 337, 345], ["Ceacam1", "PROTEIN", 351, 358], ["Ceacam1", "PROTEIN", 429, 436], ["WT T cells", "CELL_TYPE", 553, 563], ["Ceacam1\u2212/\u2212 T cells", "CELL_LINE", 585, 603], ["Ceacam1\u2212/\u2212 donor alloactivated effector T cells", "CELL_TYPE", 638, 685], ["MLN", "CELL_TYPE", 701, 704], ["IEL", "CELL_TYPE", 710, 713], ["Ceacam1\u2212/\u2212 alloactivated CD4 and CD8 T cells", "CELL_TYPE", 816, 860], ["PLN", "CELL_TYPE", 868, 871], ["Ceacam1", "PROTEIN", 882, 889], ["Ceacam1-Tg T cells", "CELL_LINE", 1052, 1070], ["donor effector T cells", "CELL_TYPE", 1102, 1124], ["MLN", "CELL_TYPE", 1132, 1135], ["PLN", "CELL_TYPE", 1137, 1140], ["increased early GVHD mortality", "PROBLEM", 23, 53], ["Ceacam1", "TREATMENT", 55, 62], ["allo-BMT recipients", "TREATMENT", 66, 85], ["increased large bowel damage", "PROBLEM", 93, 121], ["thymic GVHD", "PROBLEM", 126, 137], ["Ceacam1 regulates", "TREATMENT", 152, 169], ["donor T cell numbers", "TEST", 170, 190], ["donor CD4", "TEST", 284, 293], ["Ceacam1\u2212", "TEST", 337, 345], ["Ceacam1", "TEST", 351, 358], ["Tg T cell", "TREATMENT", 359, 368], ["allografts", "TREATMENT", 380, 390], ["allo-BMT recipients", "TREATMENT", 409, 428], ["Ceacam1 regulates", "TREATMENT", 429, 446], ["donor T cell numbers", "TEST", 447, 467], ["WT T cells", "PROBLEM", 553, 563], ["Ceacam1", "TEST", 585, 592], ["T cells", "PROBLEM", 596, 603], ["Ceacam1\u2212", "TEST", 638, 646], ["allo-BMT recipients", "TREATMENT", 717, 736], ["a concomitant decrease", "PROBLEM", 776, 798], ["Ceacam1\u2212", "TEST", 816, 824], ["Ceacam1 regulates", "TREATMENT", 882, 899], ["donor T cell numbers", "TEST", 900, 920], ["recipients of allografts", "TREATMENT", 1009, 1033], ["Ceacam1", "TEST", 1052, 1059], ["donor effector T cells", "PROBLEM", 1102, 1124], ["PLN", "TEST", 1137, 1140], ["increased", "OBSERVATION_MODIFIER", 23, 32], ["early", "OBSERVATION_MODIFIER", 33, 38], ["GVHD", "OBSERVATION", 39, 43], ["increased", "OBSERVATION_MODIFIER", 93, 102], ["large", "OBSERVATION_MODIFIER", 103, 108], ["bowel", "ANATOMY", 109, 114], ["damage", "OBSERVATION", 115, 121], ["thymic GVHD", "OBSERVATION", 126, 137], ["donor T cell numbers", "OBSERVATION", 170, 190], ["lymphoid tissues", "OBSERVATION", 194, 210], ["GVHD", "OBSERVATION", 236, 240], ["donor CD4", "OBSERVATION", 284, 293], ["donor T cell numbers", "OBSERVATION", 447, 467], ["lymphoid tissues", "OBSERVATION", 471, 487], ["GVHD", "OBSERVATION", 513, 517], ["increased", "OBSERVATION_MODIFIER", 617, 626], ["spleen", "ANATOMY", 693, 699], ["MLN", "ANATOMY", 701, 704], ["concomitant", "OBSERVATION_MODIFIER", 778, 789], ["decrease", "OBSERVATION_MODIFIER", 790, 798], ["PLN", "ANATOMY", 868, 871], ["liver", "ANATOMY", 876, 881], ["donor T cell numbers", "OBSERVATION", 900, 920], ["lymphoid tissues", "OBSERVATION", 924, 940], ["GVHD", "OBSERVATION", 966, 970], ["allografts", "OBSERVATION", 1023, 1033], ["decreased", "OBSERVATION_MODIFIER", 1081, 1090], ["donor effector T cells", "OBSERVATION", 1102, 1124], ["MLN", "ANATOMY", 1132, 1135], ["PLN", "ANATOMY", 1137, 1140], ["liver", "ANATOMY", 1146, 1151]]], ["Via histopathological analysis, we also observed decreased numbers of total lymphocytic infiltrates into the liver, small and large bowels by histopathology (Figure 3B), as well as decreased neutrophilic infiltrates in these organs (data not shown).", [["lymphocytic infiltrates", "ANATOMY", 76, 99], ["liver", "ANATOMY", 109, 114], ["bowels", "ANATOMY", 132, 138], ["neutrophilic infiltrates", "ANATOMY", 191, 215], ["organs", "ANATOMY", 225, 231], ["lymphocytic infiltrates", "TISSUE", 76, 99], ["liver", "ORGAN", 109, 114], ["bowels", "ORGAN", 132, 138], ["neutrophilic infiltrates", "PATHOLOGICAL_FORMATION", 191, 215], ["organs", "ORGAN", 225, 231], ["histopathological analysis", "TEST", 4, 30], ["total lymphocytic infiltrates into the liver", "PROBLEM", 70, 114], ["small and large bowels", "PROBLEM", 116, 138], ["decreased neutrophilic infiltrates in these organs", "PROBLEM", 181, 231], ["decreased", "OBSERVATION_MODIFIER", 49, 58], ["numbers", "OBSERVATION_MODIFIER", 59, 66], ["total", "OBSERVATION_MODIFIER", 70, 75], ["lymphocytic infiltrates", "OBSERVATION", 76, 99], ["liver", "ANATOMY", 109, 114], ["small", "OBSERVATION_MODIFIER", 116, 121], ["large", "ANATOMY_MODIFIER", 126, 131], ["bowels", "ANATOMY", 132, 138], ["decreased", "OBSERVATION_MODIFIER", 181, 190], ["neutrophilic", "OBSERVATION_MODIFIER", 191, 203], ["infiltrates", "OBSERVATION", 204, 215], ["organs", "ANATOMY", 225, 231]]], ["Finally, we assessed infiltrating T cells in WT and Ceacam1\u2212/\u2212 allo-BMT recipients, and observed increased numbers of donor alloactivated effector T cells in the MLN and IEL of Ceacam1\u2212/\u2212 allo-BMT recipients, but decreased numbers of these cells in the PLN and liver (Figure 3C).Ceacam1 regulates the sensitivity of the small intestine to radiation injury ::: ResultsThe accelerated early mortality of Ceacam1\u2212/\u2212 allo-BMT recipients, together with increased accumulation of donor T cells in GI tract and mesenteric lymph nodes, but decreased numbers peripheral lymph nodes (Figure 3C), led us to ask whether Ceacam1 had differential effects in regulating GVHD target organ damage for various target organs and tissues.", [["infiltrating T cells", "ANATOMY", 21, 41], ["effector T cells", "ANATOMY", 138, 154], ["MLN", "ANATOMY", 162, 165], ["IEL", "ANATOMY", 170, 173], ["cells", "ANATOMY", 240, 245], ["PLN", "ANATOMY", 253, 256], ["liver", "ANATOMY", 261, 266], ["small intestine", "ANATOMY", 320, 335], ["donor T cells", "ANATOMY", 474, 487], ["GI tract", "ANATOMY", 491, 499], ["mesenteric lymph nodes", "ANATOMY", 504, 526], ["peripheral lymph nodes", "ANATOMY", 550, 572], ["organ", "ANATOMY", 667, 672], ["organs", "ANATOMY", 699, 705], ["tissues", "ANATOMY", 710, 717], ["Ceacam1", "CHEMICAL", 279, 286], ["Ceacam1", "CHEMICAL", 608, 615], ["GVHD", "DISEASE", 655, 659], ["organ damage", "DISEASE", 667, 679], ["infiltrating T cells", "CELL", 21, 41], ["WT", "CELL", 45, 47], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 52, 60], ["effector T cells", "CELL", 138, 154], ["MLN", "CELL", 162, 165], ["IEL", "CELL", 170, 173], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 177, 185], ["cells", "CELL", 240, 245], ["PLN", "MULTI-TISSUE_STRUCTURE", 253, 256], ["liver", "ORGAN", 261, 266], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 279, 286], ["small intestine", "ORGAN", 320, 335], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 402, 409], ["T cells", "CELL", 480, 487], ["GI tract", "MULTI-TISSUE_STRUCTURE", 491, 499], ["mesenteric lymph nodes", "MULTI-TISSUE_STRUCTURE", 504, 526], ["peripheral lymph nodes", "MULTI-TISSUE_STRUCTURE", 550, 572], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 608, 615], ["organ", "ORGAN", 667, 672], ["organs", "ORGAN", 699, 705], ["tissues", "TISSUE", 710, 717], ["infiltrating T cells", "CELL_TYPE", 21, 41], ["donor alloactivated effector T cells", "CELL_TYPE", 118, 154], ["MLN", "CELL_TYPE", 162, 165], ["IEL", "CELL_TYPE", 170, 173], ["PLN", "CELL_TYPE", 253, 256], ["Ceacam1", "PROTEIN", 279, 286], ["donor T cells", "CELL_TYPE", 474, 487], ["Ceacam1", "PROTEIN", 608, 615], ["infiltrating T cells", "PROBLEM", 21, 41], ["WT", "TEST", 45, 47], ["Ceacam1\u2212", "TEST", 52, 60], ["allo-BMT recipients", "TREATMENT", 63, 82], ["Ceacam1\u2212", "TREATMENT", 177, 185], ["allo-BMT recipients", "TREATMENT", 188, 207], ["Ceacam1 regulates", "TREATMENT", 279, 296], ["the small intestine to radiation injury", "PROBLEM", 316, 355], ["Ceacam1", "TEST", 402, 409], ["allo-BMT recipients", "TREATMENT", 413, 432], ["increased accumulation of donor T cells in GI tract", "PROBLEM", 448, 499], ["mesenteric lymph nodes", "PROBLEM", 504, 526], ["decreased numbers peripheral lymph nodes", "PROBLEM", 532, 572], ["GVHD target organ damage", "PROBLEM", 655, 679], ["various target organs and tissues", "PROBLEM", 684, 717], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["MLN", "ANATOMY", 162, 165], ["PLN", "ANATOMY", 253, 256], ["liver", "ANATOMY", 261, 266], ["small", "OBSERVATION_MODIFIER", 320, 325], ["intestine", "ANATOMY", 326, 335], ["radiation injury", "OBSERVATION", 339, 355], ["early", "OBSERVATION_MODIFIER", 383, 388], ["mortality", "OBSERVATION_MODIFIER", 389, 398], ["increased", "OBSERVATION_MODIFIER", 448, 457], ["accumulation", "OBSERVATION_MODIFIER", 458, 470], ["donor T cells", "OBSERVATION", 474, 487], ["GI tract", "ANATOMY", 491, 499], ["mesenteric", "ANATOMY", 504, 514], ["lymph nodes", "OBSERVATION", 515, 526], ["decreased", "OBSERVATION_MODIFIER", 532, 541], ["numbers", "OBSERVATION_MODIFIER", 542, 549], ["peripheral", "OBSERVATION_MODIFIER", 550, 560], ["lymph nodes", "OBSERVATION", 561, 572], ["GVHD", "OBSERVATION", 655, 659], ["tissues", "ANATOMY", 710, 717]]], ["In the context of Ceacam1\u2212/\u2212 recipients, we therefore tested the radiation sensitivity of Ceacam1\u2212/\u2212 mice used as hosts, by irradiating WT and Ceacam1\u2212/\u2212 BALB/c mice and assessing survival.", [["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 18, 26], ["Ceacam1\u2212/\u2212 mice", "ORGANISM", 90, 105], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 143, 150], ["Ceacam1\u2212", "PROTEIN", 90, 98], ["Ceacam1", "PROTEIN", 143, 150], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 161, 165], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 161, 165], ["Ceacam1\u2212/\u2212 recipients", "TREATMENT", 18, 39], ["the radiation sensitivity", "TEST", 61, 86], ["Ceacam1\u2212/\u2212 mice", "TREATMENT", 90, 105]]], ["Ceacam1\u2212/\u2212 animals showed increased kinetics of mortality, and in some cases, overall mortality after radiation injury (Figure 4A).", [["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 0, 8], ["Ceacam1\u2212", "TREATMENT", 0, 8], ["increased kinetics of mortality", "PROBLEM", 26, 57], ["radiation injury", "PROBLEM", 102, 118], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["kinetics", "OBSERVATION_MODIFIER", 36, 44]]], ["We then enumerated regenerating and surviving crypts in the small intestine (terminal ileum) at 84 hours after irradiation to assess intestinal radiation damage, and observed that Ceacam1\u2212/\u2212 mice had fewer regenerating and surviving crypts as compared with WT counterparts (Figure 4B and D), indicating greater damage to the small intestine across a wide range of radiation doses.", [["crypts", "ANATOMY", 46, 52], ["small intestine", "ANATOMY", 60, 75], ["ileum", "ANATOMY", 86, 91], ["intestinal", "ANATOMY", 133, 143], ["crypts", "ANATOMY", 233, 239], ["small intestine", "ANATOMY", 325, 340], ["crypts", "MULTI-TISSUE_STRUCTURE", 46, 52], ["small intestine", "ORGAN", 60, 75], ["terminal ileum", "MULTI-TISSUE_STRUCTURE", 77, 91], ["intestinal", "ORGAN", 133, 143], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 180, 188], ["crypts", "MULTI-TISSUE_STRUCTURE", 233, 239], ["intestine", "ORGAN", 331, 340], ["Ceacam1\u2212", "PROTEIN", 180, 188], ["mice", "SPECIES", 191, 195], ["mice", "SPECIES", 191, 195], ["surviving crypts in the small intestine", "PROBLEM", 36, 75], ["irradiation", "TREATMENT", 111, 122], ["intestinal radiation damage", "PROBLEM", 133, 160], ["greater damage to the small intestine", "PROBLEM", 303, 340], ["radiation doses", "TREATMENT", 364, 379], ["surviving crypts", "OBSERVATION", 36, 52], ["small intestine", "ANATOMY", 60, 75], ["terminal", "ANATOMY_MODIFIER", 77, 85], ["ileum", "ANATOMY", 86, 91], ["intestinal", "ANATOMY", 133, 143], ["radiation damage", "OBSERVATION", 144, 160], ["greater", "OBSERVATION_MODIFIER", 303, 310], ["damage", "OBSERVATION", 311, 317], ["small intestine", "ANATOMY", 325, 340], ["wide", "OBSERVATION_MODIFIER", 350, 354]]], ["It is thus quite likely that our radiation-containing conditioning regimen for transplant recipients also contributes in part to their survival kinetics, selective GVHD target organ damage (Figure 2G\u2013H), and the selective accumulation of donor T cells in lymphoid tissues and target organs (Figure 3C) in these recipients.Donor Ceacam1\u2212/\u2212 CD8 T cells express higher levels of integrin \u03b14\u03b27 post-transplant ::: ResultsNext, we studied a variety of possible mechanisms by which Ceacam1 may regulate donor T cell function.", [["organ", "ANATOMY", 176, 181], ["donor T cells", "ANATOMY", 238, 251], ["lymphoid tissues", "ANATOMY", 255, 271], ["organs", "ANATOMY", 283, 289], ["Ceacam1\u2212/\u2212 CD8 T cells", "ANATOMY", 328, 350], ["T cell", "ANATOMY", 503, 509], ["GVHD", "DISEASE", 164, 168], ["organ damage", "DISEASE", 176, 188], ["Ceacam1", "CHEMICAL", 476, 483], ["recipients", "ORGANISM", 90, 100], ["organ", "ORGAN", 176, 181], ["T cells", "CELL", 244, 251], ["lymphoid tissues", "TISSUE", 255, 271], ["organs", "ORGAN", 283, 289], ["recipients", "ORGANISM", 311, 321], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 328, 336], ["integrin \u03b14\u03b27", "GENE_OR_GENE_PRODUCT", 376, 389], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 476, 483], ["donor T cell", "CELL", 497, 509], ["donor T cells", "CELL_TYPE", 238, 251], ["Donor Ceacam1\u2212/\u2212 CD8 T cells", "CELL_LINE", 322, 350], ["integrin", "PROTEIN", 376, 384], ["\u03b27", "PROTEIN", 387, 389], ["Ceacam1", "PROTEIN", 476, 483], ["our radiation-containing conditioning regimen", "TREATMENT", 29, 74], ["transplant recipients", "TREATMENT", 79, 100], ["their survival kinetics", "PROBLEM", 129, 152], ["selective GVHD target organ damage", "PROBLEM", 154, 188], ["donor T cells in lymphoid tissues", "PROBLEM", 238, 271], ["Donor Ceacam1\u2212", "TREATMENT", 322, 336], ["CD8 T cells", "TREATMENT", 339, 350], ["thus quite likely", "UNCERTAINTY", 6, 23], ["selective", "OBSERVATION_MODIFIER", 212, 221], ["accumulation", "OBSERVATION_MODIFIER", 222, 234], ["donor T cells", "OBSERVATION", 238, 251], ["lymphoid tissues", "OBSERVATION", 255, 271]]], ["We analyzed donor WT and Ceacam1\u2212/\u2212 alloactivated splenic T cells on day 14 after allo-BMT for trafficking molecules, and found that Ceacam1\u2212/\u2212 CD8+ CD44+CD62L\u2212 effector T cells expressed higher levels of integrin \u03b27 subunit and the gut homing integrin \u03b14\u03b27 (Figure 5A), which is important for intestinal GVHD [31], [32], [33].", [["splenic T cells", "ANATOMY", 50, 65], ["Ceacam1\u2212/\u2212 CD8+ CD44+CD62L\u2212 effector T cells", "ANATOMY", 133, 177], ["gut", "ANATOMY", 233, 236], ["intestinal", "ANATOMY", 294, 304], ["GVHD", "DISEASE", 305, 309], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 25, 33], ["splenic T cells", "CELL", 50, 65], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 133, 141], ["CD8", "GENE_OR_GENE_PRODUCT", 144, 147], ["CD44", "GENE_OR_GENE_PRODUCT", 149, 153], ["CD62L", "GENE_OR_GENE_PRODUCT", 154, 159], ["integrin \u03b27", "GENE_OR_GENE_PRODUCT", 205, 216], ["integrin \u03b14\u03b27", "GENE_OR_GENE_PRODUCT", 244, 257], ["Figure 5A", "GENE_OR_GENE_PRODUCT", 259, 268], ["intestinal", "ORGAN", 294, 304], ["Ceacam1\u2212/\u2212 alloactivated splenic T cells", "CELL_LINE", 25, 65], ["Ceacam1\u2212", "PROTEIN", 133, 141], ["CD8", "PROTEIN", 144, 147], ["CD44", "PROTEIN", 149, 153], ["CD62L", "PROTEIN", 154, 159], ["effector T cells", "CELL_TYPE", 161, 177], ["integrin \u03b27 subunit", "PROTEIN", 205, 224], ["gut homing integrin \u03b14\u03b27", "PROTEIN", 233, 257], ["Figure 5A", "PROTEIN", 259, 268], ["donor WT", "TEST", 12, 20], ["Ceacam1\u2212/\u2212 alloactivated splenic T cells", "TREATMENT", 25, 65], ["allo-BMT", "TREATMENT", 82, 90], ["trafficking molecules", "PROBLEM", 95, 116], ["Ceacam1\u2212", "TEST", 133, 141], ["CD8", "TEST", 144, 147], ["CD44", "TEST", 149, 153], ["CD62L", "TEST", 154, 159], ["effector T cells", "PROBLEM", 161, 177], ["integrin \u03b2", "TREATMENT", 205, 215], ["intestinal GVHD", "PROBLEM", 294, 309], ["splenic", "ANATOMY", 50, 57], ["gut", "ANATOMY", 233, 236], ["intestinal", "ANATOMY", 294, 304], ["GVHD", "OBSERVATION", 305, 309]]], ["However, WT vs. Ceacam1\u2212/\u2212 CD4 effector T cells had similar integrin \u03b27 subunit expression, yet also accumulated in greater numbers in the gut (Figure 3A), suggesting that regulation of target organ damage by Ceacam1 is very likely to involve multiple additional mechanisms beyond trafficking molecule expression.", [["Ceacam1\u2212/\u2212 CD4 effector T cells", "ANATOMY", 16, 47], ["gut", "ANATOMY", 139, 142], ["organ", "ANATOMY", 193, 198], ["organ damage", "DISEASE", 193, 205], ["Ceacam1", "CHEMICAL", 209, 216], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 16, 24], ["integrin \u03b27", "GENE_OR_GENE_PRODUCT", 60, 71], ["gut", "ORGANISM_SUBDIVISION", 139, 142], ["organ", "ORGAN", 193, 198], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 209, 216], ["Ceacam1\u2212/\u2212 CD4 effector T cells", "CELL_LINE", 16, 47], ["integrin", "PROTEIN", 60, 68], ["\u03b27 subunit", "PROTEIN", 69, 79], ["Ceacam1", "PROTEIN", 209, 216], ["Ceacam1\u2212", "TREATMENT", 16, 24], ["CD4 effector T cells", "TREATMENT", 27, 47], ["target organ damage", "PROBLEM", 186, 205], ["greater", "OBSERVATION_MODIFIER", 116, 123], ["numbers", "OBSERVATION_MODIFIER", 124, 131], ["gut", "ANATOMY", 139, 142], ["trafficking molecule expression", "OBSERVATION", 281, 312]]], ["Additionally, levels of the \u03b1E subunit, which forms integrin \u03b1E\u03b27, were similar, as were levels of CCR9, CD31, PSGL1, CCR7, CXCR3, and LFA1 (data not shown).Donor Ceacam1\u2212/\u2212 CD8 T cells express higher levels of integrin \u03b14\u03b27 post-transplant ::: ResultsWhen we assessed the expression of trafficking molecules in recipients of WT vs. Ceacam1-Tg T cell allografts, we found no significant differences in levels of \u03b27 subunit, integrin \u03b14\u03b27 (Figure 5B), or any other molecules.", [["Ceacam1\u2212/\u2212 CD8 T cells", "ANATOMY", 163, 185], ["Ceacam1-Tg T cell allografts", "ANATOMY", 333, 361], ["\u03b1E", "GENE_OR_GENE_PRODUCT", 28, 30], ["integrin \u03b1E\u03b27", "GENE_OR_GENE_PRODUCT", 52, 65], ["CCR9", "GENE_OR_GENE_PRODUCT", 99, 103], ["CD31", "GENE_OR_GENE_PRODUCT", 105, 109], ["PSGL1", "GENE_OR_GENE_PRODUCT", 111, 116], ["CCR7", "GENE_OR_GENE_PRODUCT", 118, 122], ["CXCR3", "GENE_OR_GENE_PRODUCT", 124, 129], ["LFA1", "GENE_OR_GENE_PRODUCT", 135, 139], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 163, 171], ["integrin \u03b14\u03b27", "GENE_OR_GENE_PRODUCT", 211, 224], ["recipients", "ORGANISM", 312, 322], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 333, 340], ["\u03b27 subunit", "GENE_OR_GENE_PRODUCT", 412, 422], ["integrin \u03b14\u03b27", "GENE_OR_GENE_PRODUCT", 424, 437], ["Figure 5B", "GENE_OR_GENE_PRODUCT", 439, 448], ["\u03b1E subunit", "PROTEIN", 28, 38], ["integrin \u03b1E\u03b27", "PROTEIN", 52, 65], ["CCR9", "PROTEIN", 99, 103], ["CD31", "PROTEIN", 105, 109], ["PSGL1", "PROTEIN", 111, 116], ["CCR7", "PROTEIN", 118, 122], ["CXCR3", "PROTEIN", 124, 129], ["LFA1", "PROTEIN", 135, 139], ["Donor Ceacam1\u2212/\u2212 CD8 T cells", "CELL_LINE", 157, 185], ["integrin", "PROTEIN", 211, 219], ["\u03b27", "PROTEIN", 222, 224], ["trafficking molecules", "PROTEIN", 287, 308], ["Ceacam1", "PROTEIN", 333, 340], ["\u03b27 subunit", "PROTEIN", 412, 422], ["integrin \u03b14\u03b27", "PROTEIN", 424, 437], ["Figure 5B", "PROTEIN", 439, 448], ["the \u03b1E subunit", "TEST", 24, 38], ["integrin \u03b1E\u03b2", "TEST", 52, 64], ["CCR9", "TEST", 99, 103], ["CD31", "TEST", 105, 109], ["PSGL1", "TEST", 111, 116], ["CCR7", "TEST", 118, 122], ["CXCR3", "TEST", 124, 129], ["LFA1", "TEST", 135, 139], ["Donor Ceacam1\u2212", "TREATMENT", 157, 171], ["CD8 T cells", "TREATMENT", 174, 185], ["Ceacam1", "TEST", 333, 340], ["Tg T cell allografts", "TREATMENT", 341, 361], ["significant differences in levels", "PROBLEM", 375, 408], ["integrin", "TEST", 424, 432], ["any other molecules", "PROBLEM", 454, 473], ["CCR9", "ANATOMY", 99, 103], ["CCR7", "ANATOMY", 118, 122], ["cell allografts", "OBSERVATION", 346, 361], ["no", "UNCERTAINTY", 372, 374], ["significant", "OBSERVATION_MODIFIER", 375, 386]]], ["This is consistent with the systemic reduction in GVHD in recipients of Ceacam1-Tg T cells.", [["Ceacam1-Tg T cells", "ANATOMY", 72, 90], ["GVHD", "DISEASE", 50, 54], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 72, 79], ["Ceacam1-Tg T cells", "CELL_LINE", 72, 90], ["the systemic reduction", "PROBLEM", 24, 46], ["GVHD", "PROBLEM", 50, 54], ["Ceacam1", "TEST", 72, 79], ["consistent with", "UNCERTAINTY", 8, 23], ["systemic", "OBSERVATION_MODIFIER", 28, 36], ["reduction", "OBSERVATION_MODIFIER", 37, 46], ["GVHD", "OBSERVATION", 50, 54]]], ["Finally, we assessed trafficking molecules in irradiated WT vs. Ceacam1\u2212/\u2212 recipients of identical donor allografts, and observed again that donor CD8, but not CD4 splenic T cells in Ceacam1\u2212/\u2212 recipients had a trend towards increased expression of the \u03b27 subunit, although this was not directly reflected in increased expression of integrin \u03b14\u03b27.", [["allografts", "ANATOMY", 105, 115], ["CD4 splenic T cells", "ANATOMY", 160, 179], ["allografts", "TISSUE", 105, 115], ["CD8", "GENE_OR_GENE_PRODUCT", 147, 150], ["CD4", "GENE_OR_GENE_PRODUCT", 160, 163], ["\u03b27", "GENE_OR_GENE_PRODUCT", 253, 255], ["integrin \u03b14\u03b27", "GENE_OR_GENE_PRODUCT", 333, 346], ["trafficking molecules", "PROTEIN", 21, 42], ["donor CD8", "CELL_TYPE", 141, 150], ["CD4 splenic T cells", "CELL_TYPE", 160, 179], ["\u03b27 subunit", "PROTEIN", 253, 263], ["integrin \u03b14\u03b27", "PROTEIN", 333, 346], ["Ceacam1\u2212", "TREATMENT", 64, 72], ["identical donor allografts", "TREATMENT", 89, 115], ["donor CD8", "TEST", 141, 150], ["donor allografts", "OBSERVATION", 99, 115], ["splenic", "ANATOMY", 164, 171]]], ["Taken together, these observations suggest that regulation of trafficking molecule expression by Ceacam1 is only one component of how it regulates GVHD target organ damage.Ceacam1 is expressed on T cells during alloactivation ::: ResultsCeacam1 can be found on activated T cells [7], [8], [29] and, we thus performed a kinetic analysis of Ceacam1 expression on T cells during alloactivation.", [["organ", "ANATOMY", 159, 164], ["T cells", "ANATOMY", 196, 203], ["T cells", "ANATOMY", 271, 278], ["T cells", "ANATOMY", 361, 368], ["GVHD", "DISEASE", 147, 151], ["organ damage", "DISEASE", 159, 171], ["ResultsCeacam1", "CHEMICAL", 230, 244], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 97, 104], ["organ", "ORGAN", 159, 164], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 172, 179], ["T cells", "CELL", 196, 203], ["ResultsCeacam1", "GENE_OR_GENE_PRODUCT", 230, 244], ["T cells", "CELL", 271, 278], ["[8]", "SIMPLE_CHEMICAL", 284, 287], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 339, 346], ["T cells", "CELL", 361, 368], ["Ceacam1", "PROTEIN", 97, 104], ["Ceacam1", "PROTEIN", 172, 179], ["T cells", "CELL_TYPE", 196, 203], ["ResultsCeacam1", "PROTEIN", 230, 244], ["activated T cells", "CELL_TYPE", 261, 278], ["Ceacam1", "PROTEIN", 339, 346], ["T cells", "CELL_TYPE", 361, 368], ["trafficking molecule expression", "TREATMENT", 62, 93], ["GVHD target organ damage", "PROBLEM", 147, 171], ["activated T cells", "TEST", 261, 278], ["a kinetic analysis", "TEST", 317, 335], ["Ceacam1 expression", "PROBLEM", 339, 357], ["alloactivation", "TREATMENT", 376, 390]]], ["We adoptively transferred CFSE-labeled B6 T cells into irradiated BALB/c recipients, and observed transient expression only on day 2 after alloactivation (Figure 6and data not shown).", [["B6 T cells", "ANATOMY", 39, 49], ["CFSE", "CHEMICAL", 26, 30], ["CFSE", "CHEMICAL", 26, 30], ["CFSE", "SIMPLE_CHEMICAL", 26, 30], ["B6 T cells", "CELL", 39, 49], ["BALB/c recipients", "ORGANISM", 66, 83], ["CFSE-labeled B6 T cells", "CELL_LINE", 26, 49], ["irradiated BALB/c recipients", "TREATMENT", 55, 83]]], ["Furthermore, only CFSElo alloactivated T cells, which have divided \u22654 times in 48 hours, expressed low but consistently detectable levels of Ceacam1 (Figure 6A).", [["CFSElo alloactivated T cells", "ANATOMY", 18, 46], ["T cells", "CELL", 39, 46], ["Ceacam1 (Figure 6A", "GENE_OR_GENE_PRODUCT", 141, 159], ["CFSElo alloactivated T cells", "CELL_LINE", 18, 46], ["Ceacam1", "PROTEIN", 141, 148]]], ["These kinetics are consistent with a role for Ceacam1 in regulating early events in T cell alloactivation.Ceacam1 regulates the alloactivation and proliferation of T cells ::: ResultsBecause the expression of Ceacam1 on alloreactive T cells after adoptive transfer occurred in vivo with similar kinetics as T cell alloactivation [30], we asked whether Ceacam1 on either donor alloreactive T cells or radio-resistant cells in allo-BMT recipients could regulate this process.", [["T cell", "ANATOMY", 84, 90], ["T cells", "ANATOMY", 164, 171], ["alloreactive T cells", "ANATOMY", 220, 240], ["T cell", "ANATOMY", 307, 313], ["alloreactive T cells", "ANATOMY", 376, 396], ["cells", "ANATOMY", 416, 421], ["Ceacam1", "CHEMICAL", 46, 53], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 46, 53], ["T cell", "CELL", 84, 90], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 106, 113], ["T cells", "CELL", 164, 171], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 209, 216], ["alloreactive T cells", "CELL", 220, 240], ["T cell", "CELL", 307, 313], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 352, 359], ["alloreactive T cells", "CELL", 376, 396], ["radio-resistant cells", "CELL", 400, 421], ["allo-BMT", "CELL", 425, 433], ["recipients", "ORGANISM", 434, 444], ["Ceacam1", "PROTEIN", 46, 53], ["Ceacam1", "PROTEIN", 106, 113], ["T cells", "CELL_TYPE", 164, 171], ["Ceacam1", "PROTEIN", 209, 216], ["alloreactive T cells", "CELL_TYPE", 220, 240], ["Ceacam1", "PROTEIN", 352, 359], ["donor alloreactive T cells", "CELL_TYPE", 370, 396], ["radio-resistant cells", "CELL_LINE", 400, 421], ["Ceacam1", "TREATMENT", 46, 53], ["T cell alloactivation", "TREATMENT", 84, 105], ["Ceacam1 regulates", "TREATMENT", 106, 123], ["Ceacam1 on alloreactive T cells", "TREATMENT", 209, 240], ["adoptive transfer", "TREATMENT", 247, 264], ["T cell alloactivation", "TREATMENT", 307, 328], ["Ceacam1", "TREATMENT", 352, 359], ["donor alloreactive T cells", "TREATMENT", 370, 396], ["radio-resistant cells", "TREATMENT", 400, 421], ["allo-BMT recipients", "TREATMENT", 425, 444], ["consistent with", "UNCERTAINTY", 19, 34], ["cell alloactivation", "OBSERVATION", 86, 105]]], ["We transferred CFSE-labeled purified B6 WT or Ceacam1\u2212/\u2212 splenic T cells into irradiated BALB/c recipients and analyzed donor T cells in spleens on day 3.Ceacam1 regulates the alloactivation and proliferation of T cells ::: ResultsWe observed that relative to isotype control staining, an increased percentage of alloactivated CFSElo CD4 Ceacam1\u2212/\u2212 T cells were positive for the alloactivation marker CD25, and that a greater percentage of these cells downregulated CD62L than WT T cells (Figure 6B\u2013C), suggesting that more of them became activated.", [["Ceacam1\u2212/\u2212 splenic T cells", "ANATOMY", 46, 72], ["T cells", "ANATOMY", 126, 133], ["spleens", "ANATOMY", 137, 144], ["T cells", "ANATOMY", 212, 219], ["CFSElo CD4 Ceacam1\u2212/\u2212 T cells", "ANATOMY", 327, 356], ["cells", "ANATOMY", 446, 451], ["WT T cells", "ANATOMY", 477, 487], ["CFSE", "CHEMICAL", 15, 19], ["CFSE", "CHEMICAL", 15, 19], ["CFSE", "SIMPLE_CHEMICAL", 15, 19], ["B6 WT", "ORGANISM", 37, 42], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 46, 54], ["splenic T cells", "CELL", 57, 72], ["BALB/c recipients", "ORGANISM", 89, 106], ["donor T cells", "CELL", 120, 133], ["spleens", "ORGAN", 137, 144], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 154, 161], ["T cells", "CELL", 212, 219], ["CD4", "GENE_OR_GENE_PRODUCT", 334, 337], ["CD25", "GENE_OR_GENE_PRODUCT", 401, 405], ["cells", "CELL", 446, 451], ["CD62L", "GENE_OR_GENE_PRODUCT", 466, 471], ["WT T cells", "CELL", 477, 487], ["Figure 6B\u2013C", "CELL", 489, 500], ["CFSE-labeled purified B6 WT", "CELL_LINE", 15, 42], ["Ceacam1\u2212/\u2212 splenic T cells", "CELL_LINE", 46, 72], ["donor T cells", "CELL_TYPE", 120, 133], ["Ceacam1", "PROTEIN", 154, 161], ["T cells", "CELL_TYPE", 212, 219], ["alloactivated CFSElo CD4 Ceacam1\u2212/\u2212 T cells", "CELL_LINE", 313, 356], ["alloactivation marker CD25", "PROTEIN", 379, 405], ["CD62L", "PROTEIN", 466, 471], ["WT T cells", "CELL_TYPE", 477, 487], ["WT", "TEST", 40, 42], ["Ceacam1\u2212", "TEST", 46, 54], ["splenic T cells", "TREATMENT", 57, 72], ["irradiated BALB/c recipients", "TREATMENT", 78, 106], ["donor T cells", "TREATMENT", 120, 133], ["Ceacam1 regulates", "TREATMENT", 154, 171], ["isotype control staining", "PROBLEM", 260, 284], ["alloactivated CFSElo CD4 Ceacam1\u2212", "TEST", 313, 346], ["T cells", "PROBLEM", 349, 356], ["the alloactivation marker CD25", "TEST", 375, 405], ["Figure 6B\u2013C", "TEST", 489, 500], ["splenic", "ANATOMY", 57, 64], ["spleens", "ANATOMY", 137, 144], ["increased", "OBSERVATION_MODIFIER", 289, 298]]], ["Additionally, an increased percentage of donor Ceacam1\u2212/\u2212 CD4 T cells had divided to a CFSElo alloactivated state (Figure 6D), suggesting enhanced proliferation in the absence of Ceacam1.Ceacam1 regulates the alloactivation and proliferation of T cells ::: ResultsWe repeated these experiments with alloreactive Ceacam1-Tg T cells and as expected, observed a decrease in numbers of CFSElo T cells as assessed by CFSE dilution (Figure 6E).", [["Ceacam1\u2212/\u2212 CD4 T cells", "ANATOMY", 47, 69], ["T cells", "ANATOMY", 245, 252], ["Ceacam1-Tg T cells", "ANATOMY", 312, 330], ["CFSElo T cells", "ANATOMY", 382, 396], ["CFSE", "CHEMICAL", 412, 416], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 47, 55], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 179, 186], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 187, 194], ["T cells", "CELL", 245, 252], ["Ceacam1-Tg T cells", "CELL", 312, 330], ["CFSElo T cells", "CELL", 382, 396], ["CFSE", "SIMPLE_CHEMICAL", 412, 416], ["donor Ceacam1\u2212/\u2212 CD4 T cells", "CELL_TYPE", 41, 69], ["Ceacam1", "PROTEIN", 179, 186], ["Ceacam1", "PROTEIN", 187, 194], ["T cells", "CELL_TYPE", 245, 252], ["alloreactive Ceacam1-Tg T cells", "CELL_LINE", 299, 330], ["CFSElo T cells", "CELL_TYPE", 382, 396], ["donor Ceacam1\u2212", "TEST", 41, 55], ["CD4 T cells", "PROBLEM", 58, 69], ["enhanced proliferation", "PROBLEM", 138, 160], ["Ceacam1 regulates", "TREATMENT", 187, 204], ["these experiments", "TEST", 276, 293], ["alloreactive Ceacam1", "TEST", 299, 319], ["a decrease in numbers of CFSElo T cells", "PROBLEM", 357, 396], ["increased", "OBSERVATION_MODIFIER", 17, 26], ["percentage", "OBSERVATION_MODIFIER", 27, 37], ["donor Ceacam1\u2212", "OBSERVATION", 41, 55], ["suggesting", "UNCERTAINTY", 127, 137], ["enhanced", "OBSERVATION_MODIFIER", 138, 146], ["proliferation", "OBSERVATION", 147, 160], ["decrease", "OBSERVATION_MODIFIER", 359, 367]]], ["This is consistent with an inhibitory role for Ceacam1 in the proliferation of alloreactive T cells.", [["alloreactive T cells", "ANATOMY", 79, 99], ["Ceacam1", "CHEMICAL", 47, 54], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 47, 54], ["alloreactive T cells", "CELL", 79, 99], ["Ceacam1", "PROTEIN", 47, 54], ["alloreactive T cells", "CELL_TYPE", 79, 99], ["Ceacam1", "PROBLEM", 47, 54], ["alloreactive T cells", "PROBLEM", 79, 99], ["consistent with", "UNCERTAINTY", 8, 23], ["Ceacam1", "OBSERVATION", 47, 54], ["proliferation", "OBSERVATION_MODIFIER", 62, 75], ["alloreactive T cells", "OBSERVATION", 79, 99]]], ["However, we did not observe significant differences in alloactivation between Ceacam1-Tg vs. WT donor T cells (data not shown).Ceacam1 regulates the alloactivation and proliferation of T cells ::: ResultsLastly, we assessed the role of Ceacam1 expression on radio-resistant cells in allo-BMT recipients for donor T cell alloactivation.", [["donor T cells", "ANATOMY", 96, 109], ["T cells", "ANATOMY", 185, 192], ["cells", "ANATOMY", 274, 279], ["T cell", "ANATOMY", 313, 319], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 78, 85], ["WT donor T cells", "CELL", 93, 109], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 127, 134], ["T cells", "CELL", 185, 192], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 236, 243], ["cells", "CELL", 274, 279], ["allo-BMT recipients", "CELL", 283, 302], ["donor T cell", "CELL", 307, 319], ["Ceacam1", "PROTEIN", 78, 85], ["WT donor T cells", "CELL_TYPE", 93, 109], ["Ceacam1", "PROTEIN", 127, 134], ["T cells", "CELL_TYPE", 185, 192], ["Ceacam1", "PROTEIN", 236, 243], ["radio-resistant cells", "CELL_LINE", 258, 279], ["Ceacam1", "TEST", 78, 85], ["Ceacam1 regulates", "TREATMENT", 127, 144], ["Ceacam1 expression", "PROBLEM", 236, 254], ["radio-resistant cells", "TREATMENT", 258, 279], ["allo-BMT recipients", "TREATMENT", 283, 302], ["donor T cell alloactivation", "TREATMENT", 307, 334], ["cell alloactivation", "OBSERVATION", 315, 334]]], ["We transferred CFSE-labeled B6 T cells into irradiated WT vs. Ceacam1\u2212/\u2212 BALB/c mice, and analyzed donor T cells in spleens on day 3.", [["B6 T cells", "ANATOMY", 28, 38], ["T cells", "ANATOMY", 105, 112], ["spleens", "ANATOMY", 116, 123], ["CFSE", "CHEMICAL", 15, 19], ["CFSE", "CHEMICAL", 15, 19], ["CFSE", "SIMPLE_CHEMICAL", 15, 19], ["B6 T cells", "CELL", 28, 38], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 62, 69], ["T cells", "CELL", 105, 112], ["spleens", "ORGAN", 116, 123], ["CFSE-labeled B6 T cells", "CELL_LINE", 15, 38], ["Ceacam1", "PROTEIN", 62, 69], ["donor T cells", "CELL_TYPE", 99, 112], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 80, 84], ["Ceacam1", "TREATMENT", 62, 69], ["BALB/c mice", "TREATMENT", 73, 84], ["donor T cells", "TREATMENT", 99, 112], ["spleens", "ANATOMY", 116, 123]]], ["Here, we did not observe differences in proliferation (data not shown), but donor CD4 T cells in Ceacam1\u2212/\u2212 allogeneic recipients did exhibit an increase in alloactivation as measured by CD25 (Figure 6F).Ceacam1 does not significantly influence T cell polarization, cytolysis or dendritic cell function in GVHD ::: ResultsWe measured serum cytokines in recipients of WT, Ceacam1-Tg and Ceacam1\u2212/\u2212 T cells on days 7 and 14 post-transplant, and observed that levels of IFN\u03b3, TNF, IL-2, IL-4, IL-6, IL-10, and IL-12p70 were similar (data not shown).", [["CD4 T cells", "ANATOMY", 82, 93], ["T cell", "ANATOMY", 245, 251], ["dendritic cell", "ANATOMY", 279, 293], ["serum", "ANATOMY", 334, 339], ["Ceacam1\u2212/\u2212 T cells", "ANATOMY", 386, 404], ["Ceacam1", "CHEMICAL", 204, 211], ["GVHD", "DISEASE", 306, 310], ["Ceacam1", "CHEMICAL", 204, 211], ["CD4", "GENE_OR_GENE_PRODUCT", 82, 85], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 97, 105], ["CD25", "GENE_OR_GENE_PRODUCT", 187, 191], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 204, 211], ["T cell", "CELL", 245, 251], ["dendritic cell", "CELL", 279, 293], ["serum", "ORGANISM_SUBSTANCE", 334, 339], ["recipients", "ORGANISM", 353, 363], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 371, 378], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 386, 393], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 467, 471], ["TNF", "GENE_OR_GENE_PRODUCT", 473, 476], ["IL-2", "GENE_OR_GENE_PRODUCT", 478, 482], ["IL-4", "GENE_OR_GENE_PRODUCT", 484, 488], ["IL-6", "GENE_OR_GENE_PRODUCT", 490, 494], ["IL-10", "GENE_OR_GENE_PRODUCT", 496, 501], ["IL-12p70", "GENE_OR_GENE_PRODUCT", 507, 515], ["CD4 T cells", "CELL_TYPE", 82, 93], ["CD25", "PROTEIN", 187, 191], ["Ceacam1", "PROTEIN", 204, 211], ["serum cytokines", "PROTEIN", 334, 349], ["Ceacam1-Tg and Ceacam1\u2212/\u2212 T cells", "CELL_LINE", 371, 404], ["IFN\u03b3", "PROTEIN", 467, 471], ["TNF", "PROTEIN", 473, 476], ["IL", "PROTEIN", 507, 509], ["donor CD4 T cells", "TEST", 76, 93], ["Ceacam1\u2212", "TEST", 97, 105], ["allogeneic recipients", "TREATMENT", 108, 129], ["an increase in alloactivation", "PROBLEM", 142, 171], ["cytolysis", "PROBLEM", 266, 275], ["dendritic cell function", "PROBLEM", 279, 302], ["serum cytokines", "TEST", 334, 349], ["WT", "TEST", 367, 369], ["Ceacam1", "TEST", 371, 378], ["Tg", "TEST", 379, 381], ["Ceacam1", "TEST", 386, 393], ["IFN\u03b3", "TEST", 467, 471], ["TNF", "TEST", 473, 476], ["IL", "TEST", 478, 480], ["IL", "TEST", 484, 486], ["IL", "TEST", 490, 492], ["IL", "TEST", 496, 498], ["IL", "TEST", 507, 509], ["increase", "OBSERVATION_MODIFIER", 145, 153], ["cell polarization", "OBSERVATION", 247, 264], ["dendritic cell", "OBSERVATION", 279, 293]]], ["Percentages of FoxP3+ donor regulatory T cells and expression of T-bet were also similar between recipients of WT, Ceacam1-Tg and Ceacam1\u2212/\u2212 T cells (data not shown andTable 1), and stimulation of splenocytes harvested on day 14 after BMT post-transplant from these three groups revealed essentially no IL-17+ donor T cells (not shown), and similar percentages of donor IFN\u03b3+ T cells (data not shown andTable 1).Ceacam1 does not significantly influence T cell polarization, cytolysis or dendritic cell function in GVHD ::: ResultsAs Ceacam1 can regulate the cytolytic responses of lymphocytes [34], [35], [36], [37], [38], we assessed the cytolytic function of WT vs. Ceacam1\u2212/\u2212 alloactivated CD8 T cells from the spleens of allo-BMT recipients on day 14.", [["FoxP3+ donor regulatory T cells", "ANATOMY", 15, 46], ["Ceacam1\u2212/\u2212 T cells", "ANATOMY", 130, 148], ["splenocytes", "ANATOMY", 197, 208], ["IL-17+ donor T cells", "ANATOMY", 303, 323], ["T cells", "ANATOMY", 376, 383], ["T cell", "ANATOMY", 453, 459], ["dendritic cell", "ANATOMY", 487, 501], ["lymphocytes", "ANATOMY", 581, 592], ["CD8 T cells", "ANATOMY", 693, 704], ["spleens", "ANATOMY", 714, 721], ["Ceacam1", "CHEMICAL", 412, 419], ["GVHD", "DISEASE", 514, 518], ["Ceacam1", "CHEMICAL", 412, 419], ["FoxP3", "GENE_OR_GENE_PRODUCT", 15, 20], ["T-bet", "GENE_OR_GENE_PRODUCT", 65, 70], ["recipients", "ORGANISM", 97, 107], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 115, 122], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 130, 137], ["splenocytes", "CELL", 197, 208], ["IL-17", "GENE_OR_GENE_PRODUCT", 303, 308], ["T cells", "CELL", 316, 323], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 370, 374], ["T cells", "CELL", 376, 383], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 412, 419], ["T cell", "CELL", 453, 459], ["dendritic cell", "CELL", 487, 501], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 533, 540], ["lymphocytes", "CELL", 581, 592], ["[35]", "SIMPLE_CHEMICAL", 599, 603], ["[37]", "SIMPLE_CHEMICAL", 611, 615], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 668, 676], ["CD8", "GENE_OR_GENE_PRODUCT", 693, 696], ["spleens", "ORGAN", 714, 721], ["allo-BMT recipients", "CELL", 725, 744], ["FoxP3", "PROTEIN", 15, 20], ["donor regulatory T cells", "CELL_TYPE", 22, 46], ["T-bet", "PROTEIN", 65, 70], ["Ceacam1", "PROTEIN", 115, 122], ["Ceacam1\u2212/\u2212 T cells", "CELL_LINE", 130, 148], ["splenocytes", "CELL_TYPE", 197, 208], ["IL-17", "PROTEIN", 303, 308], ["donor T cells", "CELL_TYPE", 310, 323], ["IFN\u03b3", "PROTEIN", 370, 374], ["T cells", "CELL_TYPE", 376, 383], ["Ceacam1", "PROTEIN", 412, 419], ["Ceacam1", "PROTEIN", 533, 540], ["lymphocytes", "CELL_TYPE", 581, 592], ["Ceacam1\u2212/\u2212 alloactivated CD8 T cells", "CELL_LINE", 668, 704], ["Percentages", "TEST", 0, 11], ["FoxP3", "TEST", 15, 20], ["donor regulatory T cells", "PROBLEM", 22, 46], ["T-bet", "TEST", 65, 70], ["WT", "TEST", 111, 113], ["Ceacam1", "TEST", 115, 122], ["Ceacam1", "TEST", 130, 137], ["BMT post-transplant", "TREATMENT", 235, 254], ["IL", "TEST", 303, 305], ["donor T cells", "PROBLEM", 310, 323], ["Ceacam1", "TEST", 412, 419], ["cytolysis", "PROBLEM", 474, 483], ["dendritic cell function", "PROBLEM", 487, 510], ["GVHD", "PROBLEM", 514, 518], ["the cytolytic responses", "TEST", 554, 577], ["lymphocytes", "TEST", 581, 592], ["Ceacam1\u2212", "TREATMENT", 668, 676], ["\u2212 alloactivated CD8 T cells", "TREATMENT", 677, 704], ["allo-BMT recipients", "TREATMENT", 725, 744], ["FoxP3", "OBSERVATION", 15, 20], ["splenocytes", "ANATOMY", 197, 208], ["no", "UNCERTAINTY", 300, 302], ["cell polarization", "OBSERVATION", 455, 472], ["dendritic cell", "OBSERVATION", 487, 501], ["spleens", "ANATOMY", 714, 721]]], ["Ceacam1\u2212/\u2212 CD8 T cells and WT CD8 T cells demonstrated similar cytolysis against 51Cr-radiolabeled allogeneic A20 B cell lymphoma cells and EL4 controls (Table 1).", [["Ceacam1\u2212/\u2212 CD8 T cells", "ANATOMY", 0, 22], ["WT CD8 T cells", "ANATOMY", 27, 41], ["A20 B cell lymphoma cells", "ANATOMY", 110, 135], ["EL4", "ANATOMY", 140, 143], ["51Cr", "CHEMICAL", 81, 85], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 0, 8], ["51Cr", "SIMPLE_CHEMICAL", 81, 85], ["A20 B cell lymphoma cells", "CELL", 110, 135], ["EL4 controls", "CELL", 140, 152], ["Ceacam1\u2212/\u2212 CD8 T cells", "CELL_LINE", 0, 22], ["WT CD8 T cells", "CELL_TYPE", 27, 41], ["51Cr-radiolabeled allogeneic A20 B cell lymphoma cells", "CELL_LINE", 81, 135], ["EL4 controls", "CELL_LINE", 140, 152], ["Ceacam1\u2212", "TEST", 0, 8], ["WT CD8 T cells", "TEST", 27, 41], ["similar cytolysis", "PROBLEM", 55, 72], ["51Cr", "TEST", 81, 85], ["radiolabeled allogeneic A20 B cell lymphoma cells", "TREATMENT", 86, 135], ["EL4 controls", "TEST", 140, 152], ["allogeneic A20 B cell lymphoma cells", "OBSERVATION", 99, 135]]], ["Lastly, we found no differences in DC numbers, activation state (CD80, CD86, MHC class II) from the infusion of Ceacam1\u2212/\u2212 or Ceacam1-Tg T cells (Table 1), or in Ceacam1\u2212/\u2212 allo-BMT recipients.Ceacam1\u2212/\u2212 donor T cells have enhanced graft-versus-tumor activity towards A20 lymphoma but not renal cell carcinom ::: ResultsFinally, we assessed the GVT activity of Ceacam1\u2212/\u2212 donor alloreactive T cells against A20 lymphoma and RENCA renal cell carcinoma.", [["DC", "ANATOMY", 35, 37], ["Ceacam1\u2212/\u2212", "ANATOMY", 112, 122], ["Ceacam1-Tg T cells", "ANATOMY", 126, 144], ["Ceacam1\u2212/\u2212 donor T cells", "ANATOMY", 193, 217], ["graft", "ANATOMY", 232, 237], ["tumor", "ANATOMY", 245, 250], ["A20 lymphoma", "ANATOMY", 268, 280], ["renal cell carcinom", "ANATOMY", 289, 308], ["Ceacam1\u2212/\u2212 donor alloreactive T cells", "ANATOMY", 361, 398], ["A20 lymphoma", "ANATOMY", 407, 419], ["RENCA renal cell carcinoma", "ANATOMY", 424, 450], ["tumor", "DISEASE", 245, 250], ["lymphoma", "DISEASE", 272, 280], ["lymphoma", "DISEASE", 411, 419], ["renal cell carcinoma", "DISEASE", 430, 450], ["CD80", "GENE_OR_GENE_PRODUCT", 65, 69], ["CD86", "GENE_OR_GENE_PRODUCT", 71, 75], ["MHC class II", "GENE_OR_GENE_PRODUCT", 77, 89], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 112, 120], ["\u2212", "GENE_OR_GENE_PRODUCT", 121, 122], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 126, 133], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 162, 170], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 193, 200], ["graft-versus-tumor", "CANCER", 232, 250], ["A20 lymphoma", "CANCER", 268, 280], ["renal cell carcinom", "CELL", 289, 308], ["GVT", "CANCER", 345, 348], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 361, 369], ["T cells", "CELL", 391, 398], ["A20 lymphoma", "CANCER", 407, 419], ["RENCA renal cell carcinoma", "CANCER", 424, 450], ["DC", "CELL_TYPE", 35, 37], ["CD80", "PROTEIN", 65, 69], ["CD86", "PROTEIN", 71, 75], ["MHC class II", "PROTEIN", 77, 89], ["Ceacam1\u2212", "PROTEIN", 112, 120], ["Ceacam1", "PROTEIN", 126, 133], ["Tg T cells", "CELL_TYPE", 134, 144], ["Ceacam1\u2212/\u2212 donor T cells", "CELL_LINE", 193, 217], ["Ceacam1\u2212/\u2212 donor alloreactive T cells", "CELL_LINE", 361, 398], ["CD80", "TEST", 65, 69], ["Ceacam1\u2212", "TREATMENT", 112, 120], ["Ceacam1", "TREATMENT", 126, 133], ["allo-BMT recipients", "TREATMENT", 173, 192], ["Ceacam1\u2212", "TREATMENT", 193, 201], ["donor T cells", "TREATMENT", 204, 217], ["enhanced graft", "TREATMENT", 223, 237], ["tumor activity", "PROBLEM", 245, 259], ["A20 lymphoma", "PROBLEM", 268, 280], ["Ceacam1\u2212", "TEST", 361, 369], ["\u2212 donor alloreactive T cells", "TREATMENT", 370, 398], ["A20 lymphoma", "PROBLEM", 407, 419], ["RENCA renal cell carcinoma", "PROBLEM", 424, 450], ["no", "UNCERTAINTY", 17, 19], ["graft", "OBSERVATION", 232, 237], ["tumor", "OBSERVATION", 245, 250], ["A20 lymphoma", "OBSERVATION", 268, 280], ["renal", "ANATOMY", 289, 294], ["cell carcinom", "OBSERVATION", 295, 308], ["A20 lymphoma", "OBSERVATION", 407, 419], ["renal", "ANATOMY", 430, 435], ["cell carcinoma", "OBSERVATION", 436, 450]]], ["Recipients of Ceacam1\u2212/\u2212 donor T cells had improved survival in the A20 lymphoma model (Figure 7A), but both T cell replete groups showed comparable survival in the RENCA solid tumor model (Figure 7B).", [["Ceacam1\u2212/\u2212 donor T cells", "ANATOMY", 14, 38], ["A20 lymphoma", "ANATOMY", 68, 80], ["T cell", "ANATOMY", 109, 115], ["RENCA solid tumor", "ANATOMY", 165, 182], ["lymphoma", "DISEASE", 72, 80], ["tumor", "DISEASE", 177, 182], ["Recipients", "ORGANISM", 0, 10], ["Ceacam1\u2212", "GENE_OR_GENE_PRODUCT", 14, 22], ["T cells", "CELL", 31, 38], ["A20 lymphoma", "CANCER", 68, 80], ["T cell", "CELL", 109, 115], ["RENCA solid tumor", "CANCER", 165, 182], ["Ceacam1\u2212/\u2212 donor T cells", "CELL_LINE", 14, 38], ["Ceacam1\u2212/\u2212 donor T cells", "TREATMENT", 14, 38], ["both T cell replete groups", "TEST", 104, 130], ["A20 lymphoma", "OBSERVATION", 68, 80], ["RENCA", "ANATOMY", 165, 170], ["solid tumor", "OBSERVATION", 171, 182]]], ["When we analyzed these two tumor lines for Ceacam1 expression, we noted that all A20 lymphoma cells uniformly expressed high levels, while only a subset of RENCA cells expressed some Ceacam1 (Figure 7C).DiscussionIn this report, we show that Ceacam1, which is found on both donor alloreactive T cells as well as non-hematopoietic tissues such as gastrointestinal and hepatic epithelium, can regulate both donor T cell function and the sensitivity of allo-BMT recipients to radiation-containing preparative regimens.", [["tumor lines", "ANATOMY", 27, 38], ["A20 lymphoma cells", "ANATOMY", 81, 99], ["RENCA cells", "ANATOMY", 156, 167], ["alloreactive T cells", "ANATOMY", 280, 300], ["non-hematopoietic tissues", "ANATOMY", 312, 337], ["gastrointestinal", "ANATOMY", 346, 362], ["hepatic epithelium", "ANATOMY", 367, 385], ["T cell", "ANATOMY", 411, 417], ["tumor", "DISEASE", 27, 32], ["lymphoma", "DISEASE", 85, 93], ["tumor lines", "CELL", 27, 38], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 43, 50], ["A20 lymphoma cells", "CELL", 81, 99], ["RENCA cells", "CELL", 156, 167], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 183, 190], ["Figure 7C", "GENE_OR_GENE_PRODUCT", 192, 201], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 242, 249], ["alloreactive T cells", "CELL", 280, 300], ["non-hematopoietic tissues", "TISSUE", 312, 337], ["gastrointestinal", "ORGAN", 346, 362], ["hepatic epithelium", "TISSUE", 367, 385], ["T cell", "CELL", 411, 417], ["tumor lines", "CELL_LINE", 27, 38], ["Ceacam1", "PROTEIN", 43, 50], ["A20 lymphoma cells", "CELL_LINE", 81, 99], ["RENCA cells", "CELL_LINE", 156, 167], ["Ceacam1", "PROTEIN", 183, 190], ["Ceacam1", "PROTEIN", 242, 249], ["donor alloreactive T cells", "CELL_TYPE", 274, 300], ["Ceacam1 expression", "PROBLEM", 43, 61], ["all A20 lymphoma cells", "PROBLEM", 77, 99], ["RENCA cells", "PROBLEM", 156, 167], ["Ceacam1", "PROBLEM", 242, 249], ["donor alloreactive T cells", "TREATMENT", 274, 300], ["non-hematopoietic tissues", "PROBLEM", 312, 337], ["gastrointestinal and hepatic epithelium", "PROBLEM", 346, 385], ["allo-BMT recipients", "TREATMENT", 450, 469], ["radiation", "TREATMENT", 473, 482], ["preparative regimens", "TREATMENT", 494, 514], ["tumor lines", "OBSERVATION", 27, 38], ["A20 lymphoma cells", "OBSERVATION", 81, 99], ["high", "OBSERVATION_MODIFIER", 120, 124], ["levels", "OBSERVATION_MODIFIER", 125, 131], ["Ceacam1", "OBSERVATION_MODIFIER", 183, 190], ["Ceacam1", "OBSERVATION", 242, 249], ["alloreactive T cells", "OBSERVATION", 280, 300], ["non-hematopoietic tissues", "OBSERVATION", 312, 337], ["gastrointestinal", "ANATOMY", 346, 362], ["hepatic", "ANATOMY", 367, 374], ["epithelium", "ANATOMY_MODIFIER", 375, 385]]], ["In addition, Ceacam1 on donor T cells and tumors may modulate GVT activity.", [["donor T cells", "ANATOMY", 24, 37], ["tumors", "ANATOMY", 42, 48], ["GVT", "ANATOMY", 62, 65], ["tumors", "DISEASE", 42, 48], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 13, 20], ["donor T cells", "CELL", 24, 37], ["tumors", "CANCER", 42, 48], ["GVT", "GENE_OR_GENE_PRODUCT", 62, 65], ["Ceacam1", "PROTEIN", 13, 20], ["donor T cells", "CELL_TYPE", 24, 37], ["Ceacam1 on donor T cells", "TREATMENT", 13, 37], ["tumors", "PROBLEM", 42, 48], ["Ceacam1", "OBSERVATION", 13, 20], ["GVT activity", "OBSERVATION", 62, 74]]], ["Ceacam1 on both the donor allograft and recipient tissues thus appears to represent an important regulator of GVHD and GVT morbidity and mortality via both T cell dependent and independent mechanisms, suggesting that therapeutic approaches which modulate Ceacam1 may need to assess and balance GVHD vs. GVT.DiscussionCeacam1 on T cells has previously been shown to restrain CD4 T cell polarization, cytokine secretion and cytotoxicity.", [["donor allograft", "ANATOMY", 20, 35], ["tissues", "ANATOMY", 50, 57], ["T cell", "ANATOMY", 156, 162], ["T cells", "ANATOMY", 328, 335], ["CD4 T cell", "ANATOMY", 374, 384], ["Ceacam1", "CHEMICAL", 0, 7], ["GVHD", "DISEASE", 110, 114], ["GVT", "DISEASE", 119, 122], ["GVHD", "DISEASE", 294, 298], ["GVT", "DISEASE", 303, 306], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 0, 7], ["allograft", "TISSUE", 26, 35], ["recipient tissues", "TISSUE", 40, 57], ["GVT", "CANCER", 119, 122], ["T cell", "CELL", 156, 162], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 255, 262], ["DiscussionCeacam1", "SIMPLE_CHEMICAL", 307, 324], ["T cells", "CELL", 328, 335], ["CD4 T cell", "CELL", 374, 384], ["Ceacam1", "PROTEIN", 0, 7], ["Ceacam1", "PROTEIN", 255, 262], ["DiscussionCeacam1", "PROTEIN", 307, 324], ["T cells", "CELL_TYPE", 328, 335], ["CD4", "PROTEIN", 374, 377], ["cytokine", "PROTEIN", 399, 407], ["Ceacam1", "PROBLEM", 0, 7], ["the donor allograft", "TREATMENT", 16, 35], ["GVHD", "PROBLEM", 110, 114], ["GVT morbidity", "PROBLEM", 119, 132], ["GVHD", "PROBLEM", 294, 298], ["GVT", "PROBLEM", 303, 306], ["cytokine secretion", "PROBLEM", 399, 417], ["cytotoxicity", "PROBLEM", 422, 434], ["donor allograft", "OBSERVATION", 20, 35], ["appears to represent", "UNCERTAINTY", 63, 83], ["GVHD", "OBSERVATION", 110, 114], ["cell dependent", "OBSERVATION_MODIFIER", 158, 172]]], ["In our GVHD model systems however, we found similar T cell polarization and cytokine secretion when we analyzed donor alloreactive T cells ex vivo (Table 1).", [["T cell", "ANATOMY", 52, 58], ["alloreactive T cells", "ANATOMY", 118, 138], ["GVHD", "DISEASE", 7, 11], ["T cell", "CELL", 52, 58], ["alloreactive T cells", "CELL", 118, 138], ["cytokine", "PROTEIN", 76, 84], ["donor alloreactive T cells", "CELL_TYPE", 112, 138], ["similar T cell polarization", "PROBLEM", 44, 71], ["cytokine secretion", "PROBLEM", 76, 94], ["donor alloreactive T cells", "TREATMENT", 112, 138], ["GVHD", "OBSERVATION", 7, 11], ["cell polarization", "OBSERVATION", 54, 71]]], ["We ascribe this to the strongly proinflammatory cytokine milieu found in recipients following myeloablative radiation treatment, as well as the ubiquitous presence of alloantigen, which together promote strong Th1 differentiation regardless of Ceacam1 expression.", [["alloantigen", "GENE_OR_GENE_PRODUCT", 167, 178], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 244, 251], ["proinflammatory cytokine", "PROTEIN", 32, 56], ["alloantigen", "PROTEIN", 167, 178], ["Ceacam1", "PROTEIN", 244, 251], ["myeloablative radiation treatment", "TREATMENT", 94, 127], ["Ceacam1 expression", "OBSERVATION", 244, 262]]], ["However, in our model systems Ceacam1 regulated T cell activation, and numbers of donor alloactivated T cells in both lymphoid tissues and GVHD target tissues, in patterns that generally correlated with levels target organ damage (Figures 2", [["T cell", "ANATOMY", 48, 54], ["alloactivated T cells", "ANATOMY", 88, 109], ["lymphoid tissues", "ANATOMY", 118, 134], ["GVHD target tissues", "ANATOMY", 139, 158], ["organ", "ANATOMY", 217, 222], ["GVHD", "DISEASE", 139, 143], ["organ damage", "DISEASE", 217, 229], ["Ceacam1", "GENE_OR_GENE_PRODUCT", 30, 37], ["T cell", "CELL", 48, 54], ["T cells", "CELL", 102, 109], ["lymphoid tissues", "TISSUE", 118, 134], ["GVHD target tissues", "TISSUE", 139, 158], ["organ", "ORGAN", 217, 222], ["Ceacam1", "PROTEIN", 30, 37], ["donor alloactivated T cells", "CELL_TYPE", 82, 109], ["donor alloactivated T cells", "TREATMENT", 82, 109], ["GVHD target tissues", "PROBLEM", 139, 158], ["levels target organ damage", "PROBLEM", 203, 229], ["cell activation", "OBSERVATION", 50, 65], ["both", "ANATOMY_MODIFIER", 113, 117], ["lymphoid tissues", "ANATOMY", 118, 134], ["GVHD", "OBSERVATION", 139, 143]]]], "PMC7115109": [["Cross-Border Threats to Human SecurityHuman beings are all mortal and are vulnerable to risks at various stages of their lifetime.", [["Human", "ORGANISM", 24, 29], ["Human", "SPECIES", 24, 29]]], ["Nobody can be safe from malignant diseases, sudden accidents, loss of job, separation from family and other serious contingencies.", [["malignant diseases", "DISEASE", 24, 42], ["sudden accidents", "DISEASE", 44, 60], ["loss of job", "DISEASE", 62, 73], ["malignant diseases", "PROBLEM", 24, 42], ["malignant", "OBSERVATION", 24, 33]]], ["While many risks we encounter are idiosyncratic, others are what economists call \u2018 systemic\u2019 risks that pounce on groups of people all at once.1 A multitude of individuals and households can be adversely affected by a serious and pervasive calamity such as a large-scale natural disaster, an epidemic, a financial crisis or a war.", [["calamity", "DISEASE", 240, 248], ["people", "ORGANISM", 124, 130], ["people", "SPECIES", 124, 130], ["a serious and pervasive calamity", "PROBLEM", 216, 248]]], ["When a risk becomes reality, it may inflict grave anxieties and acute deprivation on ordinary people, ruining past achievements in human development or the expanded range of choices people have come to enjoy, built up over several decades (Sen 2003).Cross-Border Threats to Human SecurityThis introduces the paradigm of human security, a framework of public action to cope effectively with crisis situations that intensify the \u2018sources of unfreedom\u2019 (Sen 1999, 3\u20134).", [["people", "ORGANISM", 94, 100], ["human", "ORGANISM", 131, 136], ["people", "ORGANISM", 182, 188], ["Human", "ORGANISM", 274, 279], ["human", "ORGANISM", 320, 325], ["people", "SPECIES", 94, 100], ["human", "SPECIES", 131, 136], ["people", "SPECIES", 182, 188], ["Human", "SPECIES", 274, 279], ["human", "SPECIES", 320, 325], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 320, 325], ["grave anxieties", "PROBLEM", 44, 59], ["acute deprivation", "PROBLEM", 64, 81], ["crisis situations", "PROBLEM", 390, 407]]], ["The goal of human security is to secure basic freedoms for everyone in the face of present and future risks and threats, by combining top-down protection and bottom-up empowerment.", [["human", "ORGANISM", 12, 17], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17]]], ["The most revolutionary feature of the human security paradigm is that the referent of security has shifted from the state to the individual human being.", [["human", "ORGANISM", 38, 43], ["human", "ORGANISM", 140, 145], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 140, 145]]], ["Layers of government, international organizations, donor agencies, business, civil society, religious communities and other organizations are all expected to contribute to this end: securing freedoms for individual human beings (CHS 2003; Kaldor 2007).Cross-Border Threats to Human SecurityIn the present volume, \u2018East Asia\u2019 is defined as a group of nations consisting of the Association of Southeast Asian Nations (ASEAN) countries, China, Japan and South Korea.", [["human", "ORGANISM", 215, 220], ["Human", "ORGANISM", 276, 281], ["human", "SPECIES", 215, 220], ["Human", "SPECIES", 276, 281], ["human", "SPECIES", 215, 220], ["government", "OBSERVATION", 10, 20], ["volume", "OBSERVATION_MODIFIER", 305, 311]]], ["This region has experienced dynamic economic growth and has enjoyed relative peace in the sense that we have not had large-scale \u2018hot wars\u2019 involving nation-states in recent decades, more precisely, since 1979 (T\u00f8nnesson 2017).", [["dynamic economic growth", "PROBLEM", 28, 51], ["dynamic", "OBSERVATION_MODIFIER", 28, 35], ["economic", "OBSERVATION_MODIFIER", 36, 44], ["growth", "OBSERVATION_MODIFIER", 45, 51]]], ["However, just like the entire global society, the East Asian region has been haunted by a number of serious threats to human security, which have been well examined in works such as Elliott and Caballero-Anthony (2013), Howe (2013), Jonsson (2009), Nishikawa (2010), Peou (2009), Song and Cook (2015), Teh (2012), Tow et al. (2013), and Watson and Pandey (2005).", [["human", "ORGANISM", 119, 124], ["human", "SPECIES", 119, 124], ["human", "SPECIES", 119, 124], ["entire", "OBSERVATION_MODIFIER", 23, 29], ["global", "OBSERVATION_MODIFIER", 30, 36], ["society", "OBSERVATION", 37, 44]]], ["The list of serious threats that the region faces, as well as that of prescriptions to cope with them, are almost endless.Cross-Border Threats to Human SecurityIn this introduction, we classify various threats to human security threefold, according to their proximate causes (Tanaka 2015 and Chapter 10.1007/978-3-319-95240-6_2 of this volume).", [["Human", "ORGANISM", 146, 151], ["human", "ORGANISM", 213, 218], ["Human", "SPECIES", 146, 151], ["human", "SPECIES", 213, 218], ["human", "SPECIES", 213, 218]]], ["The Pacific Ring of Fire and the Eurasian seismic zone are conducive to massive shakings of the surface of the earth, and to gigantic tsunami when seismic waves run through the ocean, as demonstrated in the Indian Ocean tsunami in 2004 (nearly 250,000 fatalities), the Sichuan Earthquake in 2008 (nearly 90,000 fatalities), and the Great East Japan Earthquake in 2011 (nearly 20,000 fatalities).", [["surface", "ANATOMY", 96, 103], ["fatalities", "DISEASE", 252, 262], ["Earthquake", "DISEASE", 277, 287], ["fatalities", "DISEASE", 311, 321], ["The Pacific Ring of Fire", "TREATMENT", 0, 24], ["the Eurasian seismic zone", "TREATMENT", 29, 54], ["Pacific", "OBSERVATION_MODIFIER", 4, 11], ["Ring", "OBSERVATION_MODIFIER", 12, 16], ["Fire", "OBSERVATION_MODIFIER", 20, 24], ["Eurasian", "OBSERVATION_MODIFIER", 33, 41], ["seismic zone", "OBSERVATION", 42, 54], ["massive", "OBSERVATION_MODIFIER", 72, 79], ["shakings", "OBSERVATION", 80, 88], ["surface", "ANATOMY_MODIFIER", 96, 103], ["earth", "ANATOMY", 111, 116]]], ["There are also hundreds of active volcanoes in the region.", [["active volcanoes in the region", "PROBLEM", 27, 57], ["hundreds", "OBSERVATION_MODIFIER", 15, 23], ["active", "OBSERVATION_MODIFIER", 27, 33], ["volcanoes", "OBSERVATION", 34, 43], ["region", "ANATOMY_MODIFIER", 51, 57]]], ["In addition, typhoons in the Pacific Ocean and cyclones in the Indian Ocean devastate the coastal areas of the region very often.", [["coastal", "ANATOMY_MODIFIER", 90, 97], ["region", "ANATOMY_MODIFIER", 111, 117]]], ["In 2008, some foreign countries attempted to organize a military rescue operation into Myanmar when many people were imperiled by Cyclone Nargis (that eventually claimed the lives of more than 140,000).", [["people", "ORGANISM", 105, 111], ["people", "SPECIES", 105, 111], ["a military rescue operation", "TREATMENT", 54, 81]]], ["The islands of the Philippines are also shaken by the frequent landfall of typhoons.", [["typhoons", "DISEASE", 75, 83], ["islands", "OBSERVATION_MODIFIER", 4, 11]]], ["Finally, there are dire predictions that climate change and resultant floods and droughts may wreak havoc on agricultural production and threaten food security.Cross-Border Threats to Human SecurityThe second category is the threats coming from the \u2018 living system,\u2019 such as the spread of infectious diseases, many of which are mediated by the organic bodies of humans and animals.", [["droughts", "DISEASE", 81, 89], ["infectious diseases", "DISEASE", 289, 308], ["Human", "ORGANISM", 184, 189], ["humans", "ORGANISM", 362, 368], ["Human", "SPECIES", 184, 189], ["humans", "SPECIES", 362, 368], ["humans", "SPECIES", 362, 368], ["resultant floods", "PROBLEM", 60, 76], ["infectious diseases", "PROBLEM", 289, 308], ["spread", "OBSERVATION_MODIFIER", 279, 285], ["infectious", "OBSERVATION", 289, 299], ["organic bodies", "ANATOMY_MODIFIER", 344, 358]]], ["Major diseases that have demanded urgent responses in East Asia include human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS), severe acute respiratory syndrome (SARS) and avian flu.", [["human immunodeficiency virus infection", "DISEASE", 72, 110], ["acquired immune deficiency syndrome", "DISEASE", 115, 150], ["HIV/AIDS", "DISEASE", 152, 160], ["acute respiratory syndrome", "DISEASE", 170, 196], ["SARS", "DISEASE", 198, 202], ["avian flu", "DISEASE", 208, 217], ["human immunodeficiency virus", "ORGANISM", 72, 100], ["human immunodeficiency virus", "SPECIES", 72, 100], ["avian flu", "SPECIES", 208, 217], ["human immunodeficiency virus", "SPECIES", 72, 100], ["HIV", "SPECIES", 152, 155], ["Major diseases", "PROBLEM", 0, 14], ["human immunodeficiency virus infection", "PROBLEM", 72, 110], ["acquired immune deficiency syndrome", "PROBLEM", 115, 150], ["HIV/AIDS)", "PROBLEM", 152, 161], ["severe acute respiratory syndrome", "PROBLEM", 163, 196], ["SARS", "PROBLEM", 198, 202], ["avian flu", "PROBLEM", 208, 217], ["diseases", "OBSERVATION", 6, 14], ["immune deficiency", "OBSERVATION", 124, 141], ["severe", "OBSERVATION_MODIFIER", 163, 169], ["acute", "OBSERVATION_MODIFIER", 170, 175], ["respiratory syndrome", "OBSERVATION", 176, 196]]], ["A serious disease that broke out in another region, such as the Ebola hemorrhagic fever, could have been transmitted to East Asia in the absence of protective efforts.", [["Ebola hemorrhagic fever", "DISEASE", 64, 87], ["Ebola hemorrhagic fever", "SPECIES", 64, 87], ["A serious disease", "PROBLEM", 0, 17], ["the Ebola hemorrhagic fever", "PROBLEM", 60, 87], ["serious", "OBSERVATION_MODIFIER", 2, 9], ["disease", "OBSERVATION", 10, 17], ["Ebola", "OBSERVATION_MODIFIER", 64, 69], ["hemorrhagic", "OBSERVATION_MODIFIER", 70, 81], ["fever", "OBSERVATION", 82, 87]]], ["In the meantime, cases of the Middle East respiratory syndrome coronavirus (MERS-CoV) have been reported in several East Asian countries.", [["Middle East respiratory syndrome coronavirus", "DISEASE", 30, 74], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 30, 74], ["MERS-CoV", "ORGANISM", 76, 84], ["Middle East respiratory syndrome coronavirus", "SPECIES", 30, 74], ["MERS-CoV", "SPECIES", 76, 84], ["the Middle East respiratory syndrome coronavirus", "PROBLEM", 26, 74], ["Middle", "ANATOMY_MODIFIER", 30, 36], ["respiratory syndrome", "OBSERVATION", 42, 62]]], ["Regional cooperation is indispensable to control these epidemics as they spread through the cross-border migration of people and animals, and the circulation of goods.", [["people", "ORGANISM", 118, 124], ["people", "SPECIES", 118, 124], ["these epidemics", "PROBLEM", 49, 64]]], ["Enhanced connectivity of people and goods may endanger people\u2019s health and well-being, given the rapid pace in which the global and regional economy is being integrated.Cross-Border Threats to Human SecurityThe third category is those threats directly coming from the \u2018 social system\u2019 of human beings, such as wars, violent conflict, terrorism, land grabbing, economic crises, human trafficking and an exodus of refugees.", [["violent conflict", "DISEASE", 316, 332], ["people", "ORGANISM", 25, 31], ["people", "ORGANISM", 55, 61], ["Human", "ORGANISM", 193, 198], ["human", "ORGANISM", 288, 293], ["human", "ORGANISM", 377, 382], ["people", "SPECIES", 25, 31], ["people", "SPECIES", 55, 61], ["Human", "SPECIES", 193, 198], ["human", "SPECIES", 288, 293], ["human", "SPECIES", 377, 382], ["human", "SPECIES", 288, 293], ["human", "SPECIES", 377, 382], ["the rapid pace", "TREATMENT", 93, 107], ["terrorism", "PROBLEM", 334, 343], ["economic crises", "PROBLEM", 360, 375], ["human trafficking", "TREATMENT", 377, 394]]], ["The continued division of Korea and the tension in the Taiwan Strait are graphic examples of the lingering legacy of the Cold War, and North Korea\u2019s brinkmanship diplomacy toying with nuclear missiles has been a real threat to human security in the region.", [["human", "ORGANISM", 227, 232], ["human", "SPECIES", 227, 232], ["human", "SPECIES", 227, 232], ["nuclear missiles", "PROBLEM", 184, 200], ["division", "OBSERVATION_MODIFIER", 14, 22], ["tension", "OBSERVATION_MODIFIER", 40, 47], ["nuclear missiles", "OBSERVATION", 184, 200], ["region", "ANATOMY_MODIFIER", 249, 255]]], ["Setting aside ideological confrontations, serious inequality and ethnic minority issues can be found in the borderlands, for example, in the interior regions of China, Okinawa in Japan, Mindanao in the Philippines, Aceh in Indonesia, and in the South of Thailand.", [["serious inequality and ethnic minority issues", "PROBLEM", 42, 87], ["interior", "ANATOMY_MODIFIER", 141, 149], ["regions", "ANATOMY_MODIFIER", 150, 157], ["China", "ANATOMY", 161, 166]]], ["On the other hand, as the economies in East Asia are more and more closely connected, the effects of a possible economic crisis will be felt in every corner of the region.", [["economic crisis", "PROBLEM", 112, 127], ["possible", "UNCERTAINTY", 103, 111], ["economic crisis", "OBSERVATION", 112, 127], ["region", "ANATOMY_MODIFIER", 164, 170]]], ["The idea of a human security that attaches a high value to people\u2019s welfare was openly advocated by Mr. Keizo Obuchi, the then Foreign Minister of Japan, in Singapore in May 1998 after the Asian Financial Crisis hit the region (Kurusu 2011).Cross-Border Threats to Human SecurityThe case study chapters of this book are arranged from those addressing natural disasters to those dealing with human conflicts based on this classification of sources of threats to human security.", [["human", "ORGANISM", 14, 19], ["people", "ORGANISM", 59, 65], ["Human", "ORGANISM", 265, 270], ["human", "ORGANISM", 391, 396], ["human", "ORGANISM", 461, 466], ["human", "SPECIES", 14, 19], ["people", "SPECIES", 59, 65], ["Human", "SPECIES", 265, 270], ["human", "SPECIES", 391, 396], ["human", "SPECIES", 461, 466], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 391, 396], ["human", "SPECIES", 461, 466]]], ["The earth was formed about 4.6 billion years ago, the first living organisms appeared about 4.0 billion years ago, and the first Homo sapiens was born only about 3 hundred thousand years ago.", [["Homo sapiens", "ORGANISM", 129, 141], ["Homo sapiens", "SPECIES", 129, 141], ["Homo sapiens", "SPECIES", 129, 141]]], ["These ultralong-term historical layers lie behind the three systems of the present age.Cross-Border Threats to Human SecurityAt the same time, it is important to note that the hazards emanating from these three systems are closely connected to each other.", [["Human", "ORGANISM", 111, 116], ["Human", "SPECIES", 111, 116], ["These ultralong-term historical layers", "TREATMENT", 0, 38]]], ["For example, there is no \u2018pure\u2019 natural disaster; the casualties from natural disasters like floods and earthquakes hinge on the quality of social systems, including self-help activities at the level of neighborhood communities, as well as the quality of environmental planning and civil engineering.", [["earthquakes", "DISEASE", 104, 115], ["no", "UNCERTAINTY", 22, 24]]], ["Climate change occurs at the level of the physical system but is clearly an outcome of industrial activities of humans.", [["humans", "ORGANISM", 112, 118], ["humans", "SPECIES", 112, 118], ["humans", "SPECIES", 112, 118], ["Climate change", "PROBLEM", 0, 14], ["physical system", "ANATOMY", 42, 57]]], ["It is also known that a large proportion of the deaths during famines and violent conflicts is due to the outbreak of infectious diseases in relief camps.2 Despite these entanglements, as Akihiko Tanaka indicates in Chapter 10.1007/978-3-319-95240-6_2, we have a clear division of academic disciplines corresponding to the three systems: the physical system is the subject of physical and chemical sciences and engineering; the living system is studied by biological, medical and ecological sciences; and the social system is researched by the social sciences and the humanities.", [["deaths", "DISEASE", 48, 54], ["famines", "DISEASE", 62, 69], ["infectious diseases", "DISEASE", 118, 137], ["the deaths", "PROBLEM", 44, 54], ["infectious diseases in relief camps", "PROBLEM", 118, 153], ["large", "OBSERVATION_MODIFIER", 24, 29], ["proportion", "OBSERVATION_MODIFIER", 30, 40], ["infectious", "OBSERVATION", 118, 128]]], ["Human security provides a powerful for multidisciplinary collaboration between experts with those academic backgrounds.", [["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5]]], ["Although the three systems (the earth, the ecosystem and human society) can be harmful to individual human beings, it must be noted that they are also beneficial and even indispensable for the prosperity and well-being of the entire human race: natural energy, biodiversity and robust human institutions are all parts of the three systems.", [["human", "ORGANISM", 57, 62], ["human", "ORGANISM", 101, 106], ["human", "ORGANISM", 233, 238], ["human", "ORGANISM", 285, 290], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 233, 238], ["human", "SPECIES", 285, 290], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 233, 238], ["human", "SPECIES", 285, 290], ["robust human institutions", "TREATMENT", 278, 303]]], ["We must be prepared, however, to minimize the threats from the same systems for the sake of human survival.Cross-Border Threats to Human Security", [["human", "ORGANISM", 92, 97], ["Human", "ORGANISM", 131, 136], ["human", "SPECIES", 92, 97], ["Human", "SPECIES", 131, 136], ["human", "SPECIES", 92, 97], ["human survival", "TREATMENT", 92, 106]]]], "PMC4607159": [["IntroductionAlthough extracorporeal membrane oxygenation (ECMO) has been used in severe cardiopulmonary diseases since the 1970s, the outcome in the early ECMO era was not satisfactory [1\u20133].", [["extracorporeal membrane", "ANATOMY", 21, 44], ["cardiopulmonary", "ANATOMY", 88, 103], ["cardiopulmonary diseases", "DISEASE", 88, 112], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 21, 44], ["extracorporeal membrane oxygenation", "TREATMENT", 21, 56], ["ECMO", "TREATMENT", 58, 62], ["severe cardiopulmonary diseases", "PROBLEM", 81, 112], ["membrane oxygenation", "OBSERVATION", 36, 56], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["cardiopulmonary", "ANATOMY", 88, 103], ["diseases", "OBSERVATION", 104, 112]]], ["The 2009 H1N1 influenza pandemic gave birth to several studies that suggested improved outcomes of modern ECMO [6\u20138].", [["influenza pandemic", "DISEASE", 14, 32], ["H1N1 influenza pandemic", "SPECIES", 9, 32], ["several studies", "TEST", 47, 62], ["modern ECMO", "TREATMENT", 99, 110]]], ["In the Korean epidemic of Middle East respiratory syndrome (MERS), ECMO played a key role in treating critically ill patients.IntroductionECMO enables an efficient oxygenation and elimination of carbon dioxide.", [["Middle East respiratory syndrome", "DISEASE", 26, 58], ["MERS", "DISEASE", 60, 64], ["critically ill", "DISEASE", 102, 116], ["carbon dioxide", "CHEMICAL", 195, 209], ["carbon dioxide", "CHEMICAL", 195, 209], ["patients", "ORGANISM", 117, 125], ["carbon dioxide", "SIMPLE_CHEMICAL", 195, 209], ["patients", "SPECIES", 117, 125], ["Middle East respiratory syndrome (MERS)", "SPECIES", 26, 65], ["Middle East respiratory syndrome", "PROBLEM", 26, 58], ["ECMO", "TREATMENT", 67, 71], ["carbon dioxide", "TREATMENT", 195, 209], ["Middle", "ANATOMY_MODIFIER", 26, 32], ["respiratory syndrome", "OBSERVATION", 38, 58], ["carbon dioxide", "OBSERVATION", 195, 209]]], ["ECMO can be operated in two different modes: a venovenous (VV) mode for ventilatory failure and a veno-arterial (VA) mode for respiratory and cardiac support, however, a number of complications could impinge upon the potential benefit of ECMO, and acute kidney injury (AKI) is the most frequently reported problem [9, 10].IntroductionThree major sets of criteria have been proposed to define AKI RIFLE (the Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function and End stage kidney disease), the Acute Kidney Injury Network (AKIN), and the Kidney Disease Improving Global Outcomes (KDIGO) criteria.", [["veno-arterial", "ANATOMY", 98, 111], ["respiratory", "ANATOMY", 126, 137], ["cardiac", "ANATOMY", 142, 149], ["kidney", "ANATOMY", 254, 260], ["renal", "ANATOMY", 415, 420], ["kidney", "ANATOMY", 444, 450], ["kidney", "ANATOMY", 463, 469], ["kidney", "ANATOMY", 488, 494], ["kidney", "ANATOMY", 518, 524], ["Kidney", "ANATOMY", 545, 551], ["ventilatory failure", "DISEASE", 72, 91], ["respiratory and cardiac support", "DISEASE", 126, 157], ["acute kidney injury", "DISEASE", 248, 267], ["AKI", "DISEASE", 269, 272], ["AKI", "DISEASE", 392, 395], ["renal failure", "DISEASE", 415, 428], ["Injury", "DISEASE", 430, 436], ["End stage kidney disease", "DISEASE", 508, 532], ["Acute Kidney Injury", "DISEASE", 539, 558], ["cardiac", "ORGAN", 142, 149], ["kidney", "ORGAN", 254, 260], ["renal", "ORGAN", 415, 420], ["kidney", "ORGAN", 444, 450], ["kidney", "ORGAN", 463, 469], ["kidney", "ORGAN", 488, 494], ["kidney", "ORGAN", 518, 524], ["Kidney", "ORGAN", 545, 551], ["ECMO", "TREATMENT", 0, 4], ["a venovenous (VV) mode", "TREATMENT", 45, 67], ["ventilatory failure", "PROBLEM", 72, 91], ["a veno-arterial (VA) mode", "TREATMENT", 96, 121], ["respiratory and cardiac support", "TREATMENT", 126, 157], ["ECMO", "TREATMENT", 238, 242], ["acute kidney injury", "PROBLEM", 248, 267], ["AKI", "PROBLEM", 269, 272], ["AKI RIFLE", "PROBLEM", 392, 401], ["renal failure", "PROBLEM", 415, 428], ["Injury to the kidney", "PROBLEM", 430, 450], ["Failure of kidney function", "PROBLEM", 452, 478], ["Loss of kidney function", "PROBLEM", 480, 503], ["End stage kidney disease", "PROBLEM", 508, 532], ["the Acute Kidney Injury", "PROBLEM", 535, 558], ["the Kidney Disease", "PROBLEM", 579, 597], ["ventilatory failure", "OBSERVATION", 72, 91], ["veno-arterial", "ANATOMY", 98, 111], ["cardiac", "ANATOMY", 142, 149], ["support", "OBSERVATION", 150, 157], ["acute", "OBSERVATION_MODIFIER", 248, 253], ["kidney", "ANATOMY", 254, 260], ["injury", "OBSERVATION", 261, 267], ["AKI RIFLE", "OBSERVATION", 392, 401], ["renal", "ANATOMY", 415, 420], ["failure", "OBSERVATION", 421, 428], ["Injury", "OBSERVATION", 430, 436], ["kidney", "ANATOMY", 444, 450], ["Failure", "OBSERVATION", 452, 459], ["kidney", "ANATOMY", 463, 469], ["kidney", "ANATOMY", 488, 494], ["kidney", "ANATOMY", 518, 524], ["disease", "OBSERVATION", 525, 532], ["Acute", "OBSERVATION_MODIFIER", 539, 544], ["Kidney", "ANATOMY", 545, 551], ["Injury", "OBSERVATION", 552, 558], ["Kidney", "ANATOMY", 583, 589], ["Disease", "OBSERVATION", 590, 597]]], ["Lin et al. retrospectively analyzed 46 patients who were treated with ECMO and demonstrated the good discriminatory power of the RIFILE criteria for in-hospital mortality [area under the receiver operator curve (AUROC), 0.868, p < 0.001] [11].", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["ECMO", "TREATMENT", 70, 74], ["the receiver operator curve", "TEST", 183, 210], ["AUROC", "TEST", 212, 217], ["et al", "OBSERVATION", 4, 9]]], ["Yan et al. analyzed 67 patients receiving ECMO support and showed similar results; the reported AUROC for in-hospital mortality was 0.738 (p = 0.001) and 0.799 (p <0.001) for RIFLE and AKIN criteria, respectively [12].", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["ECMO support", "TREATMENT", 42, 54], ["RIFLE and AKIN criteria", "TEST", 175, 198]]], ["However, all of the previous studies have mainly focused on the association between AKI and mortality, and none of them have evaluated the potential risk factors of AKI in adult patients [11\u201314].", [["AKI", "DISEASE", 84, 87], ["AKI", "DISEASE", 165, 168], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["the previous studies", "TEST", 16, 36], ["AKI", "PROBLEM", 84, 87], ["AKI", "PROBLEM", 165, 168], ["AKI", "OBSERVATION", 84, 87], ["AKI", "OBSERVATION", 165, 168]]], ["Therefore, we performed this retrospective cohort study to explore the risk factors for AKI and in-hospital mortality in patients receiving ECMO support.Study population ::: Materials and MethodsWe performed a retrospective cohort study in adult patients who were 15 years or older and received ECMO support at Seoul National University Bundang Hospital and Seoul National University Hospital, which are the two tertiary care hospitals.", [["AKI", "DISEASE", 88, 91], ["patients", "ORGANISM", 121, 129], ["patients", "ORGANISM", 246, 254], ["patients", "SPECIES", 121, 129], ["patients", "SPECIES", 246, 254], ["this retrospective cohort study", "TEST", 24, 55], ["AKI", "PROBLEM", 88, 91], ["ECMO support", "TREATMENT", 140, 152], ["a retrospective cohort study", "TEST", 208, 236], ["ECMO support", "TREATMENT", 295, 307]]], ["The study protocol complied with the Declaration of Helsinki and received full approval from the institutional review boards at both Seoul National University Bundang Hospital (B-1412/278-112) and Seoul National University Hospital (J-1503-003-651).", [["The study protocol", "TEST", 0, 18]]], ["Informed consent was waived because patient records/information were anonymized and de-identified prior to analysis.", [["patient", "ORGANISM", 36, 43], ["patient", "SPECIES", 36, 43], ["analysis", "TEST", 107, 115]]], ["No extramural funding was used to support this work.", [["extramural", "OBSERVATION_MODIFIER", 3, 13], ["funding", "OBSERVATION", 14, 21]]], ["A total of 681 patients consecutively received ECMO support from January 2005 to November 2014.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["ECMO support", "TREATMENT", 47, 59]]], ["Patients were excluded from the analysis if they were under 15 years of age (n = 109), if they received ECMO support for less than 24 h (n = 90), if they received ECMO insertion from other hospitals (n = 4), if they had end-stage renal disease or their initial serum creatinine levels were above 353.6 \u03bcmol/L (n = 13), or if they had been receiving continuous renal replacement therapy when ECMO were initiated (n = 66), if they initiated continuous renal replacement therapy on the date of ECMO insertion (n = 77).", [["renal", "ANATOMY", 230, 235], ["serum", "ANATOMY", 261, 266], ["renal", "ANATOMY", 360, 365], ["renal", "ANATOMY", 450, 455], ["end-stage renal disease", "DISEASE", 220, 243], ["creatinine", "CHEMICAL", 267, 277], ["creatinine", "CHEMICAL", 267, 277], ["Patients", "ORGANISM", 0, 8], ["renal", "ORGAN", 230, 235], ["serum", "ORGANISM_SUBSTANCE", 261, 266], ["creatinine", "SIMPLE_CHEMICAL", 267, 277], ["renal", "ORGAN", 360, 365], ["renal", "ORGAN", 450, 455], ["Patients", "SPECIES", 0, 8], ["the analysis", "TEST", 28, 40], ["ECMO support", "TREATMENT", 104, 116], ["ECMO insertion", "TREATMENT", 163, 177], ["end-stage renal disease", "PROBLEM", 220, 243], ["their initial serum creatinine levels", "TEST", 247, 284], ["continuous renal replacement therapy", "TREATMENT", 349, 385], ["ECMO", "TREATMENT", 391, 395], ["continuous renal replacement therapy", "TREATMENT", 439, 475], ["ECMO insertion", "TREATMENT", 491, 505], ["renal", "ANATOMY", 230, 235], ["disease", "OBSERVATION", 236, 243], ["renal", "ANATOMY", 360, 365], ["replacement", "OBSERVATION", 366, 377], ["renal", "ANATOMY", 450, 455], ["replacement", "OBSERVATION", 456, 467]]], ["Therefore, 322 patients were ultimately analyzed in the present study.Measurements and Definitions ::: Materials and MethodsThe physiologic and laboratory data within 24 h before ECMO initiation were collected retrospectively through a review of the electronic medical records.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["the present study", "TEST", 52, 69], ["laboratory data", "TEST", 144, 159]]], ["The clinical parameters that were recorded included the following: age, sex, causes of admission; causes of ECMO support, mode of ECMO, whether to perform cardiopulmonary resuscitation within 24 h, use of an intra-aortic balloon pump (IABP), ECMO settings, duration of ECMO, urine output, and ventilator settings.", [["intra-aortic", "ANATOMY", 208, 220], ["urine", "ANATOMY", 275, 280], ["urine", "ORGANISM_SUBSTANCE", 275, 280], ["The clinical parameters", "TEST", 0, 23], ["ECMO support", "TREATMENT", 108, 120], ["ECMO", "TREATMENT", 130, 134], ["cardiopulmonary resuscitation", "TREATMENT", 155, 184], ["an intra-aortic balloon pump", "TREATMENT", 205, 233], ["IABP", "TREATMENT", 235, 239], ["ECMO settings", "TREATMENT", 242, 255], ["ECMO", "TREATMENT", 269, 273], ["urine output", "TEST", 275, 287], ["ventilator settings", "TREATMENT", 293, 312], ["intra-aortic", "ANATOMY", 208, 220], ["balloon pump", "OBSERVATION", 221, 233], ["urine output", "OBSERVATION", 275, 287]]], ["Initial blood findings, including blood urea nitrogen (BUN), total bilirubin, albumin, white blood cells, hemoglobin level, platelet number, red cell distribution width (RDW), sodium, potassium, chloride, and C-reactive protein (CRP) were measured.", [["blood", "ANATOMY", 8, 13], ["blood", "ANATOMY", 34, 39], ["white blood cells", "ANATOMY", 87, 104], ["platelet", "ANATOMY", 124, 132], ["red cell", "ANATOMY", 141, 149], ["blood urea nitrogen", "CHEMICAL", 34, 53], ["bilirubin", "CHEMICAL", 67, 76], ["sodium", "CHEMICAL", 176, 182], ["potassium", "CHEMICAL", 184, 193], ["chloride", "CHEMICAL", 195, 203], ["urea", "CHEMICAL", 40, 44], ["nitrogen", "CHEMICAL", 45, 53], ["bilirubin", "CHEMICAL", 67, 76], ["sodium", "CHEMICAL", 176, 182], ["potassium", "CHEMICAL", 184, 193], ["chloride", "CHEMICAL", 195, 203], ["blood", "ORGANISM_SUBSTANCE", 8, 13], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["urea nitrogen", "SIMPLE_CHEMICAL", 40, 53], ["BUN", "SIMPLE_CHEMICAL", 55, 58], ["bilirubin", "SIMPLE_CHEMICAL", 67, 76], ["albumin", "GENE_OR_GENE_PRODUCT", 78, 85], ["white blood cells", "CELL", 87, 104], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 106, 116], ["platelet", "CELL", 124, 132], ["red cell", "CELL", 141, 149], ["sodium", "SIMPLE_CHEMICAL", 176, 182], ["potassium", "SIMPLE_CHEMICAL", 184, 193], ["chloride", "SIMPLE_CHEMICAL", 195, 203], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 209, 227], ["CRP", "GENE_OR_GENE_PRODUCT", 229, 232], ["albumin", "PROTEIN", 78, 85], ["white blood cells", "CELL_TYPE", 87, 104], ["hemoglobin", "PROTEIN", 106, 116], ["C-reactive protein", "PROTEIN", 209, 227], ["CRP", "PROTEIN", 229, 232], ["Initial blood findings", "TEST", 0, 22], ["blood urea nitrogen", "TEST", 34, 53], ["BUN", "TEST", 55, 58], ["total bilirubin", "TEST", 61, 76], ["albumin", "TEST", 78, 85], ["white blood cells", "TEST", 87, 104], ["hemoglobin level", "TEST", 106, 122], ["platelet number", "TEST", 124, 139], ["red cell distribution width", "TEST", 141, 168], ["RDW", "TEST", 170, 173], ["sodium", "TEST", 176, 182], ["potassium", "TEST", 184, 193], ["chloride", "TEST", 195, 203], ["C", "TEST", 209, 210], ["CRP", "TEST", 229, 232], ["red cell", "OBSERVATION", 141, 149], ["distribution", "OBSERVATION_MODIFIER", 150, 162], ["width", "OBSERVATION_MODIFIER", 163, 168], ["reactive", "OBSERVATION_MODIFIER", 211, 219]]], ["For the severity index, we used the Simplified Acute Physiology Score 2 (SAPS2) [15].", [["the severity index", "PROBLEM", 4, 22]]], ["To calculate the SAPS2, the worst values during the first 24 h before ECMO initiation were used.Measurements and Definitions ::: Materials and MethodsAKI and the stage of its severity were defined according to the guidelines proposed by KDIGO [16].", [["SAPS2", "DNA", 17, 22], ["the SAPS2", "TEST", 13, 22], ["ECMO initiation", "TREATMENT", 70, 85], ["MethodsAKI", "TREATMENT", 143, 153], ["its severity", "PROBLEM", 171, 183]]], ["AKI was defined in a case with either an increase in serum creatinine by \u2265 26.5 \u03bcmol/L or \u2265 1.5 times the baseline within 48 h.", [["serum", "ANATOMY", 53, 58], ["AKI", "DISEASE", 0, 3], ["creatinine", "CHEMICAL", 59, 69], ["creatinine", "CHEMICAL", 59, 69], ["serum", "ORGANISM_SUBSTANCE", 53, 58], ["creatinine", "SIMPLE_CHEMICAL", 59, 69], ["AKI", "PROBLEM", 0, 3], ["serum creatinine", "TEST", 53, 69], ["increase", "OBSERVATION_MODIFIER", 41, 49]]], ["The changes in serum creatinine according to the AKI stages were as follows: stage 1, an increase of more than or equal to 26.5 \u03bcmol/L or an increase to more than or equal to 1.5- to 2-fold of the baseline; stage 2, an increase to more than 2- to 3-fold of the baseline; stage 3, an increase to more than 3-fold of the baseline or more than or equal to 353.6 \u03bcmol/L with an acute increase of at least 44.2 \u03bcmol/L or on renal replacement therapy.", [["serum", "ANATOMY", 15, 20], ["renal", "ANATOMY", 419, 424], ["creatinine", "CHEMICAL", 21, 31], ["AKI", "DISEASE", 49, 52], ["creatinine", "CHEMICAL", 21, 31], ["serum", "ORGANISM_SUBSTANCE", 15, 20], ["creatinine", "SIMPLE_CHEMICAL", 21, 31], ["renal", "ORGAN", 419, 424], ["The changes", "PROBLEM", 0, 11], ["serum creatinine", "TEST", 15, 31], ["the AKI stages", "TEST", 45, 59], ["stage 1", "PROBLEM", 77, 84], ["stage 2", "PROBLEM", 207, 214], ["stage 3", "PROBLEM", 271, 278], ["an acute increase", "PROBLEM", 371, 388], ["renal replacement therapy", "TREATMENT", 419, 444], ["increase", "OBSERVATION_MODIFIER", 89, 97], ["increase", "OBSERVATION_MODIFIER", 141, 149], ["increase", "OBSERVATION_MODIFIER", 219, 227], ["stage 3", "OBSERVATION_MODIFIER", 271, 278], ["increase", "OBSERVATION_MODIFIER", 283, 291], ["acute", "OBSERVATION_MODIFIER", 374, 379], ["increase", "OBSERVATION_MODIFIER", 380, 388], ["renal", "ANATOMY", 419, 424], ["replacement", "OBSERVATION", 425, 436]]], ["The maximum AKI stage reached during ECMO support was used to define the incidence of AKI [17].", [["AKI", "DISEASE", 12, 15], ["AKI", "DISEASE", 86, 89], ["The maximum AKI stage", "PROBLEM", 0, 21], ["ECMO support", "TREATMENT", 37, 49], ["AKI", "PROBLEM", 86, 89], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["AKI", "OBSERVATION", 12, 15]]], ["In-hospital mortality was determined whether a death certificate had been issued or not at 90 d after ECMO insertion.", [["death", "DISEASE", 47, 52], ["ECMO insertion", "TREATMENT", 102, 116]]], ["The applied ECMO console was composed of a centrifugal pump and membrane oxygenator.", [["membrane", "ANATOMY", 64, 72], ["membrane oxygenator", "CELLULAR_COMPONENT", 64, 83], ["The applied ECMO console", "TREATMENT", 0, 24], ["a centrifugal pump", "TREATMENT", 41, 59], ["membrane oxygenator", "TREATMENT", 64, 83], ["ECMO", "OBSERVATION", 12, 16], ["membrane oxygenator", "OBSERVATION", 64, 83]]], ["The products utilized included CAPIOX EBS (Terumo Corporation, Tokyo, Japan) and QUADROX PLS (Maquet, Hirrlingen, Germany).Statistical analysis ::: Materials and MethodsThe values were expressed as the mean \u00b1 standard deviation in continuous variables and n (%) in categorical variables.", [["CAPIOX EBS (Terumo Corporation", "TREATMENT", 31, 61], ["QUADROX PLS", "TREATMENT", 81, 92], ["the mean \u00b1 standard deviation in continuous variables and n (%) in categorical variables", "PROBLEM", 198, 286]]], ["For the severely skewed variables, such as follow-up duration, the median (interquartile range, IQR) was used.", [["severely", "OBSERVATION_MODIFIER", 8, 16], ["skewed", "OBSERVATION", 17, 23]]], ["The difference was analyzed by an independent t-test in continuous variables and chi-square test in categorical variables.", [["an independent t-test", "TEST", 31, 52], ["chi-square test", "TEST", 81, 96]]], ["For the estimated survival, the Kaplan-Meier method was employed, and the statistical significance was calculated using the log-rank test.", [["the log-rank test", "TEST", 120, 137]]], ["For multivariate analysis, logistic regression analysis for AKI and Cox-proportional hazard analysis for in-hospital mortality were carried out.", [["AKI", "DISEASE", 60, 63], ["multivariate analysis", "TEST", 4, 25], ["logistic regression analysis", "TEST", 27, 55], ["AKI", "PROBLEM", 60, 63], ["Cox-proportional hazard analysis", "TEST", 68, 100]]], ["The variables in the multivariate analysis were chosen by p <0.05 in the univariate analysis.", [["the multivariate analysis", "TEST", 17, 42], ["the univariate analysis", "TEST", 69, 92]]], ["Calibration was done using the Hosmer-Lemeshow goodness-of-fit test to compare the numbers of predicted and observed in-hospital mortality and AKI.", [["AKI", "DISEASE", 143, 146], ["Calibration", "TEST", 0, 11], ["fit test", "TEST", 59, 67], ["AKI", "PROBLEM", 143, 146], ["AKI", "OBSERVATION", 143, 146]]], ["Discrimination was analyzed using AUROC.", [["AUROC", "TEST", 34, 39]]], ["The best threshold was calculated by obtaining the best Youden index (sensitivity + specificity\u20141).", [["Youden index", "TEST", 56, 68], ["specificity", "TEST", 84, 95]]], ["All of the analyses were performed using the SPSS statistics software (version 22, IBM, USA).ResultsThe mean age of the study participants was 60.3 \u00b1 15.3 years and 213 (66.1%) of the participants were male.", [["participants", "ORGANISM", 126, 138], ["participants", "ORGANISM", 184, 196], ["participants", "SPECIES", 126, 138], ["participants", "SPECIES", 184, 196], ["the analyses", "TEST", 7, 19], ["the SPSS statistics software", "TEST", 41, 69], ["the study", "TEST", 116, 125]]], ["The reasons for admission were cardiovascular disease (203, 63.0%), lung disease (49, 15.2%), malignancy (35, 10.9%) and others (35, 10.9%).", [["cardiovascular", "ANATOMY", 31, 45], ["lung", "ANATOMY", 68, 72], ["malignancy", "ANATOMY", 94, 104], ["cardiovascular disease", "DISEASE", 31, 53], ["lung disease", "DISEASE", 68, 80], ["malignancy", "DISEASE", 94, 104], ["lung", "ORGAN", 68, 72], ["cardiovascular disease", "PROBLEM", 31, 53], ["lung disease", "PROBLEM", 68, 80], ["malignancy", "PROBLEM", 94, 104], ["lung", "ANATOMY", 68, 72], ["disease", "OBSERVATION", 73, 80], ["malignancy", "OBSERVATION", 94, 104]]], ["One hundred and thirty seven (42.5%) patients had received cardiopulmonary resuscitation within 24 h prior to ECMO initiation.", [["cardiopulmonary", "ANATOMY", 59, 74], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["cardiopulmonary resuscitation", "TREATMENT", 59, 88], ["ECMO initiation", "TREATMENT", 110, 125]]], ["After the median (IQR) 2 (0\u201310) days of admission, the patients received ECMO insertion because of cardiotomy (31, 9.6%), non-operative cardiovascular causes (185, 57.5%), adult respiratory distress syndrome (ARDS) (43, 13.4%), non-ARDS lung causes (44, 13.7%) and other causes (19, 5.9%).", [["cardiovascular", "ANATOMY", 136, 150], ["respiratory", "ANATOMY", 178, 189], ["lung", "ANATOMY", 237, 241], ["cardiotomy", "DISEASE", 99, 109], ["cardiovascular causes", "DISEASE", 136, 157], ["respiratory distress syndrome", "DISEASE", 178, 207], ["ARDS", "DISEASE", 209, 213], ["non-ARDS lung causes", "DISEASE", 228, 248], ["patients", "ORGANISM", 55, 63], ["lung", "ORGAN", 237, 241], ["patients", "SPECIES", 55, 63], ["ECMO insertion", "TREATMENT", 73, 87], ["cardiotomy", "TREATMENT", 99, 109], ["non-operative cardiovascular causes", "PROBLEM", 122, 157], ["adult respiratory distress syndrome", "PROBLEM", 172, 207], ["ARDS", "PROBLEM", 209, 213], ["non-ARDS lung causes", "PROBLEM", 228, 248], ["cardiotomy", "OBSERVATION", 99, 109], ["cardiovascular", "ANATOMY", 136, 150], ["respiratory", "OBSERVATION", 178, 189], ["distress syndrome", "OBSERVATION", 190, 207], ["lung", "ANATOMY", 237, 241]]], ["Two hundred and thirty (71.4%) and 92 (28.6%) patients received VA and VV ECMO support, respectively.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["VV", "SPECIES", 71, 73], ["VA", "TREATMENT", 64, 66], ["VV ECMO support", "TREATMENT", 71, 86]]], ["One hundred and six (32.9%) patients were undergoing IABP on the date of ECMO insertion.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["IABP", "TREATMENT", 53, 57], ["ECMO insertion", "TREATMENT", 73, 87]]], ["The median (IQR) duration from ECMO initiation to death or discharge was 21 (8\u201340) days.", [["death", "DISEASE", 50, 55]]], ["The incidence of AKI comprising all KDIGO grades was 82.3%.", [["AKI", "DISEASE", 17, 20], ["AKI", "PROBLEM", 17, 20], ["all KDIGO grades", "TEST", 32, 48], ["AKI", "OBSERVATION", 17, 20]]], ["The median (IQR) durations for AKI and in-hospital mortality were 2 (1\u20137) days and 9 (4\u201323) days, respectively.ResultsWe explored the factors associated with in-hospital mortality.", [["AKI", "DISEASE", 31, 34], ["AKI", "PROBLEM", 31, 34]]], ["AKI developed less frequently in the survivor group than in the non-survivor group.", [["AKI", "DISEASE", 0, 3], ["non-survivor", "CANCER", 64, 76], ["AKI", "PROBLEM", 0, 3], ["less", "OBSERVATION_MODIFIER", 14, 18], ["frequently", "OBSERVATION_MODIFIER", 19, 29]]], ["Moreover, stage 3 AKI developed significantly less in the survivors than in the non-survivors.", [["AKI", "DISEASE", 18, 21], ["stage 3 AKI", "PROBLEM", 10, 21], ["stage 3", "OBSERVATION_MODIFIER", 10, 17], ["AKI", "OBSERVATION", 18, 21], ["significantly", "OBSERVATION_MODIFIER", 32, 45], ["less", "OBSERVATION_MODIFIER", 46, 50]]], ["SAPS2 and the serum sodium level were significantly lower in the survivors than in the non-survivors.", [["serum", "ANATOMY", 14, 19], ["sodium", "CHEMICAL", 20, 26], ["sodium", "CHEMICAL", 20, 26], ["SAPS2", "GENE_OR_GENE_PRODUCT", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 14, 19], ["sodium", "SIMPLE_CHEMICAL", 20, 26], ["SAPS2", "PROTEIN", 0, 5], ["SAPS2", "TEST", 0, 5], ["the serum sodium level", "TEST", 10, 32], ["lower", "OBSERVATION_MODIFIER", 52, 57]]], ["Ventilator settings, such as positive end expiratory pressure and peak inspiratory pressure before ECMO insertion, did not affect the survival rate.", [["Ventilator settings", "TREATMENT", 0, 19], ["positive end expiratory pressure", "TEST", 29, 61], ["peak inspiratory pressure", "TEST", 66, 91], ["ECMO insertion", "TREATMENT", 99, 113], ["inspiratory pressure", "OBSERVATION", 71, 91]]], ["The ECMO pump speed was significantly lower in the survivors than in the non-survivors.", [["The ECMO pump", "TREATMENT", 0, 13], ["ECMO", "OBSERVATION", 4, 8]]], ["Age, causes of admission, causes of ECMO support, mode of ECMO, use of IABP, length of stay before ECMO insertion, duration of ECMO support, initial urine output, BUN, creatinine, RDW and CRP were associated with in-hospital mortality (Table 1).", [["urine", "ANATOMY", 149, 154], ["creatinine", "CHEMICAL", 168, 178], ["creatinine", "CHEMICAL", 168, 178], ["urine", "ORGANISM_SUBSTANCE", 149, 154], ["BUN", "SIMPLE_CHEMICAL", 163, 166], ["creatinine", "SIMPLE_CHEMICAL", 168, 178], ["RDW", "SIMPLE_CHEMICAL", 180, 183], ["CRP", "GENE_OR_GENE_PRODUCT", 188, 191], ["BUN", "PROTEIN", 163, 166], ["RDW", "PROTEIN", 180, 183], ["CRP", "PROTEIN", 188, 191], ["ECMO support", "TREATMENT", 36, 48], ["ECMO", "TREATMENT", 58, 62], ["IABP", "TREATMENT", 71, 75], ["ECMO insertion", "TREATMENT", 99, 113], ["ECMO support", "TREATMENT", 127, 139], ["initial urine output", "TEST", 141, 161], ["BUN", "TEST", 163, 166], ["creatinine", "TEST", 168, 178], ["RDW", "TEST", 180, 183], ["CRP", "TEST", 188, 191]]], ["We performed a multivariate Cox-proportional hazard regression analysis to adjust confounding effects among the selected variables.", [["a multivariate Cox-proportional hazard regression analysis", "TREATMENT", 13, 71], ["confounding effects", "PROBLEM", 82, 101]]], ["Compared to the non-AKI group, the stage 3 AKI group significantly increased the risk of in-hospital mortality whereas the stage 1 and 2 AKI groups did not (Table 2).", [["AKI", "DISEASE", 43, 46], ["AKI", "DISEASE", 137, 140], ["non-AKI", "CANCER", 16, 23], ["the stage 3 AKI group", "PROBLEM", 31, 52], ["the stage 1 and 2 AKI groups", "PROBLEM", 119, 147], ["AKI", "OBSERVATION", 43, 46]]], ["In the Kaplan-Meier survival curves according to the stages of AKI, the estimated mean (95% CI) survival in the non-AKI group and the stage 1, 2, and 3 groups were 65.7 (55.2\u201376.2) days, 54.0 (45.8\u201362.3) days, 53.8 (38.7\u201369.0) days and 33.6 (27.9\u201339.4) days, respectively (p < 0.001 by log-rank test).", [["AKI", "DISEASE", 63, 66], ["non-AKI", "CANCER", 112, 119], ["AKI", "PROBLEM", 63, 66], ["the non-AKI group", "TEST", 108, 125], ["log-rank test", "TEST", 286, 299], ["AKI", "OBSERVATION", 63, 66]]], ["In the post-hoc analysis, the stage 3 AKI group, but not the stage 1 (p = 0.14) or 2 (p = 0.43) AKI groups, showed a significant difference in survival compared with the non-AKI group (Fig 1).", [["AKI", "DISEASE", 38, 41], ["AKI", "DISEASE", 96, 99], ["the post-hoc analysis", "TEST", 3, 24], ["the stage 3 AKI group", "PROBLEM", 26, 47], ["AKI groups", "TEST", 96, 106], ["a significant difference in survival", "PROBLEM", 115, 151], ["AKI", "OBSERVATION", 38, 41], ["significant", "OBSERVATION_MODIFIER", 117, 128], ["difference", "OBSERVATION_MODIFIER", 129, 139]]], ["With every increment in SAPS2, serum sodium level, and ECMO pump speed (1 score in SAPS2, 1 mmol/L in serum sodium level, and 1,000 rpm in ECMO pump speed), the risks of in-hospital mortality were increased, with HRs (95% CI, p-value) of 1.02 (1.004\u20131.035, 0.01), 1.042 (1.014\u20131.070, 0.003) and 1.333 (1.020\u20131.742, 0.04), respectively (Table 2).", [["serum", "ANATOMY", 31, 36], ["serum", "ANATOMY", 102, 107], ["sodium", "CHEMICAL", 37, 43], ["sodium", "CHEMICAL", 108, 114], ["sodium", "CHEMICAL", 37, 43], ["sodium", "CHEMICAL", 108, 114], ["SAPS2", "SIMPLE_CHEMICAL", 24, 29], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["sodium", "SIMPLE_CHEMICAL", 37, 43], ["serum", "ORGANISM_SUBSTANCE", 102, 107], ["sodium", "SIMPLE_CHEMICAL", 108, 114], ["SAPS2", "PROTEIN", 24, 29], ["SAPS2", "TEST", 24, 29], ["serum sodium level", "TEST", 31, 49], ["ECMO pump speed", "TEST", 55, 70], ["SAPS2", "TEST", 83, 88], ["serum sodium level", "TEST", 102, 120], ["ECMO pump speed", "TREATMENT", 139, 154], ["HRs", "TEST", 213, 216], ["CI", "TEST", 222, 224], ["p-value", "TEST", 226, 233]]], ["We performed a calibration and discrimination analysis of SAPS2, serum sodium level, and ECMO pump speed to predict in-hospital mortality.", [["serum", "ANATOMY", 65, 70], ["sodium", "CHEMICAL", 71, 77], ["sodium", "CHEMICAL", 71, 77], ["SAPS2", "SIMPLE_CHEMICAL", 58, 63], ["serum", "ORGANISM_SUBSTANCE", 65, 70], ["sodium", "SIMPLE_CHEMICAL", 71, 77], ["a calibration", "TEST", 13, 26], ["discrimination analysis", "TEST", 31, 54], ["SAPS2", "TEST", 58, 63], ["serum sodium level", "TEST", 65, 83], ["ECMO pump", "TREATMENT", 89, 98]]], ["The AUROC analysis showed the discriminative power of these variables.", [["The AUROC analysis", "TEST", 0, 18]]], ["The cut-off values of SAPS2, serum sodium level, and ECMO pump speed for in-hospital mortality were a score of 69.5, 147.6 mmol/L, and 2.19 x 103 rpm, respectively (Table 3).ResultsWe compared clinical characteristics according to the mode of ECMO.", [["serum", "ANATOMY", 29, 34], ["sodium", "CHEMICAL", 35, 41], ["sodium", "CHEMICAL", 35, 41], ["SAPS2", "SIMPLE_CHEMICAL", 22, 27], ["serum", "ORGANISM_SUBSTANCE", 29, 34], ["sodium", "SIMPLE_CHEMICAL", 35, 41], ["The cut-off values", "TEST", 0, 18], ["SAPS2", "TEST", 22, 27], ["serum sodium level", "TEST", 29, 47], ["ECMO pump", "TREATMENT", 53, 62], ["a score", "TEST", 100, 107], ["ECMO", "TREATMENT", 243, 247]]], ["The length of the hospital stay before ECMO insertion was shorter in patients with VA mode than in those with VV mode.", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["VV", "SPECIES", 110, 112], ["ECMO insertion", "TREATMENT", 39, 53], ["VA mode", "TREATMENT", 83, 90], ["length", "OBSERVATION_MODIFIER", 4, 10]]], ["The level of CRP was lower in the VA mode group than in the VV mode group.", [["CRP", "GENE_OR_GENE_PRODUCT", 13, 16], ["CRP", "PROTEIN", 13, 16], ["CRP", "TEST", 13, 16], ["CRP", "OBSERVATION", 13, 16], ["lower", "OBSERVATION_MODIFIER", 21, 26]]], ["Nonetheless, SAPS2 was not different between the two groups.", [["SAPS2", "GENE_OR_GENE_PRODUCT", 13, 18], ["SAPS2", "PROTEIN", 13, 18], ["SAPS2", "TEST", 13, 18]]], ["The initial ECMO settings were also comparable between the two groups.", [["The initial ECMO settings", "TREATMENT", 0, 25], ["ECMO", "OBSERVATION", 12, 16]]], ["According to the linear regression analysis, there was no correlation between SAPS2 and ECMO speed either in VV mode (R2 = 0.003, p = 0.59) or VA mode (R2 = 0.001, p = 0.709).", [["the linear regression analysis", "TEST", 13, 43], ["SAPS2", "TEST", 78, 83], ["ECMO speed", "TEST", 88, 98], ["R2", "TEST", 118, 120], ["p", "TEST", 130, 131], ["VA mode", "TEST", 143, 150], ["R2", "TEST", 152, 154], ["p", "TEST", 164, 165]]], ["The mortality within 2 weeks after ECMO insertion was significantly higher in patients with VA mode than in those with VV mode (p = 0.03), whereas the overall in-hospital mortality was significantly lower in the VA mode group than that in the VV mode group (p = 0.02).", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["VV", "SPECIES", 119, 121], ["ECMO insertion", "TREATMENT", 35, 49], ["higher", "OBSERVATION_MODIFIER", 68, 74]]], ["Compared to the patients with the VV mode, those with the VA mode had shorter stays in the intensive care unit and hospital; however, there was no difference in the occurrence of AKI between the two groups (Table 4).ResultsBecause AKI, especially stage 3 AKI, showed a significant association with in-hospital mortality, we attempted to detect the risk factors associated with AKI and stage 3 AKI.", [["AKI", "DISEASE", 179, 182], ["AKI", "DISEASE", 231, 234], ["AKI", "DISEASE", 255, 258], ["AKI", "DISEASE", 377, 380], ["AKI", "DISEASE", 393, 396], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["VV", "SPECIES", 34, 36], ["AKI", "PROBLEM", 179, 182], ["AKI", "PROBLEM", 231, 234], ["stage 3 AKI", "PROBLEM", 247, 258], ["the risk factors", "PROBLEM", 344, 360], ["AKI", "PROBLEM", 377, 380], ["stage 3 AKI", "PROBLEM", 385, 396], ["no", "UNCERTAINTY", 144, 146], ["difference", "OBSERVATION_MODIFIER", 147, 157], ["AKI", "OBSERVATION", 179, 182], ["AKI", "OBSERVATION", 231, 234], ["stage 3", "OBSERVATION_MODIFIER", 385, 392], ["AKI", "OBSERVATION", 393, 396]]], ["We compared the characteristics between the patients with and without AKI.", [["AKI", "DISEASE", 70, 73], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["AKI", "PROBLEM", 70, 73], ["AKI", "OBSERVATION", 70, 73]]], ["The initial ECMO pump speed was lower in those without AKI than in those with AKI.", [["AKI", "DISEASE", 55, 58], ["AKI", "DISEASE", 78, 81], ["The initial ECMO pump", "TREATMENT", 0, 21], ["AKI", "PROBLEM", 55, 58], ["AKI", "PROBLEM", 78, 81], ["ECMO", "OBSERVATION", 12, 16], ["AKI", "OBSERVATION", 78, 81]]], ["Those without AKI received ECMO support for a shorter period of time than those with AKI.", [["AKI", "DISEASE", 14, 17], ["AKI", "DISEASE", 85, 88], ["AKI", "PROBLEM", 14, 17], ["ECMO support", "TREATMENT", 27, 39], ["AKI", "PROBLEM", 85, 88], ["without", "UNCERTAINTY", 6, 13], ["AKI", "OBSERVATION", 14, 17], ["AKI", "OBSERVATION", 85, 88]]], ["The length of stay before ECMO insertion, BUN, total bilirubin, RDW and SAPS2 were associated with the occurrence of AKI.", [["bilirubin", "CHEMICAL", 53, 62], ["AKI", "DISEASE", 117, 120], ["bilirubin", "CHEMICAL", 53, 62], ["BUN", "SIMPLE_CHEMICAL", 42, 45], ["bilirubin", "GENE_OR_GENE_PRODUCT", 53, 62], ["RDW", "GENE_OR_GENE_PRODUCT", 64, 67], ["SAPS2", "GENE_OR_GENE_PRODUCT", 72, 77], ["BUN", "PROTEIN", 42, 45], ["RDW", "PROTEIN", 64, 67], ["SAPS2", "PROTEIN", 72, 77], ["ECMO insertion", "TREATMENT", 26, 40], ["BUN", "TEST", 42, 45], ["total bilirubin", "TEST", 47, 62], ["RDW", "TEST", 64, 67], ["SAPS2", "TEST", 72, 77], ["AKI", "PROBLEM", 117, 120], ["length", "OBSERVATION_MODIFIER", 4, 10], ["AKI", "OBSERVATION", 117, 120]]], ["In the multivariate logistic regression analysis, the initial ECMO pump speed and the duration of ECMO support showed a statistical significance with ORs (95% CI, p-value) of 2.018 (1.129\u20133.609, p = 0.02) per 1,000 rpm in ECMO pump speed and 1.124 (1.035\u20131.22, p = 0.005) per day in duration of ECMO support (Table 5).", [["the initial ECMO pump speed", "TREATMENT", 50, 77], ["ECMO support", "TREATMENT", 98, 110], ["ORs", "TEST", 150, 153], ["CI", "TEST", 159, 161], ["p-value", "TEST", 163, 170], ["p", "TEST", 195, 196], ["ECMO pump speed", "TEST", 222, 237], ["ECMO support", "TREATMENT", 295, 307]]], ["These variables were also significant risk factors for developing stage 3 AKI (Table 6).ResultsThere was an additional risk factor in stage 3 AKI.", [["AKI", "DISEASE", 74, 77], ["AKI", "DISEASE", 142, 145], ["significant risk factors", "PROBLEM", 26, 50], ["stage 3 AKI", "PROBLEM", 66, 77], ["stage 3 AKI", "PROBLEM", 134, 145], ["AKI", "OBSERVATION", 74, 77], ["stage 3", "OBSERVATION_MODIFIER", 134, 141], ["AKI", "OBSERVATION", 142, 145]]], ["The RDW was significantly lower in those without stage 3 AKI than in those with stage 3 AKI.", [["AKI", "DISEASE", 57, 60], ["AKI", "DISEASE", 88, 91], ["RDW", "PROTEIN", 4, 7], ["The RDW", "TEST", 0, 7], ["stage 3 AKI", "PROBLEM", 49, 60], ["stage 3 AKI", "PROBLEM", 80, 91], ["significantly", "OBSERVATION_MODIFIER", 12, 25], ["lower", "OBSERVATION_MODIFIER", 26, 31], ["without", "UNCERTAINTY", 41, 48], ["stage 3", "OBSERVATION_MODIFIER", 49, 56], ["AKI", "OBSERVATION", 57, 60], ["stage 3", "OBSERVATION_MODIFIER", 80, 87], ["AKI", "OBSERVATION", 88, 91]]], ["In the multivariate logistic regression analysis, the RDW was still statistically significant, with an OR (95% CI, p-value) of 1.308 (1.053\u20131.625, 0.02) for every 1% increase (Table 6).", [["the RDW", "TEST", 50, 57], ["CI", "TEST", 111, 113], ["p-value", "TEST", 115, 122], ["significant", "OBSERVATION_MODIFIER", 82, 93]]], ["In the calibration and discrimination analysis, stage 3 AKI was well-calibrated and discriminated by a cut-off value of 14.1% for RDW (Table 3).", [["AKI", "DISEASE", 56, 59], ["RDW", "PROTEIN", 130, 133], ["discrimination analysis", "TEST", 23, 46], ["stage 3 AKI", "PROBLEM", 48, 59], ["a cut-off value", "TEST", 101, 116], ["RDW", "TEST", 130, 133], ["AKI", "OBSERVATION", 56, 59]]], ["We compared patient characteristics according to the RDW status.", [["patient", "ORGANISM", 12, 19], ["RDW", "PROTEIN", 53, 56], ["patient", "SPECIES", 12, 19]]], ["Patients with an RDW above 14.1% showed significantly higher level of CRP than did those with an RDW below 14.1%.", [["Patients", "ORGANISM", 0, 8], ["CRP", "GENE_OR_GENE_PRODUCT", 70, 73], ["CRP", "PROTEIN", 70, 73], ["Patients", "SPECIES", 0, 8], ["an RDW", "TEST", 14, 20], ["significantly higher level of CRP", "PROBLEM", 40, 73], ["an RDW", "TEST", 94, 100]]], ["Moreover, patients with an RDW above 14.1% showed considerably lower hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration than did those with an RDW below 14.1% (Table 7).DiscussionIn this work, we investigated the risk factors of AKI and in-hospital mortality in patients receiving ECMO support.", [["corpuscular", "ANATOMY", 86, 97], ["corpuscular", "ANATOMY", 111, 122], ["corpuscular", "ANATOMY", 144, 155], ["AKI", "DISEASE", 290, 293], ["patients", "ORGANISM", 10, 18], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 69, 79], ["corpuscular", "ORGANISM_SUBSTANCE", 86, 97], ["corpuscular", "ORGANISM_SUBSTANCE", 111, 122], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 123, 133], ["corpuscular", "ORGANISM_SUBSTANCE", 144, 155], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 156, 166], ["patients", "ORGANISM", 323, 331], ["hemoglobin", "PROTEIN", 69, 79], ["hemoglobin", "PROTEIN", 123, 133], ["hemoglobin", "PROTEIN", 156, 166], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 323, 331], ["an RDW", "TEST", 24, 30], ["considerably lower hemoglobin", "PROBLEM", 50, 79], ["mean corpuscular volume", "TEST", 81, 104], ["mean corpuscular hemoglobin", "TEST", 106, 133], ["mean corpuscular hemoglobin concentration", "TEST", 139, 180], ["an RDW", "TEST", 201, 207], ["AKI", "PROBLEM", 290, 293], ["ECMO support", "TREATMENT", 342, 354], ["corpuscular volume", "OBSERVATION", 86, 104], ["corpuscular hemoglobin", "OBSERVATION", 111, 133], ["AKI", "OBSERVATION", 290, 293]]], ["Here, we found that the initial pump speed of ECMO was associated with in-hospital mortality and AKI.", [["AKI", "DISEASE", 97, 100], ["ECMO", "TREATMENT", 46, 50], ["AKI", "PROBLEM", 97, 100], ["AKI", "OBSERVATION", 97, 100]]], ["The elevated RDW could be suggested as the risk factor for severe AKI in these patients.", [["AKI", "DISEASE", 66, 69], ["RDW", "SIMPLE_CHEMICAL", 13, 16], ["patients", "ORGANISM", 79, 87], ["RDW", "PROTEIN", 13, 16], ["patients", "SPECIES", 79, 87], ["The elevated RDW", "PROBLEM", 0, 16], ["severe AKI", "PROBLEM", 59, 69], ["elevated", "OBSERVATION_MODIFIER", 4, 12], ["RDW", "OBSERVATION", 13, 16], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["AKI", "OBSERVATION", 66, 69]]], ["This was the first study to identify the risk factors of AKI in adult patients receiving ECMO support.", [["AKI", "DISEASE", 57, 60], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["the first study", "TEST", 9, 24], ["AKI", "PROBLEM", 57, 60], ["ECMO support", "TREATMENT", 89, 101], ["AKI", "OBSERVATION", 57, 60]]], ["Because AKI is the most common complication and a major risk factor of mortality, defining the risk factors for AKI in these patients is extremely important [9\u201314].", [["AKI", "DISEASE", 8, 11], ["AKI", "DISEASE", 112, 115], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["AKI", "PROBLEM", 8, 11], ["AKI", "PROBLEM", 112, 115]]], ["This study is the largest ECMO assessment ever reported.", [["This study", "TEST", 0, 10], ["the largest ECMO assessment", "TEST", 14, 41], ["largest", "OBSERVATION_MODIFIER", 18, 25], ["ECMO", "OBSERVATION", 26, 30]]], ["Moreover, the association of pump speed with AKI and mortality is a novel finding.DiscussionWe showed that AKI, especially stage 3 AKI, was a significant risk factor for in-hospital mortality in patients receiving ECMO support.", [["AKI", "DISEASE", 45, 48], ["AKI", "DISEASE", 107, 110], ["AKI", "DISEASE", 131, 134], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 195, 203], ["AKI", "PROBLEM", 45, 48], ["AKI", "PROBLEM", 107, 110], ["stage 3 AKI", "PROBLEM", 123, 134], ["ECMO support", "TREATMENT", 214, 226], ["AKI", "OBSERVATION", 45, 48], ["AKI", "OBSERVATION", 107, 110]]], ["SAPS2 and serum sodium level were also important risk factors of in-hospital mortality.", [["serum", "ANATOMY", 10, 15], ["sodium", "CHEMICAL", 16, 22], ["sodium", "CHEMICAL", 16, 22], ["SAPS2", "GENE_OR_GENE_PRODUCT", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 10, 15], ["sodium", "SIMPLE_CHEMICAL", 16, 22], ["SAPS2", "PROTEIN", 0, 5], ["SAPS2", "TEST", 0, 5], ["serum sodium level", "TEST", 10, 28]]], ["Along with these well-known and expected findings [11\u201313, 18\u201320], we found that the initial pump speed of ECMO was significantly related to in-hospital mortality, with a 33% increased risk for every 1,000 rpm increase.", [["ECMO", "TREATMENT", 106, 110], ["a 33% increased risk", "PROBLEM", 168, 188], ["ECMO", "OBSERVATION", 106, 110]]], ["The initial pump speed of ECMO was also a risk factor for both AKI and stage 3 AKI.", [["AKI", "DISEASE", 63, 66], ["AKI", "DISEASE", 79, 82], ["ECMO", "TREATMENT", 26, 30], ["a risk factor", "PROBLEM", 40, 53], ["both AKI", "PROBLEM", 58, 66], ["stage 3 AKI", "PROBLEM", 71, 82], ["AKI", "OBSERVATION", 63, 66], ["stage 3", "OBSERVATION_MODIFIER", 71, 78], ["AKI", "OBSERVATION", 79, 82]]], ["On the other hand, the blood flow rate of ECMO was not associated with in-hospital mortality or AKI.", [["blood", "ANATOMY", 23, 28], ["AKI", "DISEASE", 96, 99], ["blood", "ORGANISM_SUBSTANCE", 23, 28], ["the blood flow rate", "TEST", 19, 38], ["ECMO", "TREATMENT", 42, 46], ["AKI", "PROBLEM", 96, 99], ["AKI", "OBSERVATION", 96, 99]]], ["Why a high pump speed, but not a high blood flow rate of ECMO, increases the risk of in-hospital mortality and AKI is not clear at this time.", [["blood", "ANATOMY", 38, 43], ["AKI", "DISEASE", 111, 114], ["blood", "ORGANISM_SUBSTANCE", 38, 43], ["ECMO", "TREATMENT", 57, 61], ["AKI", "PROBLEM", 111, 114], ["AKI", "OBSERVATION", 111, 114], ["clear", "OBSERVATION", 122, 127]]], ["However, the ECMO pump can induce hemolysis, leukocyte and platelet destruction, and complement activation [21, 22].", [["leukocyte", "ANATOMY", 45, 54], ["platelet", "ANATOMY", 59, 67], ["hemolysis", "DISEASE", 34, 43], ["leukocyte", "CELL", 45, 54], ["platelet", "CELL", 59, 67], ["the ECMO pump", "TREATMENT", 9, 22], ["hemolysis", "PROBLEM", 34, 43], ["leukocyte", "TEST", 45, 54], ["platelet destruction", "PROBLEM", 59, 79], ["hemolysis", "OBSERVATION", 34, 43], ["platelet destruction", "OBSERVATION", 59, 79]]], ["Blood flow through the ECMO circuit is driven by centrifugal pump.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood flow", "TEST", 0, 10], ["the ECMO circuit", "TREATMENT", 19, 35], ["centrifugal pump", "TREATMENT", 49, 65], ["flow", "OBSERVATION_MODIFIER", 6, 10], ["ECMO circuit", "OBSERVATION", 23, 35], ["centrifugal pump", "OBSERVATION", 49, 65]]], ["A rotating impeller in centrifugal pumps spins, which creates a constrained vortex that suctions blood into the pump and propels it out toward the membrane oxygenator [23].", [["blood", "ANATOMY", 97, 102], ["membrane", "ANATOMY", 147, 155], ["blood", "ORGANISM_SUBSTANCE", 97, 102], ["membrane", "CELLULAR_COMPONENT", 147, 155], ["A rotating impeller in centrifugal pumps spins", "TREATMENT", 0, 46], ["a constrained vortex", "TREATMENT", 62, 82], ["the pump", "TREATMENT", 108, 116], ["the membrane oxygenator", "TREATMENT", 143, 166], ["constrained vortex", "OBSERVATION", 64, 82]]], ["Hemolysis has been reported to be associated with AKI [24].", [["Hemolysis", "DISEASE", 0, 9], ["AKI", "DISEASE", 50, 53], ["Hemolysis", "PROBLEM", 0, 9], ["AKI", "PROBLEM", 50, 53], ["AKI", "OBSERVATION", 50, 53]]], ["In addition, Lou et al. found that the pump speed was a risk factor for hemolysis and that hemolysis was associated with adverse outcomes in pediatric patients receiving ECMO [25].", [["hemolysis", "DISEASE", 72, 81], ["hemolysis", "DISEASE", 91, 100], ["ECMO", "CHEMICAL", 170, 174], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["a risk factor", "PROBLEM", 54, 67], ["hemolysis", "PROBLEM", 72, 81], ["hemolysis", "PROBLEM", 91, 100], ["ECMO", "TREATMENT", 170, 174]]], ["Although we did not evaluate the degree of hemolysis in our patients, we postulate that hemolysis caused by high revolutions of the ECMO pump might result in AKI and in-hospital mortality.", [["hemolysis", "DISEASE", 43, 52], ["hemolysis", "DISEASE", 88, 97], ["AKI", "DISEASE", 158, 161], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["hemolysis", "PROBLEM", 43, 52], ["hemolysis", "PROBLEM", 88, 97], ["the ECMO pump", "TREATMENT", 128, 141], ["AKI", "PROBLEM", 158, 161], ["hemolysis", "OBSERVATION", 43, 52], ["hemolysis", "OBSERVATION", 88, 97], ["AKI", "OBSERVATION", 158, 161]]], ["To provide stable cardiac output in the VA mode and adequate oxygenation in the VV mode, adequate blood flow should be maintained.", [["cardiac", "ANATOMY", 18, 25], ["blood", "ANATOMY", 98, 103], ["cardiac", "ORGAN", 18, 25], ["blood", "ORGANISM_SUBSTANCE", 98, 103], ["VV", "SPECIES", 80, 82], ["stable", "OBSERVATION_MODIFIER", 11, 17], ["cardiac", "ANATOMY", 18, 25], ["output", "OBSERVATION", 26, 32], ["adequate oxygenation", "OBSERVATION", 52, 72]]], ["Therefore, clinicians raise the ECMO pump speed as much as possible to maintain adequate blood flow.", [["blood", "ANATOMY", 89, 94], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["the ECMO pump speed", "TREATMENT", 28, 47]]], ["The blood flow rate that was applied to 90% of our patients was less than 4.1 L/min.", [["blood", "ANATOMY", 4, 9], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["The blood flow rate", "TEST", 0, 19]]], ["A high blood flow extracorporeal circuit that pumped up to 7 L/min [26] did not apply to our patients; however, 43.8% (141/321) of our patients were treated with a pump speed higher than the cut-off value of 2.19 x 103 rpm.", [["blood", "ANATOMY", 7, 12], ["blood", "ORGANISM_SUBSTANCE", 7, 12], ["patients", "ORGANISM", 93, 101], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 135, 143], ["A high blood flow extracorporeal circuit", "TREATMENT", 0, 40], ["a pump speed", "TREATMENT", 162, 174], ["flow", "OBSERVATION_MODIFIER", 13, 17], ["extracorporeal circuit", "OBSERVATION", 18, 40]]], ["For these reasons, we speculate that pump speed, but not a blood flow, is a predictor of death in this study.DiscussionWe compared the clinical characteristics of patients from the VA and VV ECMO modes.", [["blood", "ANATOMY", 59, 64], ["death", "DISEASE", 89, 94], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171], ["VV", "SPECIES", 188, 190], ["a blood flow", "TEST", 57, 69], ["this study", "TEST", 98, 108], ["VV ECMO modes", "TREATMENT", 188, 201]]], ["Patients with the VV mode had higher levels of CRP, showed higher mortality, and had longer stays in the hospital compared with those with the VA mode; however, the mortality within 2 weeks after ECMO insertion was higher in patients with the VA mode.", [["Patients", "ORGANISM", 0, 8], ["CRP", "GENE_OR_GENE_PRODUCT", 47, 50], ["patients", "ORGANISM", 225, 233], ["CRP", "PROTEIN", 47, 50], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 225, 233], ["the VV mode", "TEST", 14, 25], ["CRP", "TEST", 47, 50], ["ECMO insertion", "TREATMENT", 196, 210], ["higher", "OBSERVATION_MODIFIER", 215, 221]]], ["We speculated that the patients with the VA mode deteriorated rapidly but recovered soon if they were not severe enough for death.", [["death", "DISEASE", 124, 129], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["death", "PROBLEM", 124, 129]]], ["In contrast, patients with the VV mode seemed to show slower but poorer outcomes than those with the VA mode.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["VV", "SPECIES", 31, 33], ["the VV mode", "TEST", 27, 38], ["slower", "OBSERVATION_MODIFIER", 54, 60]]], ["The different disease process of the patients treated with the VA and VV ECMO modes [27] might be related to these findings.", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["The different disease process", "PROBLEM", 0, 29], ["the VA and VV ECMO modes", "TREATMENT", 59, 83], ["different", "OBSERVATION_MODIFIER", 4, 13], ["disease", "OBSERVATION", 14, 21]]], ["Future prospective studies will be needed to investigate whether ECMO mode determines outcomes.DiscussionIn this study, the higher the RDW was, the more frequently stage 3 AKI occurred.", [["AKI", "DISEASE", 172, 175], ["Future prospective studies", "TEST", 0, 26], ["this study", "TEST", 108, 118], ["the higher the RDW", "PROBLEM", 120, 138], ["AKI", "PROBLEM", 172, 175], ["AKI", "OBSERVATION", 172, 175]]], ["To the best of our knowledge, this is the first study to suggest a potential role of the RDW in AKI.", [["AKI", "DISEASE", 96, 99], ["RDW", "PROTEIN", 89, 92], ["the first study", "TEST", 38, 53], ["the RDW", "PROBLEM", 85, 92], ["AKI", "PROBLEM", 96, 99], ["AKI", "OBSERVATION", 96, 99]]], ["Recently, the use of the RDW as a simple and inexpensive biomarker to predict mortality in chronic heart failure [18, 28], liver disease [29], and critical illness [30] has increased.", [["heart", "ANATOMY", 99, 104], ["liver", "ANATOMY", 123, 128], ["chronic heart failure", "DISEASE", 91, 112], ["liver disease", "DISEASE", 123, 136], ["critical illness", "DISEASE", 147, 163], ["heart", "ORGAN", 99, 104], ["liver", "ORGAN", 123, 128], ["RDW", "PROTEIN", 25, 28], ["the RDW", "PROBLEM", 21, 28], ["chronic heart failure", "PROBLEM", 91, 112], ["liver disease", "PROBLEM", 123, 136], ["critical illness", "PROBLEM", 147, 163], ["chronic", "OBSERVATION_MODIFIER", 91, 98], ["heart", "ANATOMY", 99, 104], ["failure", "OBSERVATION", 105, 112], ["liver", "ANATOMY", 123, 128], ["disease", "OBSERVATION", 129, 136], ["increased", "OBSERVATION_MODIFIER", 173, 182]]], ["Moreover, the RDW has been reported to be associated with many pathological conditions such as colon cancer, inflammatory bowel disease, celiac disease, rheumatoid arthritis, Alzheimer\u2019s disease, and contrast-induced nephropathy [31, 32].", [["colon cancer", "ANATOMY", 95, 107], ["bowel", "ANATOMY", 122, 127], ["celiac", "ANATOMY", 137, 143], ["colon cancer", "DISEASE", 95, 107], ["inflammatory bowel disease", "DISEASE", 109, 135], ["celiac disease", "DISEASE", 137, 151], ["rheumatoid arthritis", "DISEASE", 153, 173], ["Alzheimer\u2019s disease", "DISEASE", 175, 194], ["nephropathy", "DISEASE", 217, 228], ["colon cancer", "CANCER", 95, 107], ["bowel", "ORGAN", 122, 127], ["RDW", "PROTEIN", 14, 17], ["the RDW", "TEST", 10, 17], ["many pathological conditions", "PROBLEM", 58, 86], ["colon cancer", "PROBLEM", 95, 107], ["inflammatory bowel disease", "PROBLEM", 109, 135], ["celiac disease", "PROBLEM", 137, 151], ["rheumatoid arthritis", "PROBLEM", 153, 173], ["Alzheimer\u2019s disease", "PROBLEM", 175, 194], ["contrast-induced nephropathy", "PROBLEM", 200, 228], ["colon", "ANATOMY", 95, 100], ["cancer", "OBSERVATION", 101, 107], ["inflammatory", "OBSERVATION_MODIFIER", 109, 121], ["bowel", "ANATOMY", 122, 127], ["disease", "OBSERVATION", 128, 135], ["celiac", "ANATOMY", 137, 143], ["rheumatoid arthritis", "OBSERVATION", 153, 173]]], ["Although the exact mechanism of this relationship is not clear, inflammation is a proposed underlying factor [33, 34].", [["inflammation", "DISEASE", 64, 76], ["inflammation", "PROBLEM", 64, 76], ["inflammation", "OBSERVATION", 64, 76]]], ["This proposed factor can also be supported by our data, which indicate that the elevated RDW was associated with high CRP levels in the patients.", [["CRP", "GENE_OR_GENE_PRODUCT", 118, 121], ["patients", "ORGANISM", 136, 144], ["RDW", "PROTEIN", 89, 92], ["CRP", "PROTEIN", 118, 121], ["patients", "SPECIES", 136, 144], ["the elevated RDW", "PROBLEM", 76, 92], ["high CRP levels", "PROBLEM", 113, 128], ["elevated", "OBSERVATION_MODIFIER", 80, 88], ["RDW", "OBSERVATION", 89, 92]]], ["In this study, patients with an RDW greater than 14.1% showed lower RBC indices than did those with an RDW less than 14.1%.", [["RBC", "ANATOMY", 68, 71], ["patients", "ORGANISM", 15, 23], ["RBC", "CELL", 68, 71], ["RBC", "CELL_TYPE", 68, 71], ["patients", "SPECIES", 15, 23], ["this study", "TEST", 3, 13], ["an RDW", "TEST", 29, 35], ["lower RBC indices", "PROBLEM", 62, 79], ["an RDW", "TEST", 100, 106]]], ["Because anemia is a risk factor for AKI [35], the low RBC indices found in the elevated RDW group might contribute to increase the odds of stage 3 AKI occurring.DiscussionThe current study suffered from several limitations.", [["RBC", "ANATOMY", 54, 57], ["anemia", "DISEASE", 8, 14], ["AKI", "DISEASE", 36, 39], ["AKI", "DISEASE", 147, 150], ["RBC", "CELL", 54, 57], ["anemia", "PROBLEM", 8, 14], ["AKI", "PROBLEM", 36, 39], ["the low RBC indices", "PROBLEM", 46, 65], ["the elevated RDW group", "PROBLEM", 75, 97], ["stage 3 AKI", "PROBLEM", 139, 150], ["The current study", "TEST", 171, 188], ["low RBC", "OBSERVATION_MODIFIER", 50, 57], ["stage 3", "OBSERVATION_MODIFIER", 139, 146], ["AKI", "OBSERVATION", 147, 150]]], ["First, this study is a retrospective cohort study; however, the variables before ECMO insertion were well retrieved with a less than 10% missing rate.", [["this study", "TEST", 7, 17], ["a retrospective cohort study", "TEST", 21, 49], ["ECMO insertion", "TREATMENT", 81, 95]]], ["Moreover, this is the largest study to explore the association of AKI and mortality in patients receiving ECMO support [11\u201313].", [["AKI", "DISEASE", 66, 69], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["the largest study", "TEST", 18, 35], ["AKI", "PROBLEM", 66, 69], ["ECMO support", "TREATMENT", 106, 118], ["AKI", "OBSERVATION", 66, 69]]], ["A low level of missing data and a large number of patients could partially compensate for the weakness of the study design.", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["A low level of missing data", "PROBLEM", 0, 27], ["the weakness", "PROBLEM", 90, 102], ["the study", "TEST", 106, 115], ["low", "OBSERVATION_MODIFIER", 2, 5], ["large", "OBSERVATION_MODIFIER", 34, 39], ["weakness", "OBSERVATION", 94, 102]]], ["Second, we classified the patients into their KDIGO stage based only on their serum creatinine concentration.", [["serum", "ANATOMY", 78, 83], ["creatinine", "CHEMICAL", 84, 94], ["creatinine", "CHEMICAL", 84, 94], ["patients", "ORGANISM", 26, 34], ["serum", "ORGANISM_SUBSTANCE", 78, 83], ["creatinine", "SIMPLE_CHEMICAL", 84, 94], ["patients", "SPECIES", 26, 34], ["their serum creatinine concentration", "TEST", 72, 108]]], ["Urine volume is a sensitive marker for the early detection of AKI in patients on ECMO.", [["Urine", "ANATOMY", 0, 5], ["AKI", "DISEASE", 62, 65], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["Urine volume", "TEST", 0, 12], ["AKI", "PROBLEM", 62, 65], ["ECMO", "TREATMENT", 81, 85], ["volume", "OBSERVATION", 6, 12], ["AKI", "OBSERVATION", 62, 65]]], ["Decreased urine volume during ECMO treatment and/or on the day of ECMO removal can be attributed to decreased cardiac output following decannulation, and can be correlated with acute cardiorenal syndrome type 1 [27, 36, 37].", [["urine", "ANATOMY", 10, 15], ["cardiac", "ANATOMY", 110, 117], ["decreased cardiac output", "DISEASE", 100, 124], ["acute cardiorenal syndrome", "DISEASE", 177, 203], ["urine", "ORGANISM_SUBSTANCE", 10, 15], ["cardiac", "ORGAN", 110, 117], ["Decreased urine volume", "PROBLEM", 0, 22], ["ECMO treatment", "TREATMENT", 30, 44], ["ECMO removal", "TREATMENT", 66, 78], ["decreased cardiac output", "PROBLEM", 100, 124], ["decannulation", "TREATMENT", 135, 148], ["acute cardiorenal syndrome", "PROBLEM", 177, 203], ["urine volume", "OBSERVATION", 10, 22], ["decreased", "OBSERVATION_MODIFIER", 100, 109], ["cardiac", "ANATOMY", 110, 117], ["output", "OBSERVATION", 118, 124], ["decannulation", "OBSERVATION", 135, 148], ["acute", "OBSERVATION_MODIFIER", 177, 182], ["cardiorenal syndrome", "OBSERVATION", 183, 203]]], ["Third, we could not provide direct evidence that hemolysis due to a high pump speed resulted in AKI in this study.", [["hemolysis", "DISEASE", 49, 58], ["AKI", "DISEASE", 96, 99], ["hemolysis", "PROBLEM", 49, 58], ["a high pump speed", "PROBLEM", 66, 83], ["AKI", "PROBLEM", 96, 99], ["this study", "TEST", 103, 113], ["hemolysis", "OBSERVATION", 49, 58], ["AKI", "OBSERVATION", 96, 99]]], ["We should have measured plasma-free hemoglobin, which is an indicator of hemolysis.", [["plasma", "ANATOMY", 24, 30], ["hemolysis", "DISEASE", 73, 82], ["plasma", "ORGANISM_SUBSTANCE", 24, 30], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 36, 46], ["hemoglobin", "PROTEIN", 36, 46], ["plasma-free hemoglobin", "TEST", 24, 46], ["hemolysis", "PROBLEM", 73, 82], ["hemolysis", "OBSERVATION", 73, 82]]], ["Furthermore, we did not obtain information on the cannulation site and mean venous pressure in the ECMO circuit.", [["venous", "ANATOMY", 76, 82], ["venous", "MULTI-TISSUE_STRUCTURE", 76, 82], ["the cannulation site", "TREATMENT", 46, 66], ["mean venous pressure", "TEST", 71, 91], ["the ECMO circuit", "TREATMENT", 95, 111], ["cannulation", "OBSERVATION", 50, 61], ["venous", "ANATOMY", 76, 82], ["pressure", "OBSERVATION_MODIFIER", 83, 91], ["ECMO circuit", "OBSERVATION", 99, 111]]], ["Finally, this study was composed of data from two centers, which could limit the generalizability.DiscussionIn conclusion, AKI is a significant risk factor for in-hospital mortality in patients receiving ECMO support.", [["AKI", "DISEASE", 123, 126], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 185, 193], ["this study", "TEST", 9, 19], ["AKI", "PROBLEM", 123, 126], ["ECMO support", "TREATMENT", 204, 216]]], ["The initial pump speed of ECMO is associated with in-hospital mortality and strongly related to AKI, especially stage 3 AKI.", [["AKI", "DISEASE", 96, 99], ["AKI", "DISEASE", 120, 123], ["ECMO", "TREATMENT", 26, 30], ["AKI", "PROBLEM", 96, 99], ["stage 3 AKI", "PROBLEM", 112, 123], ["AKI", "OBSERVATION", 96, 99], ["AKI", "OBSERVATION", 120, 123]]], ["Therefore, once adequate blood flow is maintained, clinicians must be careful not to further increase the ECMO pump speed.", [["blood", "ANATOMY", 25, 30], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["the ECMO pump speed", "TREATMENT", 102, 121]]], ["Because the elevated RDW was also strongly related to stage 3 AKI, special attention should be paid to patients with abnormal RDW values to prevent AKI.", [["AKI", "DISEASE", 62, 65], ["AKI", "DISEASE", 148, 151], ["patients", "ORGANISM", 103, 111], ["RDW", "SIMPLE_CHEMICAL", 126, 129], ["RDW", "PROTEIN", 21, 24], ["RDW", "PROTEIN", 126, 129], ["patients", "SPECIES", 103, 111], ["the elevated RDW", "PROBLEM", 8, 24], ["stage 3 AKI", "PROBLEM", 54, 65], ["abnormal RDW values", "PROBLEM", 117, 136], ["AKI", "PROBLEM", 148, 151], ["elevated", "OBSERVATION_MODIFIER", 12, 20], ["RDW", "OBSERVATION", 21, 24], ["AKI", "OBSERVATION", 62, 65], ["AKI", "OBSERVATION", 148, 151]]]], "cbcd88dac23e8a431cbcef0d629ff1e70c1a95a4": [["Trends in upper gastrointestinal bleeding during the COVID-19 pandemic Zain A. Sobani, Swathi Paleti, Sameen Khalid, Euriko Torrazza Perez, Tarun RustagiUniversity of New Mexico, NM, USA The COVID-19 pandemic has significantly impacted the entire world, including the United States and specifically its healthcare system.", [["upper gastrointestinal", "ANATOMY", 10, 32], ["upper gastrointestinal bleeding", "DISEASE", 10, 41], ["upper gastrointestinal", "ORGANISM_SUBDIVISION", 10, 32], ["upper gastrointestinal bleeding", "PROBLEM", 10, 41], ["the COVID", "TEST", 49, 58], ["upper", "ANATOMY_MODIFIER", 10, 15], ["gastrointestinal", "ANATOMY", 16, 32], ["bleeding", "OBSERVATION", 33, 41]]], ["Based on recommendations from all major Gastrointestinal Societies [1] , we postponed all nonurgent procedures at our institution with effect from March 16th, 2020.", [["all nonurgent procedures", "TREATMENT", 86, 110], ["Gastrointestinal", "ANATOMY", 40, 56]]], ["After postponing non-emergent procedures, we aimed to evaluate the trends of upper gastrointestinal (GI) bleeding and esophagogastroduodenoscopy (EGD) performed during the COVID-19 pandemic.", [["upper gastrointestinal", "ANATOMY", 77, 99], ["upper gastrointestinal (GI) bleeding", "DISEASE", 77, 113], ["upper gastrointestinal", "ORGANISM_SUBDIVISION", 77, 99], ["postponing non-emergent procedures", "TREATMENT", 6, 40], ["upper gastrointestinal (GI) bleeding", "PROBLEM", 77, 113], ["esophagogastroduodenoscopy", "TEST", 118, 144], ["EGD", "TEST", 146, 149], ["the COVID", "TEST", 168, 177], ["pandemic", "PROBLEM", 181, 189], ["upper", "ANATOMY_MODIFIER", 77, 82], ["gastrointestinal", "ANATOMY", 83, 99]]], ["We conducted a retrospective review of all patients undergoing EGDs at our institution during the study period (March 16 to April 15, 2020).", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["EGDs", "TREATMENT", 63, 67], ["the study", "TEST", 94, 103]]], ["In addition, we collected similar data from the preceding 2 months (January 1 to February 29, 2020) and the same time period from the preceding year (March 16 to April 15, 2019) for comparison, to account for any seasonal variation.Trends in upper gastrointestinal bleeding during the COVID-19 pandemic Zain A. Sobani, Swathi Paleti, Sameen Khalid, Euriko Torrazza Perez, Tarun RustagiPrior to COVID-19, we performed an average of 398\u00b138.3 EGDs per month, of which 23.5% (93.67\u00b113.58) were performed on an inpatient basis.", [["upper gastrointestinal", "ANATOMY", 242, 264], ["upper gastrointestinal bleeding", "DISEASE", 242, 273], ["upper gastrointestinal", "ORGANISM_SUBDIVISION", 242, 264], ["any seasonal variation", "PROBLEM", 209, 231], ["upper gastrointestinal bleeding", "PROBLEM", 242, 273], ["the COVID", "TEST", 281, 290], ["upper", "ANATOMY_MODIFIER", 242, 247], ["gastrointestinal", "ANATOMY", 248, 264], ["bleeding", "OBSERVATION", 265, 273]]], ["With an overall reduction in inpatient procedures of about 49.82%, the proportion of patients undergoing inpatient EGD for GI bleeding was comparatively higher (78.7% vs. 65.1%; P=0.0925), as well as the proportion of EGDs for GI bleeding performed in the intensive care unit (ICU) (51.4% vs. 33.3%; P=0.0415) ( Table 1) .", [["GI", "ANATOMY", 123, 125], ["GI", "ANATOMY", 227, 229], ["bleeding", "DISEASE", 126, 134], ["EGDs", "DISEASE", 218, 222], ["GI bleeding", "DISEASE", 227, 238], ["patients", "ORGANISM", 85, 93], ["GI", "PATHOLOGICAL_FORMATION", 227, 229], ["patients", "SPECIES", 85, 93], ["inpatient procedures", "TEST", 29, 49], ["inpatient EGD", "TEST", 105, 118], ["GI bleeding", "PROBLEM", 123, 134], ["P", "TEST", 178, 179], ["GI bleeding", "PROBLEM", 227, 238], ["P", "TEST", 300, 301], ["overall", "OBSERVATION_MODIFIER", 8, 15], ["reduction", "OBSERVATION_MODIFIER", 16, 25], ["bleeding", "OBSERVATION", 126, 134], ["bleeding", "OBSERVATION", 230, 238]]], ["There was no change in the proportion of patients with GI bleeding requiring endoscopic intervention during this time period (32.4% vs. 32.2%; P=1).", [["GI", "ANATOMY", 55, 57], ["bleeding", "DISEASE", 58, 66], ["patients", "ORGANISM", 41, 49], ["GI", "ORGANISM_SUBDIVISION", 55, 57], ["patients", "SPECIES", 41, 49], ["GI bleeding", "PROBLEM", 55, 66], ["endoscopic intervention", "TREATMENT", 77, 100], ["P", "TEST", 143, 144], ["no", "UNCERTAINTY", 10, 12], ["change", "OBSERVATION_MODIFIER", 13, 19], ["GI", "ANATOMY", 55, 57], ["bleeding", "OBSERVATION", 58, 66]]], ["Despite a shift in the proportion of patients, there was no trend noted in the absolute number of inpatients with hemodynamically unstable GI bleeding, EGDs performed in the ICU or the number of inpatients undergoing EGD for variceal bleeding (Table 1) .Trends in upper gastrointestinal bleeding during the COVID-19 pandemic Zain A. Sobani, Swathi Paleti, Sameen Khalid, Euriko Torrazza Perez, Tarun RustagiWhen preparing for the COVID-19 pandemic, we expected the same baseline prevalence of emergent conditions, including acute exacerbations of chronic disease, acute infections, GI emergencies, cerebrovascular and coronary events, with the addition of the patients presenting with COVID-19.", [["GI", "ANATOMY", 139, 141], ["variceal", "ANATOMY", 225, 233], ["upper gastrointestinal", "ANATOMY", 264, 286], ["GI", "ANATOMY", 582, 584], ["cerebrovascular", "ANATOMY", 598, 613], ["coronary", "ANATOMY", 618, 626], ["bleeding", "DISEASE", 142, 150], ["EGDs", "DISEASE", 152, 156], ["variceal bleeding", "DISEASE", 225, 242], ["upper gastrointestinal bleeding", "DISEASE", 264, 295], ["chronic disease", "DISEASE", 547, 562], ["infections", "DISEASE", 570, 580], ["GI emergencies", "DISEASE", 582, 596], ["cerebrovascular and coronary events", "DISEASE", 598, 633], ["COVID-19", "CHEMICAL", 685, 693], ["patients", "ORGANISM", 37, 45], ["GI", "PATHOLOGICAL_FORMATION", 139, 141], ["upper gastrointestinal", "ORGANISM_SUBDIVISION", 264, 286], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 598, 613], ["coronary", "MULTI-TISSUE_STRUCTURE", 618, 626], ["patients", "ORGANISM", 660, 668], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 660, 668], ["hemodynamically unstable GI bleeding", "PROBLEM", 114, 150], ["EGDs", "TEST", 152, 156], ["EGD", "TEST", 217, 220], ["variceal bleeding", "PROBLEM", 225, 242], ["upper gastrointestinal bleeding", "PROBLEM", 264, 295], ["the COVID", "TEST", 303, 312], ["emergent conditions", "PROBLEM", 493, 512], ["acute exacerbations of chronic disease", "PROBLEM", 524, 562], ["acute infections", "PROBLEM", 564, 580], ["GI emergencies", "PROBLEM", 582, 596], ["cerebrovascular and coronary events", "PROBLEM", 598, 633], ["COVID", "TEST", 685, 690], ["bleeding", "OBSERVATION", 142, 150], ["variceal", "ANATOMY", 225, 233], ["bleeding", "OBSERVATION", 234, 242], ["upper", "ANATOMY_MODIFIER", 264, 269], ["gastrointestinal", "ANATOMY", 270, 286], ["bleeding", "OBSERVATION", 287, 295], ["acute", "OBSERVATION_MODIFIER", 524, 529], ["exacerbations", "OBSERVATION", 530, 543], ["chronic", "OBSERVATION_MODIFIER", 547, 554], ["disease", "OBSERVATION", 555, 562], ["acute", "OBSERVATION_MODIFIER", 564, 569], ["infections", "OBSERVATION", 570, 580], ["cerebrovascular", "ANATOMY", 598, 613], ["coronary", "ANATOMY", 618, 626]]], ["This was however refuted by studies on other acute emergencies such as myocardial infarction [2, 3] .Trends in upper gastrointestinal bleeding during the COVID-19 pandemic Zain A. Sobani, Swathi Paleti, Sameen Khalid, Euriko Torrazza Perez, Tarun RustagiHowever, we found no change in the absolute number of patients with hemodynamically unstable GI bleeding, the number of EGDs performed in the ICU or the number of EGDs performed for variceal bleeding.", [["myocardial", "ANATOMY", 71, 81], ["upper gastrointestinal", "ANATOMY", 111, 133], ["GI", "ANATOMY", 347, 349], ["variceal", "ANATOMY", 436, 444], ["myocardial infarction", "DISEASE", 71, 92], ["upper gastrointestinal bleeding", "DISEASE", 111, 142], ["bleeding", "DISEASE", 350, 358], ["EGDs", "DISEASE", 374, 378], ["variceal bleeding", "DISEASE", 436, 453], ["myocardial", "MULTI-TISSUE_STRUCTURE", 71, 81], ["upper gastrointestinal", "ORGANISM_SUBDIVISION", 111, 133], ["patients", "ORGANISM", 308, 316], ["GI", "ORGANISM_SUBDIVISION", 347, 349], ["patients", "SPECIES", 308, 316], ["other acute emergencies", "PROBLEM", 39, 62], ["myocardial infarction", "PROBLEM", 71, 92], ["upper gastrointestinal bleeding", "PROBLEM", 111, 142], ["the COVID", "TEST", 150, 159], ["hemodynamically unstable GI bleeding", "PROBLEM", 322, 358], ["EGDs", "TEST", 374, 378], ["EGDs", "TEST", 417, 421], ["variceal bleeding", "PROBLEM", 436, 453], ["myocardial", "ANATOMY", 71, 81], ["infarction", "OBSERVATION", 82, 92], ["upper", "ANATOMY_MODIFIER", 111, 116], ["gastrointestinal", "ANATOMY", 117, 133], ["bleeding", "OBSERVATION", 134, 142], ["no", "UNCERTAINTY", 272, 274], ["change", "OBSERVATION_MODIFIER", 275, 281], ["GI", "ANATOMY", 347, 349], ["bleeding", "OBSERVATION", 350, 358], ["variceal", "ANATOMY", 436, 444], ["bleeding", "OBSERVATION", 445, 453]]], ["This may in part be attributed to the more vivid presentation of overt GI bleeding, making it hard to ignore.", [["GI", "ANATOMY", 71, 73], ["GI bleeding", "DISEASE", 71, 82], ["GI", "ORGANISM_SUBDIVISION", 71, 73], ["overt GI bleeding", "PROBLEM", 65, 82], ["GI", "ANATOMY", 71, 73], ["bleeding", "OBSERVATION", 74, 82]]], ["There was, however, a significant reduction in the number of EGDs done on an inpatient basis, indicating fewer overall inpatient admissions and more stringent triage criteria for endoscopy during this COVID-19 study period.", [["a significant reduction", "PROBLEM", 20, 43], ["EGDs", "TEST", 61, 65], ["endoscopy", "TEST", 179, 188], ["this COVID", "TEST", 196, 206], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["reduction", "OBSERVATION_MODIFIER", 34, 43]]], ["The increased proportions can be explained by a reduction in the number of non-urgent procedures.Trends in upper gastrointestinal bleeding during the COVID-19 pandemic Zain A. Sobani, Swathi Paleti, Sameen Khalid, Euriko Torrazza Perez, Tarun RustagiIt is imperative for gastroenterologists to be aware that GI symptoms were noted to be among the repertoire of COVID-19, especially in patients with severe disease and in the later stages of the pandemic.", [["upper gastrointestinal", "ANATOMY", 107, 129], ["GI", "ANATOMY", 308, 310], ["upper gastrointestinal bleeding", "DISEASE", 107, 138], ["upper gastrointestinal", "ORGANISM_SUBDIVISION", 107, 129], ["COVID-19", "CELL", 361, 369], ["patients", "ORGANISM", 385, 393], ["patients", "SPECIES", 385, 393], ["non-urgent procedures", "TREATMENT", 75, 96], ["upper gastrointestinal bleeding", "PROBLEM", 107, 138], ["the COVID", "TEST", 146, 155], ["Euriko Torrazza Perez", "TREATMENT", 214, 235], ["GI symptoms", "PROBLEM", 308, 319], ["COVID", "TEST", 361, 366], ["severe disease", "PROBLEM", 399, 413], ["the pandemic", "PROBLEM", 441, 453], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["can be explained", "UNCERTAINTY", 26, 42], ["reduction", "OBSERVATION_MODIFIER", 48, 57], ["upper", "ANATOMY_MODIFIER", 107, 112], ["gastrointestinal", "ANATOMY", 113, 129], ["bleeding", "OBSERVATION", 130, 138], ["severe", "OBSERVATION_MODIFIER", 399, 405], ["disease", "OBSERVATION", 406, 413], ["pandemic", "OBSERVATION", 445, 453]]], ["Further data suggest that GI bleeding was present in about 4-13.7% patients with COVID-19 [4] .", [["GI", "ANATOMY", 26, 28], ["GI bleeding", "DISEASE", 26, 37], ["COVID-19", "CHEMICAL", 81, 89], ["GI", "PATHOLOGICAL_FORMATION", 26, 28], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["Further data", "TEST", 0, 12], ["GI bleeding", "PROBLEM", 26, 37], ["COVID", "TEST", 81, 86], ["GI", "ANATOMY", 26, 28], ["bleeding", "OBSERVATION", 29, 37]]], ["Based on our data, and given that our region still has not reached Letters to the Editor 544 its expected peak of COVID-19, we expect to see an increase in the number of patients with hemodynamically unstable bleeding with the surge of COVID-19.Georgios Tziatzios a , Konstantinos Triantafyllou a , Paraskevas Gkolfakis bAttikon University General Hospital, Medical School, National and Kapodistrian University of Athens, Greece; Erasme University Hospital, Universit\u00e9 Libre de Bruxelles, Brussels, BelgiumGeorgios Tziatzios a , Konstantinos Triantafyllou a , Paraskevas Gkolfakis bIn a recently published meta-analysis, the authors reported a significantly higher pneumonia risk among cirrhotic patients exposed to proton pump inhibitors (PPIs) [1] .", [["bleeding", "DISEASE", 209, 217], ["pneumonia", "DISEASE", 665, 674], ["cirrhotic", "DISEASE", 686, 695], ["COVID-19", "CHEMICAL", 236, 244], ["patients", "ORGANISM", 170, 178], ["patients", "ORGANISM", 696, 704], ["proton pump inhibitors", "SIMPLE_CHEMICAL", 716, 738], ["patients", "SPECIES", 170, 178], ["patients", "SPECIES", 696, 704], ["our data", "TEST", 9, 17], ["COVID", "TEST", 114, 119], ["hemodynamically unstable bleeding", "PROBLEM", 184, 217], ["COVID", "TEST", 236, 241], ["a significantly higher pneumonia risk", "PROBLEM", 642, 679], ["proton pump inhibitors", "TREATMENT", 716, 738], ["PPIs)", "TREATMENT", 740, 745], ["increase", "OBSERVATION_MODIFIER", 144, 152], ["unstable", "OBSERVATION_MODIFIER", 200, 208], ["bleeding", "OBSERVATION", 209, 217], ["pneumonia", "OBSERVATION", 665, 674], ["cirrhotic", "OBSERVATION_MODIFIER", 686, 695]]], ["In this case, the authors evaluated observational studies of different designs, definitions and populations; none of those studies was initially conducted to explore the primary outcome of the meta-analysis.", [["observational studies", "TEST", 36, 57], ["those studies", "TEST", 117, 130], ["the meta-analysis", "TEST", 189, 206]]], ["Trying to mathematically harmonize data from irrelevant studies increases the risk of heterogeneity and introduces bias.", [["irrelevant studies", "TEST", 45, 63]]], ["Moreover, one would expect an adjustment for major cofounders, such as the severity of the underlying liver disease, the dose and duration of PPI administration, and the presence or not of significant comorbidities.", [["liver", "ANATOMY", 102, 107], ["liver disease", "DISEASE", 102, 115], ["liver", "ORGAN", 102, 107], ["the underlying liver disease", "PROBLEM", 87, 115], ["PPI administration", "TREATMENT", 142, 160], ["significant comorbidities", "PROBLEM", 189, 214], ["liver", "ANATOMY", 102, 107], ["disease", "OBSERVATION", 108, 115]]], ["However, such an adjustment would be the interest of a meta-regression analysis that is difficult to perform when putting together observational studies.", [["a meta-regression analysis", "TEST", 53, 79], ["observational studies", "TEST", 131, 152]]], ["In our opinion, performing a systematic review without a meta-analysis would be more reasonable, since the retrieved data did not fulfill the necessary criteria to calculate a summarized measure effect [3] .", [["a meta-analysis", "TEST", 55, 70]]], ["Besides, heterogeneity is an issue that must always be anticipated before conducting any analysis.", [["any analysis", "TEST", 85, 97], ["heterogeneity", "OBSERVATION", 9, 22]]], ["Numerical estimation of heterogeneity may be statistically possible but remains imperfect, since it depends on several parameters [4] .", [["may be statistically possible", "UNCERTAINTY", 38, 67]]], ["Even if statistical tests fail to demonstrate significant heterogeneity, the quality of the findings may still be undermined, and the authors should a priori present a rigorous sensitivity analysis to investigate it [3] .Georgios Tziatzios a , Konstantinos Triantafyllou a , Paraskevas Gkolfakis bSignificant publication bias was also evident in this study.", [["statistical tests", "TEST", 8, 25], ["significant heterogeneity", "PROBLEM", 46, 71], ["a rigorous sensitivity analysis", "TEST", 166, 197], ["this study", "TEST", 346, 356], ["significant", "OBSERVATION_MODIFIER", 46, 57], ["heterogeneity", "OBSERVATION", 58, 71], ["publication bias", "OBSERVATION", 309, 325]]], ["Publication bias is one of the most powerful sources of bias, appearing when a considerable amount of data has been missed or overlooked [5] .", [["bias", "OBSERVATION", 56, 60]]], ["Arguably, the consequences of publication bias have been studied in relation to meta-analyses of randomized controlled trials, while its effect when observational studies are included is less clear [6] .", [["publication bias", "PROBLEM", 30, 46], ["randomized controlled trials", "TREATMENT", 97, 125], ["observational studies", "TEST", 149, 170]]], ["Still, it could be even more important, because the incidence of adverse events may be estimated erroneously, leading to imprecise associations between clinical variables [7].", [["adverse events", "PROBLEM", 65, 79]]], ["Instead of simply listing this as a study limitation, the authors should have tried to deal with it effectively, given that this may impact the effect sizes.Georgios Tziatzios a , Konstantinos Triantafyllou a , Paraskevas Gkolfakis bLastly, the authors report as statistically significant the finding that PPI use is associated with greater pneumonia risk (risk ratio 1.36, 95% confidence interval 1.00-1.85).", [["PPI", "CHEMICAL", 306, 309], ["pneumonia", "DISEASE", 341, 350], ["a study limitation", "TEST", 34, 52], ["greater pneumonia risk", "PROBLEM", 333, 355], ["risk ratio", "TEST", 357, 367], ["sizes", "OBSERVATION_MODIFIER", 151, 156], ["associated with", "UNCERTAINTY", 317, 332], ["greater", "OBSERVATION_MODIFIER", 333, 340], ["pneumonia", "OBSERVATION", 341, 350]]], ["However, as witnessed both by the result itself (P=0.05) and by the corresponding forest plot, where the diamond shape touches the line of no effect, this is incorrect.", [["line", "OBSERVATION_MODIFIER", 131, 135], ["no", "UNCERTAINTY", 139, 141], ["effect", "OBSERVATION_MODIFIER", 142, 148]]], ["There is a trend towards a link between PPI use and pneumonia development, but it fails to reach significance.", [["pneumonia", "DISEASE", 52, 61], ["PPI use", "TREATMENT", 40, 47], ["pneumonia development", "PROBLEM", 52, 73], ["pneumonia", "OBSERVATION", 52, 61]]]], "27ba0c4e79182b6be1a98b1448bb934b815c4ca5": [["I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (\"BMJ\") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.", [["CC", "CHEMICAL", 284, 286], ["right", "ANATOMY_MODIFIER", 33, 38]]]], "7b718c2197a63bf718cebed2894fe47f7d90c6b6": [["Human coronaviruses (HCoV) are commonly detected in nasopharyngeal aspirates (NPAs) from children with respiratory tract infections (RTIs).", [["nasopharyngeal aspirates", "ANATOMY", 52, 76], ["NPAs", "ANATOMY", 78, 82], ["respiratory tract", "ANATOMY", 103, 120], ["respiratory tract infections", "DISEASE", 103, 131], ["RTIs", "DISEASE", 133, 137], ["Human", "ORGANISM", 0, 5], ["coronaviruses", "ORGANISM", 6, 19], ["HCoV", "CANCER", 21, 25], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 52, 76], ["NPAs", "CANCER", 78, 82], ["children", "ORGANISM", 89, 97], ["tract", "ORGANISM_SUBDIVISION", 115, 120], ["Human", "SPECIES", 0, 5], ["children", "SPECIES", 89, 97], ["Human coronaviruses", "SPECIES", 0, 19], ["HCoV", "SPECIES", 21, 25], ["Human coronaviruses", "PROBLEM", 0, 19], ["nasopharyngeal aspirates", "PROBLEM", 52, 76], ["respiratory tract infections", "PROBLEM", 103, 131], ["nasopharyngeal", "ANATOMY", 52, 66], ["aspirates", "OBSERVATION", 67, 76], ["respiratory tract", "ANATOMY", 103, 120]]], ["They were first described in the 1960s as agents of the common cold [1] [2] [3] .", [["cold [1] [2] [3]", "SIMPLE_CHEMICAL", 63, 79]]], ["Recently, HCoV has received renewed interest, due to both more sensitive diagnostic methods and increased attention to HCoV after the SARS outbreak in 2002, resulting in the identification of new HCoV subtypes [4] [5] [6] [7] .", [["HCoV", "CHEMICAL", 10, 14], ["SARS", "DISEASE", 134, 138], ["HCoV", "GENE_OR_GENE_PRODUCT", 10, 14], ["HCoV", "CANCER", 119, 123], ["[4] [5] [6] [7]", "SIMPLE_CHEMICAL", 210, 225], ["HCoV", "PROTEIN", 10, 14], ["HCoV", "SPECIES", 10, 14], ["HCoV", "SPECIES", 119, 123], ["new HCoV subtypes", "PROBLEM", 192, 209]]]], "PMC7538047": [["Aim of work ::: BackgroundIn the current study, we aim to evaluate the angiographic and clinical characteristics of COVID-19 patients presented by ST-elevation myocardial infarction (STEMI).Study population ::: MethodsThe present study retrospectively included 26 patients with STEMI and confirmed diagnosis of COVID-19.", [["myocardial", "ANATOMY", 160, 170], ["ST-elevation myocardial infarction", "DISEASE", 147, 181], ["STEMI", "DISEASE", 183, 188], ["STEMI", "DISEASE", 278, 283], ["patients", "ORGANISM", 125, 133], ["myocardial", "MULTI-TISSUE_STRUCTURE", 160, 170], ["patients", "ORGANISM", 264, 272], ["patients", "SPECIES", 125, 133], ["patients", "SPECIES", 264, 272], ["the current study", "TEST", 29, 46], ["COVID", "TEST", 116, 121], ["ST-elevation myocardial infarction", "PROBLEM", 147, 181], ["STEMI", "PROBLEM", 183, 188], ["Methods", "TREATMENT", 211, 218], ["The present study", "TEST", 218, 235], ["STEMI", "PROBLEM", 278, 283], ["COVID", "TEST", 311, 316], ["myocardial", "ANATOMY", 160, 170], ["infarction", "OBSERVATION", 171, 181]]], ["All patients treated with a primary percutaneous coronary intervention (PPCI) during the period from March 2020 till June 2020.Study population ::: MethodsThe study was approved by the local ethical committee.", [["percutaneous", "ANATOMY", 36, 48], ["coronary", "ANATOMY", 49, 57], ["patients", "ORGANISM", 4, 12], ["coronary", "MULTI-TISSUE_STRUCTURE", 49, 57], ["patients", "SPECIES", 4, 12], ["a primary percutaneous coronary intervention", "TREATMENT", 26, 70], ["PPCI", "TREATMENT", 72, 76], ["Methods", "TREATMENT", 148, 155], ["The study", "TEST", 155, 164], ["coronary", "ANATOMY", 49, 57]]], ["As our study is retrospective and data were collected after patients discharged from the hospital, there is no consent for participation in our study.Study population ::: MethodsConfirmed acute STEMI was defined based on the presence of typical anginal pain more than 20 min, associated with new left bundle branch block or new ST-elevation at the J-point in two contiguous leads with the cut-point: > 1 mm in all leads other than leads V2\u2013V3 where the following cut-points apply: > 2 mm in men > 40 years, > 2.5 mm in men <40 years, or > 1.5 mm in women regardless of age.", [["left bundle branch", "ANATOMY", 296, 314], ["STEMI", "DISEASE", 194, 199], ["anginal pain", "DISEASE", 245, 257], ["patients", "ORGANISM", 60, 68], ["men", "ORGANISM", 491, 494], ["men", "ORGANISM", 519, 522], ["women", "ORGANISM", 549, 554], ["patients", "SPECIES", 60, 68], ["men", "SPECIES", 491, 494], ["men", "SPECIES", 519, 522], ["women", "SPECIES", 549, 554], ["our study", "TEST", 3, 12], ["our study", "TEST", 140, 149], ["acute STEMI", "PROBLEM", 188, 199], ["typical anginal pain", "PROBLEM", 237, 257], ["new left bundle branch block", "PROBLEM", 292, 320], ["new ST-elevation at the J", "PROBLEM", 324, 349], ["the cut-point", "TEST", 385, 398], ["acute", "OBSERVATION_MODIFIER", 188, 193], ["STEMI", "OBSERVATION", 194, 199], ["new", "OBSERVATION_MODIFIER", 292, 295], ["left", "ANATOMY_MODIFIER", 296, 300], ["bundle", "ANATOMY_MODIFIER", 301, 307], ["branch", "ANATOMY_MODIFIER", 308, 314], ["block", "OBSERVATION", 315, 320], ["new", "OBSERVATION_MODIFIER", 324, 327], ["elevation", "OBSERVATION_MODIFIER", 331, 340], ["J-point", "OBSERVATION_MODIFIER", 348, 355]]], ["The diagnosis was confirmed by the elevation in troponin levels [6].Study population ::: MethodsPatients who have symptoms suspicious for COVID-19, e.g., progressively worsening shortness of breath, cough, fever, body aches, and unexplained hypoxemia were referred for chest CT without contrast.", [["body", "ANATOMY", 213, 217], ["chest", "ANATOMY", 269, 274], ["shortness of breath", "DISEASE", 178, 197], ["cough", "DISEASE", 199, 204], ["fever", "DISEASE", 206, 211], ["body aches", "DISEASE", 213, 223], ["hypoxemia", "DISEASE", 241, 250], ["troponin", "GENE_OR_GENE_PRODUCT", 48, 56], ["body", "ORGANISM_SUBDIVISION", 213, 217], ["troponin", "PROTEIN", 48, 56], ["the elevation in troponin levels", "PROBLEM", 31, 63], ["symptoms", "PROBLEM", 114, 122], ["COVID", "TEST", 138, 143], ["progressively worsening shortness of breath", "PROBLEM", 154, 197], ["cough", "PROBLEM", 199, 204], ["fever", "PROBLEM", 206, 211], ["body aches", "PROBLEM", 213, 223], ["unexplained hypoxemia", "PROBLEM", 229, 250], ["chest CT", "TEST", 269, 277], ["elevation", "OBSERVATION_MODIFIER", 35, 44], ["worsening", "OBSERVATION_MODIFIER", 168, 177], ["hypoxemia", "OBSERVATION", 241, 250], ["chest", "ANATOMY", 269, 274]]], ["Laboratory tests (complete blood count, C-reactive protein (CRP), and serum ferritin) were done.", [["blood", "ANATOMY", 27, 32], ["serum", "ANATOMY", 70, 75], ["blood", "ORGANISM_SUBSTANCE", 27, 32], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 40, 58], ["CRP", "GENE_OR_GENE_PRODUCT", 60, 63], ["serum", "ORGANISM_SUBSTANCE", 70, 75], ["ferritin", "GENE_OR_GENE_PRODUCT", 76, 84], ["C-reactive protein", "PROTEIN", 40, 58], ["CRP", "PROTEIN", 60, 63], ["serum ferritin", "PROTEIN", 70, 84], ["Laboratory tests", "TEST", 0, 16], ["complete blood count", "TEST", 18, 38], ["C", "TEST", 40, 41], ["reactive protein", "TEST", 42, 58], ["CRP", "TEST", 60, 63], ["serum ferritin", "TEST", 70, 84]]], ["COVID-19 was confirmed with reverse transcription-polymerase chain reaction assays.Angiographic procedure ::: MethodsCoronary angiography and percutaneous coronary intervention were done through the femoral or radial approach.", [["percutaneous", "ANATOMY", 142, 154], ["coronary", "ANATOMY", 155, 163], ["femoral", "ANATOMY", 199, 206], ["radial", "ANATOMY", 210, 216], ["COVID-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["coronary", "MULTI-TISSUE_STRUCTURE", 155, 163], ["femoral", "MULTI-TISSUE_STRUCTURE", 199, 206], ["COVID-19", "DNA", 0, 8], ["COVID", "TEST", 0, 5], ["MethodsCoronary angiography", "TEST", 110, 137], ["percutaneous coronary intervention", "TREATMENT", 142, 176], ["coronary", "ANATOMY", 155, 163], ["femoral", "ANATOMY", 199, 206], ["radial", "ANATOMY_MODIFIER", 210, 216]]], ["All patients received the following regimen: (1) ticagrelor 180 mg initial dose followed by a maintenance dose of 90 mg twice daily or clopidogrel 600 mg loading dose orally followed by a maintenance dose of 75 mg/day if ticagrelor is contraindicated, (2) aspirin 300 mg followed by 75\u2013100 mg/day, and (3) during the procedure patients received unfractionated heparin (100 IU/kg), the dose was reduced to (70 IU/kg) in case of administration of glycoprotein IIb/IIIa inhibitor (eptifibatide).Angiographic procedure ::: MethodsThrombolysis in myocardial infarction (TIMI) flow rate [7] was assessed before and at the end PPCI.Angiographic procedure ::: MethodsObstructive coronary artery disease was defined as a \u2265 50% stenosis in the coronary artery lumen [8].Angiographic procedure ::: MethodsThrombus burden (TB) was graded (G) as G0 = no thrombus, G1 = possible thrombus, G2 = small [greatest dimension \u2264 1/2 vessel diameter (VD)], G3 = moderate (> 1/2 but < 2VD), G4 = large (\u2265 2VD), G5 = unable to assess TB due to vessel occlusion.", [["myocardial", "ANATOMY", 542, 552], ["coronary artery", "ANATOMY", 671, 686], ["coronary artery lumen", "ANATOMY", 734, 755], ["thrombus", "ANATOMY", 841, 849], ["thrombus", "ANATOMY", 865, 873], ["vessel", "ANATOMY", 912, 918], ["vessel", "ANATOMY", 1020, 1026], ["ticagrelor", "CHEMICAL", 49, 59], ["clopidogrel", "CHEMICAL", 135, 146], ["ticagrelor", "CHEMICAL", 221, 231], ["aspirin", "CHEMICAL", 256, 263], ["heparin", "CHEMICAL", 360, 367], ["eptifibatide", "CHEMICAL", 478, 490], ["myocardial infarction", "DISEASE", 542, 563], ["TIMI", "DISEASE", 565, 569], ["MethodsObstructive coronary artery disease", "DISEASE", 652, 694], ["stenosis", "DISEASE", 718, 726], ["TB", "DISEASE", 811, 813], ["thrombus", "DISEASE", 841, 849], ["thrombus", "DISEASE", 865, 873], ["TB", "DISEASE", 1010, 1012], ["vessel occlusion", "DISEASE", 1020, 1036], ["ticagrelor", "CHEMICAL", 49, 59], ["clopidogrel", "CHEMICAL", 135, 146], ["ticagrelor", "CHEMICAL", 221, 231], ["aspirin", "CHEMICAL", 256, 263], ["eptifibatide", "CHEMICAL", 478, 490], ["patients", "ORGANISM", 4, 12], ["ticagrelor", "SIMPLE_CHEMICAL", 49, 59], ["clopidogrel", "SIMPLE_CHEMICAL", 135, 146], ["ticagrelor", "SIMPLE_CHEMICAL", 221, 231], ["aspirin", "SIMPLE_CHEMICAL", 256, 263], ["patients", "ORGANISM", 327, 335], ["heparin", "SIMPLE_CHEMICAL", 360, 367], ["glycoprotein IIb/IIIa", "GENE_OR_GENE_PRODUCT", 445, 466], ["eptifibatide", "SIMPLE_CHEMICAL", 478, 490], ["myocardial", "MULTI-TISSUE_STRUCTURE", 542, 552], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 671, 686], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 734, 749], ["thrombus", "PATHOLOGICAL_FORMATION", 841, 849], ["thrombus", "PATHOLOGICAL_FORMATION", 865, 873], ["vessel", "MULTI-TISSUE_STRUCTURE", 912, 918], ["vessel", "MULTI-TISSUE_STRUCTURE", 1020, 1026], ["glycoprotein IIb", "PROTEIN", 445, 461], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 327, 335], ["ticagrelor", "TREATMENT", 49, 59], ["a maintenance dose", "TREATMENT", 92, 110], ["clopidogrel", "TREATMENT", 135, 146], ["ticagrelor", "TREATMENT", 221, 231], ["aspirin", "TREATMENT", 256, 263], ["the procedure", "TREATMENT", 313, 326], ["unfractionated heparin", "TREATMENT", 345, 367], ["glycoprotein IIb/IIIa inhibitor", "TREATMENT", 445, 476], ["eptifibatide", "TREATMENT", 478, 490], ["MethodsThrombolysis", "TREATMENT", 519, 538], ["myocardial infarction", "PROBLEM", 542, 563], ["TIMI) flow rate", "TEST", 565, 580], ["MethodsObstructive coronary artery disease", "PROBLEM", 652, 694], ["a \u2265 50% stenosis in the coronary artery lumen", "PROBLEM", 710, 755], ["Angiographic procedure", "TREATMENT", 760, 782], ["MethodsThrombus burden", "PROBLEM", 787, 809], ["thrombus", "PROBLEM", 841, 849], ["thrombus", "PROBLEM", 865, 873], ["G3", "TEST", 935, 937], ["TB", "PROBLEM", 1010, 1012], ["vessel occlusion", "PROBLEM", 1020, 1036], ["myocardial", "ANATOMY", 542, 552], ["infarction", "OBSERVATION", 553, 563], ["coronary artery", "ANATOMY", 671, 686], ["disease", "OBSERVATION", 687, 694], ["stenosis", "OBSERVATION", 718, 726], ["coronary artery", "ANATOMY", 734, 749], ["lumen", "ANATOMY_MODIFIER", 750, 755], ["no", "UNCERTAINTY", 838, 840], ["thrombus", "OBSERVATION", 841, 849], ["possible", "UNCERTAINTY", 856, 864], ["thrombus", "OBSERVATION", 865, 873], ["small", "OBSERVATION_MODIFIER", 880, 885], ["greatest", "OBSERVATION_MODIFIER", 887, 895], ["vessel", "ANATOMY", 912, 918], ["diameter", "OBSERVATION_MODIFIER", 919, 927], ["moderate", "OBSERVATION_MODIFIER", 940, 948], ["vessel", "ANATOMY", 1020, 1026], ["occlusion", "OBSERVATION", 1027, 1036]]], ["In patients with G5 thrombus, burden score was calculated after passage of wire or small non-inflated balloon through the lesion [9].Echocardiographic evaluation ::: MethodsEchocardiographic evaluation was performed using the commercially available GE Vivid 7 echocardiograph with 2.5 MHz transducer.", [["G5 thrombus", "ANATOMY", 17, 28], ["lesion", "ANATOMY", 122, 128], ["thrombus", "DISEASE", 20, 28], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["G5 thrombus", "PROBLEM", 17, 28], ["burden score", "PROBLEM", 30, 42], ["passage of wire or small non-inflated balloon", "TREATMENT", 64, 109], ["the lesion", "PROBLEM", 118, 128], ["Echocardiographic evaluation", "TEST", 133, 161], ["MethodsEchocardiographic evaluation", "TEST", 166, 201], ["2.5 MHz transducer", "TREATMENT", 281, 299], ["thrombus", "OBSERVATION", 20, 28], ["small", "OBSERVATION_MODIFIER", 83, 88], ["non-inflated balloon", "OBSERVATION", 89, 109], ["lesion", "OBSERVATION", 122, 128]]], ["LV ejection fraction (EF) was evaluated (using the biplane method of disks) [10].Statistical analysis ::: MethodsAll statistical studies were carried out using Statistical Package for Social Sciences software (SPSS 20.0 for Windows, SPSS Inc., Chicago, IL).", [["LV", "ANATOMY", 0, 2], ["LV", "MULTI-TISSUE_STRUCTURE", 0, 2], ["LV ejection fraction", "TEST", 0, 20], ["EF", "TEST", 22, 24], ["the biplane method of disks", "TREATMENT", 47, 74], ["Methods", "TREATMENT", 106, 113], ["All statistical studies", "TEST", 113, 136], ["ejection fraction", "OBSERVATION", 3, 20]]], ["The quantitative variables are expressed as mean \u00b1 standard deviation (SD).", [["mean \u00b1 standard deviation (SD)", "PROBLEM", 44, 74]]], ["Normally distributed scale variables were expressed as mean \u00b1 standard deviation.", [["distributed", "OBSERVATION_MODIFIER", 9, 20], ["scale", "OBSERVATION_MODIFIER", 21, 26]]], ["Categorical variables were expressed in numbers and percentages.Baseline clinical characteristics (Table 1Tab1table) ::: ResultsMale patients represented 69.2% (n = 18), while female patients represented 30.8% (n = 8).", [["patients", "ORGANISM", 133, 141], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 133, 141], ["patients", "SPECIES", 183, 191], ["Categorical variables", "TEST", 0, 21]]], ["The mean age of the patients were 57.37 years \u00b1 8.75 with range 28\u201373 years.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28]]], ["Regarding traditional risk factors the incidence of diabetes, hypertension, current smoking status, and dyslipidemia were 38.5% (n = 10), 42.3% (n = 11), 50.0% (n = 13), 38.5% (n = 10), respectively.", [["diabetes", "DISEASE", 52, 60], ["hypertension", "DISEASE", 62, 74], ["dyslipidemia", "DISEASE", 104, 116], ["traditional risk factors", "PROBLEM", 10, 34], ["diabetes", "PROBLEM", 52, 60], ["hypertension", "PROBLEM", 62, 74], ["dyslipidemia", "PROBLEM", 104, 116], ["diabetes", "OBSERVATION", 52, 60], ["hypertension", "OBSERVATION", 62, 74]]], ["Three patients (11.5%) had history of prior percutaneous coronary intervention (PCI) and 1 patient (3.8%) had history of prior CABG.", [["percutaneous", "ANATOMY", 44, 56], ["coronary", "ANATOMY", 57, 65], ["patients", "ORGANISM", 6, 14], ["coronary", "MULTI-TISSUE_STRUCTURE", 57, 65], ["patient", "ORGANISM", 91, 98], ["patients", "SPECIES", 6, 14], ["patient", "SPECIES", 91, 98], ["prior percutaneous coronary intervention", "TREATMENT", 38, 78], ["PCI", "TREATMENT", 80, 83], ["prior CABG", "TREATMENT", 121, 131], ["coronary", "ANATOMY", 57, 65], ["CABG", "OBSERVATION", 127, 131]]]], "b5cc9beeba0814dc5d529ef3f886aa995f2d1ef5": [["INTRODUCTIONAsymptomatic shedding of human rhinovirus (HRV; 1, 2), and human coronavirus (hCoV; 3) has been documented in immune competent children and in adult hematopoietic cell transplant (HCT) recipients [4] .", [["hematopoietic cell transplant", "ANATOMY", 161, 190], ["HCT", "ANATOMY", 192, 195], ["human coronavirus", "DISEASE", 71, 88], ["human", "ORGANISM", 37, 42], ["rhinovirus", "ORGANISM", 43, 53], ["human", "ORGANISM", 71, 76], ["coronavirus", "ORGANISM", 77, 88], ["hCoV; 3", "GENE_OR_GENE_PRODUCT", 90, 97], ["children", "ORGANISM", 139, 147], ["hematopoietic cell", "CELL", 161, 179], ["HCT", "CELL", 192, 195], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 71, 76], ["coronavirus", "SPECIES", 77, 88], ["children", "SPECIES", 139, 147], ["human rhinovirus", "SPECIES", 37, 53], ["HRV", "SPECIES", 55, 58], ["human coronavirus", "SPECIES", 71, 88], ["INTRODUCTIONAsymptomatic shedding of human rhinovirus", "PROBLEM", 0, 53], ["human coronavirus (hCoV", "PROBLEM", 71, 94], ["adult hematopoietic cell transplant", "TREATMENT", 155, 190], ["HCT) recipients", "TREATMENT", 192, 207], ["hematopoietic cell transplant", "OBSERVATION", 161, 190]]], ["However, asymptomatic shedding of respiratory viruses, as detected by molecular methods, in children undergoing HCT has not been well described.PATIENTS AND METHODSThis was a prospective longitudinal cohort study of children up to 18 years of age at St. Jude Children's Research Hospital (SJRCH), undergoing allogeneic HCT between January 2008 and March 2011.", [["respiratory viruses", "DISEASE", 34, 53], ["children", "ORGANISM", 92, 100], ["HCT", "CANCER", 112, 115], ["children", "ORGANISM", 216, 224], ["children", "SPECIES", 92, 100], ["children", "SPECIES", 216, 224], ["asymptomatic shedding of respiratory viruses", "PROBLEM", 9, 53], ["HCT", "TEST", 112, 115], ["allogeneic HCT", "TREATMENT", 308, 322], ["asymptomatic", "OBSERVATION_MODIFIER", 9, 21], ["respiratory viruses", "OBSERVATION", 34, 53]]], ["Patients were enrolled regardless of the presence or absence of symptoms of upper respiratory tract (URTI) or a lower respiratory tract infection (LRTI), prior to transplant.", [["upper respiratory tract", "ANATOMY", 76, 99], ["lower respiratory tract", "ANATOMY", 112, 135], ["upper respiratory tract", "DISEASE", 76, 99], ["URTI", "DISEASE", 101, 105], ["lower respiratory tract infection", "DISEASE", 112, 145], ["LRTI", "DISEASE", 147, 151], ["Patients", "ORGANISM", 0, 8], ["upper respiratory", "ORGANISM_SUBDIVISION", 76, 93], ["tract", "ORGANISM_SUBDIVISION", 94, 99], ["tract", "ORGANISM_SUBDIVISION", 130, 135], ["Patients", "SPECIES", 0, 8], ["symptoms", "PROBLEM", 64, 72], ["upper respiratory tract (URTI)", "PROBLEM", 76, 106], ["a lower respiratory tract infection", "PROBLEM", 110, 145], ["transplant", "TREATMENT", 163, 173], ["upper", "ANATOMY_MODIFIER", 76, 81], ["respiratory tract", "ANATOMY", 82, 99], ["lower", "ANATOMY_MODIFIER", 112, 117], ["respiratory tract", "ANATOMY", 118, 135], ["infection", "OBSERVATION", 136, 145]]], ["The study was approved by the institutional review board.", [["The study", "TEST", 0, 9]]], ["Consent was obtained from all parents/guardians, and patients 18 years of age.PATIENTS AND METHODSA nasopharyngeal wash (NPW) was obtained in the week prior to the stem cell infusion, and then every 2 weeks until day +100.", [["nasopharyngeal", "ANATOMY", 100, 114], ["stem cell", "ANATOMY", 164, 173], ["patients", "ORGANISM", 53, 61], ["nasopharyngeal", "ORGAN", 100, 114], ["stem cell", "CELL", 164, 173], ["patients", "SPECIES", 53, 61], ["METHODSA nasopharyngeal wash (NPW", "TREATMENT", 91, 124], ["the stem cell infusion", "TREATMENT", 160, 182], ["nasopharyngeal", "ANATOMY", 100, 114], ["stem cell", "OBSERVATION", 164, 173]]], ["Only patients with the pre-HCT sample were considered evaluable, and followed prospectively until day +100.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["the pre-HCT sample", "TEST", 19, 37]]], ["Patients were evaluated for symptoms and signs of URTI / LRTI in the 3 week period prior to the first wash.PATIENTS AND METHODSTotal nucleic acid was extracted from 250\u00b5L of original sample the same day, using the Biomerieux MiniMag or EasyMag extraction system (Durham, NC), stored at \u221280\u00b0 C, and batch analyzed at regular intervals.", [["URTI", "DISEASE", 50, 54], ["LRTI", "DISEASE", 57, 61], ["nucleic acid", "CHEMICAL", 133, 145], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["symptoms", "PROBLEM", 28, 36], ["URTI / LRTI", "PROBLEM", 50, 61], ["METHODSTotal nucleic acid", "TEST", 120, 145], ["the Biomerieux MiniMag", "TREATMENT", 210, 232], ["EasyMag extraction system", "TREATMENT", 236, 261]]], ["Molecular testing was performed using the MultiCode-PLx Respiratory PCR panel (EraGen Biosciences, Madison, WI).", [["Molecular testing", "TEST", 0, 17], ["the MultiCode", "TEST", 38, 51], ["Respiratory PCR panel", "TEST", 56, 77]]], ["Nucleic acid underwent reverse transcription, PCR and capture using beads with attached probes targeting influenza A, influenza B, parainfluenza virus 1-3, respiratory syncytial virus (RSV), human adenovirus (hADV), human metapneumovirus, enterovirus, HRV, and hCoV.", [["Nucleic acid", "CHEMICAL", 0, 12], ["influenza A", "DISEASE", 105, 116], ["influenza B", "DISEASE", 118, 129], ["respiratory syncytial virus", "DISEASE", 156, 183], ["influenza A", "ORGANISM", 105, 116], ["influenza B,", "ORGANISM", 118, 130], ["parainfluenza virus 1-3", "ORGANISM", 131, 154], ["respiratory syncytial virus", "ORGANISM", 156, 183], ["RSV", "ORGANISM", 185, 188], ["human", "ORGANISM", 191, 196], ["adenovirus", "ORGANISM", 197, 207], ["hADV", "ORGANISM", 209, 213], ["human", "ORGANISM", 216, 221], ["metapneumovirus", "ORGANISM", 222, 237], ["enterovirus", "ORGANISM", 239, 250], ["hCoV", "GENE_OR_GENE_PRODUCT", 261, 265], ["influenza B", "SPECIES", 118, 129], ["parainfluenza virus 1", "SPECIES", 131, 152], ["respiratory syncytial virus", "SPECIES", 156, 183], ["human", "SPECIES", 191, 196], ["human", "SPECIES", 216, 221], ["metapneumovirus", "SPECIES", 222, 237], ["influenza A", "SPECIES", 105, 116], ["respiratory syncytial virus", "SPECIES", 156, 183], ["RSV", "SPECIES", 185, 188], ["human", "SPECIES", 191, 196], ["hADV", "SPECIES", 209, 213], ["human metapneumovirus", "SPECIES", 216, 237], ["HRV", "SPECIES", 252, 255], ["Nucleic acid", "TEST", 0, 12], ["reverse transcription", "TREATMENT", 23, 44], ["PCR", "TEST", 46, 49], ["capture using beads", "TREATMENT", 54, 73], ["influenza", "PROBLEM", 105, 114], ["influenza B", "TEST", 118, 129], ["parainfluenza virus", "PROBLEM", 131, 150], ["respiratory syncytial virus", "PROBLEM", 156, 183], ["human adenovirus (hADV", "PROBLEM", 191, 213], ["human metapneumovirus", "PROBLEM", 216, 237], ["enterovirus", "PROBLEM", 239, 250], ["HRV", "TEST", 252, 255], ["respiratory syncytial", "ANATOMY", 156, 177], ["metapneumovirus", "OBSERVATION", 222, 237]]], ["The reaction products were hybridized to a microsphere-based array, and analyzed on a bench-top flowcell, Luminex-200 (Luminex Corporation, Austin, TX).", [["The reaction products", "TREATMENT", 0, 21], ["a bench-top flowcell", "TREATMENT", 84, 104], ["Luminex", "TREATMENT", 106, 113]]], ["This assay has shown an analytical limit of detection of 2.5 copies per reaction using cloned target sequences for all assayed respiratory viruses [5] , and sensitivity in clinical samples exceeding that of conventional culture and antigen detection methods [6] .PATIENTS AND METHODSRoutine detection of respiratory viruses in symptomatic patients at SJCRH took place using a panel of individual real-time PCR assays (\"clinical assays\"), targeting hADV, influenza A, influenza B, human metapneumovirus, parainfluenza virus 1-3, and RSV.", [["samples", "ANATOMY", 181, 188], ["respiratory viruses", "DISEASE", 304, 323], ["influenza A", "DISEASE", 454, 465], ["influenza B", "DISEASE", 467, 478], ["human metapneumovirus", "DISEASE", 480, 501], ["patients", "ORGANISM", 339, 347], ["hADV", "GENE_OR_GENE_PRODUCT", 448, 452], ["influenza A", "ORGANISM", 454, 465], ["influenza B", "ORGANISM", 467, 478], ["human metapneumovirus", "ORGANISM", 480, 501], ["parainfluenza virus 1", "ORGANISM", 503, 524], ["-3", "ORGANISM", 524, 526], ["RSV", "ORGANISM", 532, 535], ["cloned target sequences", "DNA", 87, 110], ["patients", "SPECIES", 339, 347], ["human", "SPECIES", 480, 485], ["metapneumovirus", "SPECIES", 486, 501], ["parainfluenza virus 1", "SPECIES", 503, 524], ["hADV", "SPECIES", 448, 452], ["influenza A", "SPECIES", 454, 465], ["human metapneumovirus", "SPECIES", 480, 501], ["RSV", "SPECIES", 532, 535], ["This assay", "TEST", 0, 10], ["cloned target sequences", "TEST", 87, 110], ["all assayed respiratory viruses", "PROBLEM", 115, 146], ["clinical samples", "TEST", 172, 188], ["conventional culture", "TEST", 207, 227], ["respiratory viruses", "PROBLEM", 304, 323], ["a panel", "TEST", 374, 381], ["PCR assays", "TEST", 406, 416], ["clinical assays", "TEST", 419, 434], ["hADV", "PROBLEM", 448, 452], ["influenza", "PROBLEM", 454, 463], ["influenza B", "PROBLEM", 467, 478], ["human metapneumovirus", "PROBLEM", 480, 501], ["parainfluenza virus", "PROBLEM", 503, 522], ["RSV", "PROBLEM", 532, 535], ["respiratory viruses", "OBSERVATION", 304, 323]]], ["NPW from symptomatic patients on study were tested using both the clinical and research-based assays.", [["NPW", "SIMPLE_CHEMICAL", 0, 3], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["study", "TEST", 33, 38], ["symptomatic", "OBSERVATION_MODIFIER", 9, 20]]], ["Data from the clinical assays were not included in the research study.", [["the clinical assays", "TEST", 10, 29], ["the research study", "TEST", 51, 69]]], ["Physicians were blinded to data from the research study.PATIENTS AND METHODSInfection was defined as detection of respiratory virus, associated with URTI and / or LRTI.", [["respiratory virus", "DISEASE", 114, 131], ["URTI", "DISEASE", 149, 153], ["LRTI", "DISEASE", 163, 167], ["the research study", "TEST", 37, 55], ["respiratory virus", "PROBLEM", 114, 131], ["URTI", "PROBLEM", 149, 153], ["LRTI", "PROBLEM", 163, 167], ["respiratory virus", "OBSERVATION", 114, 131], ["LRTI", "OBSERVATION", 163, 167]]], ["The day of infection onset was defined as the day when the sample was collected corresponding to the first positive diagnostic test.", [["infection", "DISEASE", 11, 20], ["infection", "PROBLEM", 11, 20], ["infection", "OBSERVATION", 11, 20]]], ["Duration of viral shedding was time in days from the collection of the first positive to the first negative test.Statistical analysesThe prevalence of respiratory virus shedding on day 0, when the first sample was collected pre-HCT, and the 95% exact confidence intervals based on Binomial distribution were provided.", [["viral shedding", "PROBLEM", 12, 26], ["Statistical analyses", "TEST", 113, 133], ["respiratory virus", "PROBLEM", 151, 168], ["viral shedding", "OBSERVATION", 12, 26], ["respiratory virus", "OBSERVATION", 151, 168]]], ["Association between transplant-related variables and respiratory virus shedding was studied in the framework of Cox's proportional hazard model.", [["transplant", "TREATMENT", 20, 30], ["related variables", "PROBLEM", 31, 48], ["respiratory virus shedding", "PROBLEM", 53, 79], ["transplant", "OBSERVATION", 20, 30], ["respiratory virus", "OBSERVATION", 53, 70]]], ["Analyses were performed for a first episode of respiratory virus shedding.", [["Analyses", "TEST", 0, 8], ["respiratory virus shedding", "PROBLEM", 47, 73], ["respiratory virus", "OBSERVATION", 47, 64]]], ["Transplant-related variables were abstracted from a prospectively collected database.", [["a prospectively collected database", "TEST", 50, 84]]], ["SAS version 9.2 (SAS Institute, Cary, NC) was used for statistical analyses.RESULTSA total of 33 (42%) of 78 eligible asymptomatic patients who were approached, consented for study participation.", [["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["SAS version", "TEST", 0, 11], ["Cary, NC)", "TREATMENT", 32, 41], ["statistical analyses", "TEST", 55, 75], ["RESULTSA", "TEST", 76, 84]]], ["Eighty two samples were collected from these 33 patients.", [["samples", "ANATOMY", 11, 18], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56]]], ["Of these patients, 14 (42%) only had the baseline sample collected pre-HCT, and refused further samples owing to the unpleasant sensation of saline in the nasopharynx.", [["samples", "ANATOMY", 96, 103], ["nasopharynx", "ANATOMY", 155, 166], ["patients", "ORGANISM", 9, 17], ["saline", "SIMPLE_CHEMICAL", 141, 147], ["nasopharynx", "ORGAN", 155, 166], ["patients", "SPECIES", 9, 17], ["the baseline sample", "TEST", 37, 56], ["further samples", "TEST", 88, 103], ["nasopharynx", "ANATOMY", 155, 166]]], ["A median of 3 (range 2-8) samples, were collected on the remaining 19 patients.RESULTSThe mean age was 10.9 (range 0.9-18) years.", [["samples", "ANATOMY", 26, 33], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["RESULTSThe mean age", "TEST", 79, 98]]], ["Twenty (61%) patients were male, whites 20 (61%) comprised the majority, and acute leukemia 24 (73%) was the most common diagnosis.", [["acute leukemia", "ANATOMY", 77, 91], ["acute leukemia", "DISEASE", 77, 91], ["patients", "ORGANISM", 13, 21], ["acute leukemia", "CANCER", 77, 91], ["patients", "SPECIES", 13, 21], ["whites", "TEST", 33, 39], ["acute leukemia", "PROBLEM", 77, 91], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["leukemia", "OBSERVATION", 83, 91]]], ["Fourteen (43%) patients had a haplo-identical HCT, 13 (39%) patients underwent HCT from a matched-unrelated donor.", [["HCT", "DISEASE", 46, 49], ["patients", "ORGANISM", 15, 23], ["HCT", "CANCER", 46, 49], ["patients", "ORGANISM", 60, 68], ["HCT", "CANCER", 79, 82], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 60, 68], ["a haplo-identical HCT", "TEST", 28, 49], ["HCT", "TEST", 79, 82], ["a matched-unrelated donor", "TREATMENT", 88, 113]]], ["Total body irradiation was given in 10 (47%) patients.", [["body", "ANATOMY", 6, 10], ["body", "ORGANISM_SUBDIVISION", 6, 10], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["Total body irradiation", "TREATMENT", 0, 22], ["body", "ANATOMY", 6, 10], ["irradiation", "OBSERVATION", 11, 22]]], ["Twelve patients (36%) had acute graft-vs-host disease.", [["graft", "ANATOMY", 32, 37], ["acute graft-vs-host disease", "DISEASE", 26, 53], ["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["acute graft-vs-host disease", "PROBLEM", 26, 53], ["acute", "OBSERVATION_MODIFIER", 26, 31], ["graft", "OBSERVATION", 32, 37], ["host disease", "OBSERVATION", 41, 53]]], ["None of the patients had a history of prior respiratory illness in the 3 weeks prior to HCT.", [["respiratory", "ANATOMY", 44, 55], ["respiratory illness", "DISEASE", 44, 63], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["prior respiratory illness", "PROBLEM", 38, 63], ["HCT", "TEST", 88, 91], ["respiratory", "ANATOMY", 44, 55], ["illness", "OBSERVATION", 56, 63]]], ["HRV was detected in 5 patients, and hADV in 3 patients, in the baseline sample pre-HCT.", [["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 46, 54], ["hADV", "SPECIES", 36, 40], ["HRV", "TEST", 0, 3], ["hADV", "PROBLEM", 36, 40], ["the baseline sample pre-HCT", "TEST", 59, 86]]], ["Two additional patients shed HRV, and one shed hCoVNL63 post-HCT (Figure 1 ).", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["HRV", "TEST", 29, 32], ["HCT", "TEST", 61, 64]]], ["On day 0, the prevalence of any respiratory virus was 0.24 (95% exact CI 0.13-0.39), and the prevalence of HRV was 0.15 (95% exact CI 0.08-0.28).", [["any respiratory virus", "PROBLEM", 28, 49], ["exact CI", "TEST", 64, 72], ["HRV", "TEST", 107, 110], ["exact CI", "TEST", 125, 133], ["respiratory virus", "ANATOMY", 32, 49]]], ["Two patients had co-infections with HRV / hADV, and hADV / RSV post-HCT.", [["co-infections", "DISEASE", 17, 30], ["patients", "ORGANISM", 4, 12], ["hADV", "ORGANISM", 52, 56], ["RSV", "ORGANISM", 59, 62], ["patients", "SPECIES", 4, 12], ["hADV", "SPECIES", 42, 46], ["hADV", "SPECIES", 52, 56], ["RSV", "SPECIES", 59, 62], ["co-infections", "PROBLEM", 17, 30], ["HRV", "PROBLEM", 36, 39], ["hADV", "PROBLEM", 42, 46], ["hADV", "PROBLEM", 52, 56], ["RSV", "PROBLEM", 59, 62], ["HCT", "TEST", 68, 71], ["co-infections", "OBSERVATION", 17, 30]]], ["Cox-proportional hazard model showed no relationship between transplant variables and respiratory virus detection.RESULTSOf the 11 patients where a respiratory virus was detected, follow up samples were obtained in 8 patients for a median of 6 (range 2-12) weeks.", [["samples", "ANATOMY", 190, 197], ["patients", "ORGANISM", 131, 139], ["patients", "ORGANISM", 217, 225], ["patients", "SPECIES", 131, 139], ["patients", "SPECIES", 217, 225], ["Cox-proportional hazard model", "TEST", 0, 29], ["relationship between transplant variables", "PROBLEM", 40, 81], ["respiratory virus detection", "PROBLEM", 86, 113], ["a respiratory virus", "PROBLEM", 146, 165], ["follow up samples", "TEST", 180, 197], ["no relationship", "UNCERTAINTY", 37, 52], ["respiratory virus", "OBSERVATION", 86, 103], ["respiratory", "ANATOMY", 148, 159], ["virus", "OBSERVATION", 160, 165]]], ["Three patients shed the same virus for 4 weeks or more, and 3 shed for 2 weeks (Figure 1 ).", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14]]], ["Two patients (5 and 7) developed URTI from HRV, 14 and 34 days after onset of asymptomatic HRV shedding.", [["URTI", "DISEASE", 33, 37], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["URTI from HRV", "PROBLEM", 33, 46], ["asymptomatic HRV shedding", "PROBLEM", 78, 103]]], ["Strain-typing of HRV was not performed.", [["HRV", "PROBLEM", 17, 20]]], ["URTI symptoms developed one week after detection of hCoVNL63 in an asymptomatic patient (11).", [["URTI symptoms", "DISEASE", 0, 13], ["hCoVNL63", "CHEMICAL", 52, 60], ["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87], ["URTI symptoms", "PROBLEM", 0, 13], ["hCoVNL63", "TREATMENT", 52, 60]]], ["URTI resolved without progression.", [["URTI", "DISEASE", 0, 4], ["URTI", "PROBLEM", 0, 4], ["progression", "PROBLEM", 22, 33], ["without", "UNCERTAINTY", 14, 21], ["progression", "OBSERVATION_MODIFIER", 22, 33]]], ["No respiratory adverse outcomes or nosocomial outbreaks were noted.DISCUSSIONHRV has been described to be associated with LRTI in adult HCT recipients [7, 8] .", [["respiratory", "ANATOMY", 3, 14], ["LRTI", "DISEASE", 122, 126], ["HCT", "CANCER", 136, 139], ["respiratory adverse outcomes", "PROBLEM", 3, 31], ["nosocomial outbreaks", "PROBLEM", 35, 55], ["LRTI", "PROBLEM", 122, 126], ["adult HCT recipients", "TREATMENT", 130, 150], ["respiratory", "ANATOMY", 3, 14], ["adverse", "OBSERVATION_MODIFIER", 15, 22], ["nosocomial", "OBSERVATION_MODIFIER", 35, 45], ["outbreaks", "OBSERVATION", 46, 55]]], ["In a prospective longitudinal surveillance study, asymptomatic shedding of HRV was seen in 6 of 45 (13%) adult HCT patients.", [["HCT", "ANATOMY", 111, 114], ["HCT", "DISEASE", 111, 114], ["HCT", "CANCER", 111, 114], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["a prospective longitudinal surveillance study", "TEST", 3, 48], ["asymptomatic shedding of HRV", "PROBLEM", 50, 78]]], ["HRV was detected only once in 5 of these patients; in the sixth patient, viral shedding lasted for 5 weeks [4] .", [["patients", "ORGANISM", 41, 49], ["patient", "ORGANISM", 64, 71], ["patients", "SPECIES", 41, 49], ["patient", "SPECIES", 64, 71], ["HRV", "PROBLEM", 0, 3], ["viral shedding", "PROBLEM", 73, 87]]], ["Asymptomatic shedding of HRV was more common in childhood recipients of HCT in our series, and viral shedding lasted longer.DISCUSSIONhCoV has also been noted to be associated with LRTI in adult HCT recipients [4, 9] .", [["HCT", "DISEASE", 72, 75], ["LRTI", "DISEASE", 181, 185], ["HCT", "CANCER", 72, 75], ["DISCUSSIONhCoV", "PROTEIN", 124, 138], ["Asymptomatic shedding of HRV", "PROBLEM", 0, 28], ["HCT", "TEST", 72, 75], ["viral shedding", "PROBLEM", 95, 109], ["LRTI", "PROBLEM", 181, 185], ["adult HCT recipients", "TREATMENT", 189, 209]]], ["Asymptomatic shedding of hCoV was seen in 9 of 22 (41%) adult HCT patients, and the median duration of viral shedding in 4 patients, was 4 weeks [4] .DISCUSSIONThe use of NPW has been shown to increase the sensitivity of detection of respiratory viruses, compared to nasal swabs [10] .", [["HCT", "ANATOMY", 62, 65], ["nasal swabs", "ANATOMY", 267, 278], ["HCT", "DISEASE", 62, 65], ["NPW", "CHEMICAL", 171, 174], ["respiratory viruses", "DISEASE", 234, 253], ["hCoV", "GENE_OR_GENE_PRODUCT", 25, 29], ["HCT", "CANCER", 62, 65], ["patients", "ORGANISM", 66, 74], ["patients", "ORGANISM", 123, 131], ["NPW", "SIMPLE_CHEMICAL", 171, 174], ["NPW", "PROTEIN", 171, 174], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 123, 131], ["Asymptomatic shedding of hCoV", "PROBLEM", 0, 29], ["NPW", "TREATMENT", 171, 174], ["respiratory viruses", "PROBLEM", 234, 253], ["nasal swabs", "TEST", 267, 278], ["respiratory viruses", "OBSERVATION", 234, 253]]], ["However, children do not accept NPW well, and this accounted for patients who either declined to participate in the study, or withdrew after the first sample.", [["children", "ORGANISM", 9, 17], ["patients", "ORGANISM", 65, 73], ["children", "SPECIES", 9, 17], ["patients", "SPECIES", 65, 73], ["the study", "TEST", 112, 121]]], ["The small numbers of patients further precluded correlation of URTI or duration of shedding with transplant associated variables, and limits our ability to draw conclusions on the implications of asymptomatic detection of respiratory virus in the transplant setting.", [["URTI", "DISEASE", 63, 67], ["respiratory virus", "DISEASE", 222, 239], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["URTI", "PROBLEM", 63, 67], ["transplant", "TREATMENT", 97, 107], ["asymptomatic detection", "TEST", 196, 218], ["respiratory virus", "PROBLEM", 222, 239], ["small", "OBSERVATION_MODIFIER", 4, 9], ["numbers", "OBSERVATION_MODIFIER", 10, 17], ["respiratory virus", "OBSERVATION", 222, 239]]], ["This underscores the need for subsequent studies with sequential collection of samples to determine the course of asymptomatic shedding in HCT patients.DISCUSSIONOur study had the advantage of being prospective and demonstrates asymptomatic shedding of respiratory viruses using molecular methods in pediatric HCT patients.", [["HCT", "ANATOMY", 139, 142], ["HCT", "ANATOMY", 310, 313], ["HCT", "DISEASE", 139, 142], ["respiratory viruses", "DISEASE", 253, 272], ["HCT", "DISEASE", 310, 313], ["HCT", "CANCER", 139, 142], ["patients", "ORGANISM", 143, 151], ["HCT", "CANCER", 310, 313], ["patients", "ORGANISM", 314, 322], ["patients", "SPECIES", 143, 151], ["patients", "SPECIES", 314, 322], ["subsequent studies", "TEST", 30, 48], ["sequential collection of samples", "TEST", 54, 86], ["asymptomatic shedding in HCT patients", "PROBLEM", 114, 151], ["DISCUSSIONOur study", "TEST", 152, 171], ["asymptomatic shedding of respiratory viruses", "PROBLEM", 228, 272], ["respiratory viruses", "OBSERVATION", 253, 272]]], ["Inferences on causality, based on detection of HRV and hCoV in symptomatic HCT patients, should be made with caution, since these viruses are shed and detectable in asymptomatic patients.", [["HCT", "ANATOMY", 75, 78], ["HCT", "CANCER", 75, 78], ["patients", "ORGANISM", 79, 87], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 178, 186], ["HRV", "TEST", 47, 50], ["hCoV", "TEST", 55, 59], ["symptomatic HCT patients", "TREATMENT", 63, 87], ["these viruses", "PROBLEM", 124, 137], ["viruses", "OBSERVATION", 130, 137]]], ["Future studies using a quantitative detection approach with viral load cutoffs to determine which children with asymptomatic shedding prior to transplant are predisposed to develop symptomatic disease are warranted.", [["children", "ORGANISM", 98, 106], ["children", "SPECIES", 98, 106], ["Future studies", "TEST", 0, 14], ["a quantitative detection approach", "TEST", 21, 54], ["viral load cutoffs", "TREATMENT", 60, 78], ["asymptomatic shedding", "PROBLEM", 112, 133], ["transplant", "TREATMENT", 143, 153], ["symptomatic disease", "PROBLEM", 181, 200]]], ["This may have implications for infection control in pediatric HCT units.", [["infection", "DISEASE", 31, 40], ["infection control", "TREATMENT", 31, 48], ["pediatric HCT units", "TREATMENT", 52, 71], ["infection", "OBSERVATION", 31, 40]]], ["Patients with human rhinovirus (HRV), human adenovirus (hADV), respiratory syncytial virus (RSV), and human coronavirus (hCoV), detected at week 0 (first nasal wash pretransplant), and at 2,4,6,8,10,12, and 14 weeks after the first wash.", [["nasal", "ANATOMY", 154, 159], ["human rhinovirus (HRV)", "DISEASE", 14, 36], ["respiratory syncytial virus (RSV)", "DISEASE", 63, 96], ["human coronavirus", "DISEASE", 102, 119], ["Patients", "ORGANISM", 0, 8], ["human rhinovirus", "ORGANISM", 14, 30], ["human adenovirus (hADV), respiratory syncytial virus", "ORGANISM", 38, 90], ["RSV", "ORGANISM", 92, 95], ["human", "ORGANISM", 102, 107], ["coronavirus", "ORGANISM", 108, 119], ["hCoV", "CANCER", 121, 125], ["nasal", "ORGANISM_SUBDIVISION", 154, 159], ["Patients", "SPECIES", 0, 8], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 38, 43], ["respiratory syncytial virus", "SPECIES", 63, 90], ["human", "SPECIES", 102, 107], ["coronavirus", "SPECIES", 108, 119], ["human rhinovirus", "SPECIES", 14, 30], ["HRV", "SPECIES", 32, 35], ["human adenovirus", "SPECIES", 38, 54], ["hADV", "SPECIES", 56, 60], ["respiratory syncytial virus", "SPECIES", 63, 90], ["RSV", "SPECIES", 92, 95], ["human coronavirus", "SPECIES", 102, 119], ["hCoV", "SPECIES", 121, 125], ["human rhinovirus (HRV)", "PROBLEM", 14, 36], ["human adenovirus (hADV)", "PROBLEM", 38, 61], ["respiratory syncytial virus (RSV)", "PROBLEM", 63, 96], ["human coronavirus (hCoV)", "PROBLEM", 102, 126], ["respiratory", "ANATOMY", 63, 74], ["syncytial virus", "OBSERVATION", 75, 90]]], ["Follow up samples where a wash was done but no virus detected are shown as negative (\u2212).", [["samples", "ANATOMY", 10, 17], ["Follow up samples", "TEST", 0, 17], ["a wash", "TEST", 24, 30], ["virus", "PROBLEM", 47, 52]]]]}